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Abstract 
Osteoarthritis (OA) is a common, multifactorial musculoskeletal disease that is 
characterised by joint pain and reduced joint function. It is a polygenic disease and 
progresses as a result of the focal loss of the articular cartilage of the synovial joint. 
rs143383 is a C to T transition single nucleotide polymorphism (SNP) located in the 5ʹ 
untranslated region (UTR) of the growth differentiation factor 5 gene GDF5. The T 
allele of the SNP is associated with an increased risk of OA and of a number of other 
common musculoskeletal diseases. This susceptibility is mediated by the T allele 
producing less GDF5 transcript relative to the C allele, a phenomenon known as 
differential allelic expression (DAE). The aim of my study was to identify trans-acting 
factors that bind to rs143383 and which regulate this GDF5 DAE. Protein binding to the 
gene was investigated by two experimental approaches: 1) competition and supershift 
electrophoretic mobility shift assays (EMSAs) and; 2) an oligonucleotide pull down 
assay followed by quantitative mass spectrometry. Binding was then confirmed in vivo 
by chromatin immunoprecipitation (ChIP), and the functional effects of candidate 
proteins investigated by RNA interference (RNAi) and over expression. Using these 
approaches the trans-acting factors Sp1, Sp3, P15 and DEAF-1 were identified as 
interacting with the GDF5 5ʹUTR. Knockdown and over expression of the factors 
demonstrated that they were repressors of GDF5 expression. Depletion of DEAF-1 
modulated the DAE of GDF5 and this differential allelic effect was confirmed 
following over expression, with the rs143383 T allele being repressed to a significantly 
greater extent than the rs143383 C allele. In combination, Sp1 and DEAF-1 had the 
greatest repressive activity. The genotype of a second GDF5 5ʹUTR SNP, rs143384, 
which is located downstream of rs143383, has been previously found to impact upon 
the DAE at rs143383. Thus protein binding to rs143384 was also investigated using 
EMSAs. In conclusion, I identified four trans-acting factors that modulate the 
expression of GDF5 via the OA susceptibility locus rs143383.  
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Chapter 1: General Introduction 
1.1 Arthritis 
Arthritis is a term that describes the breakdown of the normal functioning of the joint 
and literally means painful inflammation and stiffness of the joint. This term 
encompasses a spectrum of musculoskeletal conditions in which the articular surfaces of 
the joint no longer have the ability to function properly, resulting in loss of joint 
stability and almost always pain.  These conditions have variable presentations and 
patient outcomes. There are over 200 types of musculoskeletal conditions and typically 
these can be categorised into five groups; inflammatory arthritis such as rheumatoid, 
non inflammatory or degenerative arthritis such as osteoarthritis (OA), soft tissue 
musculoskeletal pain, back pain and connective tissue diseases such as lupus [1, 2].  
1.1.1 Osteoarthritis and its Prevalence 
OA is the most common musculoskeletal disorder in the world with 80% of individuals 
aged over 75 years in Western populations showing radiographic evidence of the 
disease [3]. An estimated 8 million people in the UK have OA and this high prevalence 
is ever increasing due to the ageing of the population and the increasing incidence of 
obesity [1].  Characterised by the progressive loss of articular cartilage, OA is a chronic, 
highly disabling disease that can cause a significant burden on individuals. There is 
substantial variation in the clinical presentation and outcomes of OA, owing to the large 
number of risk factors and pathologies associated with the disease. This means that it is 
not possible to treat the disease as a single disorder, instead, OA is considered as a 
heterogeneous group of disorders which may have differing aetiologies [4, 5]. In older 
patients, OA is one of the most common diagnoses in general practice medicine and is a 
leading cause of disability [6].  
In addition to a functional disability and reduced quality of life, patients may also suffer 
financially as a result of loss of wages and increased medical costs. OA constitutes a 
large economic burden on society, amounting to 1-2% of gross national product [7]. 
This is a result of medical expenses (medication, physiotherapy and surgery) and of 
indirect costs such as time off work, loss of productivity whilst at work, and increased 
resources required for informal care giving [8].  
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1.1.2 Defining OA 
Osteoarthritis can be characterised into primary OA, with cause unknown, or secondary 
OA, where the cause can be identified; for example, arising from a developmental 
disorder, trauma or metabolic syndrome [4]. Additionally, the number and distribution 
of the joint sites that are affected can be used to classify OA; OA can be joint specific, 
known as localised disease, with knees and hips tending to be the most commonly 
affected, or it can be more generalised, affecting a number of joints [9]. OA is usually 
defined by structural changes that are detailed radiographically; in end stage disease 
structural changes can include joint space narrowing, subchondral bone sclerosis, 
subchondral cyst and osteophyte formation [3].  
Grading systems are available to define the severity of OA, with the Kellgren and 
Lawrence (KL) scale being most commonly used to grade disease severity on a scale of 
0-4; a score of 0 signifies absence of OA changes and a score greater than 2 signifies 
definitive radiographic OA [10]. Magnetic Resonance Imaging (MRI) can also be used 
to examine joint structures and is suggested to be more sensitive and enables a more 
precise tracking of the disease in comparison with tracking joint space narrowing 
radiographically [11].  Symptomatic OA defines the presence of radiographic changes 
in addition to joint symptoms. The most common OA symptom is pain; patients can 
also experience joint stiffness, tenderness, functional limitation, variable inflammation 
and crepitus [12]. The disability associated with these symptoms can impact upon a 
patients quality of life and make everyday tasks difficult, which can lead to social 
isolation and depression [13]. Furthermore, evidence is now emerging that patients with 
OA have an increased risk of mortality [14].  
The degree of pain, joint stiffness and loss of physical function that patients experience 
can be quantified using a numerical index such as the Western Ontario McMaster 
Osteoarthritis Index (WOMAC) [15]. However, presence of pain is not necessarily 
correlated with radiographic evidence of disease and research has shown that there is 
discordance between these features; a population-based study found that significant 
structural changes were asymptomatic in over 50% of subjects, whereas only 15% of 
patients experiencing knee pain had KL stage 2-4 OA changes. This further complicates 
the definition and diagnosis of OA, with a number of physicians wrongly diagnosing 
OA in patients without radiographic evidence of OA, or patients with radiographic 
changes being missed due to lack of symptoms [16].  
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1.1.3 OA Treatment 
Therapeutic interventions for OA are limited; current management of the disease 
involves non pharmacological treatments such as exercise and lifestyle changes in 
addition to pharmacological treatments such as non steroidal anti-inflammatory drugs 
(NSAIDS) and analgesics. Although these treatments can reduce pain and decrease 
inflammation, they do not target the underlying cause of the disease and have little 
impact on slowing the progression to advanced OA. Clinical trials testing potential OA 
disease modifying drugs have had limited success, with arthroplasty remaining the basis 
for curative therapy [17, 18].   
Acetaminophen is given initially as a first line oral analgesic followed by NSAIDs if 
required [17].  NSAIDs primarily target the enzyme cyclooxygenase (COX), an enzyme 
responsible for the formation of biological mediators of pain, the prostanoids. There are 
two COX isoforms, COX1 and COX2, and inhibitors against these enzymes have been 
used in the treatment of arthritis [19, 20]. Classical COX inhibitors are not selective and 
inhibit both isoforms of the enzyme. Although they demonstrated clinical efficacy, they 
were associated with adverse gastrointestinal (GI) side effects, prompting the 
production of the next generation of COX inhibitors which were specific for COX2 
inhibition.  The adverse side effects are a result of the widespread expression of COX1 
compared to the limited expression of COX2 which is located at sites of inflammation 
and in the kidneys [19]. COX2 specific inhibitors (such as rofecoxib) became the 
preferred choice for treatment and lacked GI complications, however the association of 
rofecoxib with increased risk of myocardial infarction and stroke prompted its 
withdrawal from the market and raised concerns as to the safety of these drugs [21]. For 
patients who are contraindicated with COX inhibitors, opiod analgesics can be used. 
Topical NSAIDs can also be used, providing a local high dose of drug whilst 
minimising systemic side effects. Another option for OA pain, most commonly for use 
in the knee, is intra-articular injections of corticosteroids, although there are concerns 
that this treatment may enhance OA progression [22].   
Surgery is usually considered in patients who have severe disease or in patients who are 
suffering from pain and disability, and who are showing no improvement following 
pharmacological intervention. The surgical options available include arthroscopy 
(which may involve debridement and lavage or small corrective surgery), osteotomy 
(which involves the re-alignment of the joint), joint fusion for the spine, hand and foot 
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and finally arthroplasty (which involves total joint replacement and is usually the option 
for advanced OA cases) [23].   
Currently, the focus for treatment research is to identify disease modifying OA drugs 
(DMOADs). Trials examining the efficacy of substances such as glucosamine sulphate 
and chondroitin sulphate have concluded that these compounds have structure 
modifying properties [24]. A two year, randomised placebo controlled trial in the USA, 
the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), has however 
provided evidence that these compounds do not significantly affect loss of cartilage or 
pain. These compounds had similar effects to those observed in subjects who were 
taking a COX2 inhibitor or a placebo [25].  
Other approaches have focussed on targeting the pathophysiological changes that occur 
in OA, for example the targeting of catabolic enzymes such as matrix 
metalloproteinases (MMPs) or targeting factors that promote synovial hyperplasia such 
as the cytokine IL-1β. Trials testing MMP inhibitors have been complicated by painful 
musculoskeletal adverse effects such as tendonitis due to their broad protease inhibition. 
More selective inhibitors are under investigation to reduce the side effect risk [26]. An 
inhibitor of IL-1β, diacerein, has shown conflicting effects, with some studies reporting 
a positive anti-inflammatory effect, whilst others have reported no differences [27, 28].  
Other options are to target bone remodelling or to try and promote cartilage repair. 
There is also interest in the use of mesenchymal stem cells for autologous 
transplantation. This involves the removal of stem cells from a patient, the 
differentiation of these cells in vitro (for example into chondrocytes) and then the 
transplantation of these cells back into the patient at the required site for new tissue 
growth [29]. Mesenchymal stem cells are found in the bone marrow and in many adult 
tissues and are capable of self renewal. Furthermore, these cells have the capacity to 
differentiate into a variety of cell lineages, including chondrocytes, adipocytes and 
osteoblasts [30, 31]. These cells therefore have the capacity to regenerate cartilage in 
vivo and thus in the future could be used for the treatment of OA. A recent study has 
further investigated the use of stem cells, by performing a high throughput screen to 
identify molecules which promote chondrocyte differentiation. Kartogenin was 
identified by this study and was found to induce chondrogenesis by regulating CBFβ 
and RUNX1 transcription [32]. Furthermore, there is interest in generating new scaffolds 
for cartilage tissue engineering to promote cartilage repair.  
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In addition, growth factors such as TGFβ and members of the bone morphogenetic 
protein family are under consideration as potential OA therapeutics, although recent 
evidence suggests that the use of TGFβ superfamily members for bone tissue 
engineering has failed to duplicate in humans the promising results that were obtained 
in animal models [33].   
1.2 Joint Structure and Function 
Joints allowing free movement of the bone are known as diarthroses or synovial joints 
and comprise most of the joints of the body. The synovial joint is a complex organ that 
is composed of a number of tissue types surrounded by a fibrous capsule, as shown in 
Figure 1.1. These tissues include the articular cartilage, capsule, synovium, synovial 
fluid, tendon, ligament and subchondral bone. In addition, in joints such as the knee, the 
fat pad, menisci and patella are present. All of these tissues have specialised roles and 
are interdependent on each other, whereby damage or pathology in one tissue could 
adversely affect any one of these tissues. Together their composition allows the 
articulation and frictionless movement of joints, permitting pain free functioning. 
Damage to these tissues can alter the integrity of the joint, which may limit joint 
function, cause pain and could promote the onset of OA.   
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Figure 1.1  
Structure of the synovial joint and composition of the extracellular matrix (ECM). The 
synovial joint is composed of a number of tissue types surrounded by a fibrous capsule. 
The articular capsule consists of the fibrous capsule and synovial membrane. The 
fibrous capsule surrounds a number of tissues including; articular cartilage, synovial 
fluid, meniscus, tendon, ligament, and the subchondral bone, covered by the periosteum. 
The articular cartilage consists of four different zones; the superficial zone (SZ), middle 
zone, deep zone and calcified zone. The triple helical structure of collagen is shown, as 
well as the structure of aggrecan, with its characteristic protein core, three globular 
domains and GAG chains. Finally, the composition of the ECM is shown; chondrocytes 
are surrounded by a matrix consisting mainly of collagen and aggrecan. Cartilage 
oligomeric matrix protein (COMP) and fibronectin (a high molecular weight 
glycoprotein) are also present within the ECM. The cartilage zones figure is taken from 
[34]. The collagen and aggrecan molecule figure is taken from [35].The ECM figure is 
from [36].  
 
1.2.1 Articular Cartilage 
Articular cartilage is the smooth coating covering the ends of skeletal bones, acting as a 
load bearing material, functioning to reduce friction and to help absorb shear and 
compressive stresses [37]. The articular cartilage contains a single unique cell type 
called the chondrocyte. These large and mature cells are able to function in a hypoxic 
environment that is avascular, alymphatic and aneuronal.  Chondrocytes derive their 
nutrients from the surrounding synovial fluid and importantly, these cells are not inert; 
they synthesise, secrete and maintain their surrounding extracellular matrix (ECM). 
Collagen
Aggrecan
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Although chondrocytes make up only a small proportion of the cartilage (5%), their 
metabolism is responsible for the presence and maintenance of their surrounding matrix. 
The balance between the catabolism and anabolism of this matrix, mediated by the 
chondrocyte, is crucial for cartilage homeostasis [38, 39].   
The ECM consists of proteoglycans (aggrecan being the most abundant) surrounded by 
a network of collagen (mainly type II) and water. Collagen is the most widely expressed 
protein within the body and is vital in providing cartilage with its structural properties. 
Collagen molecules have a characteristic triple helical structure and align to form fibrils 
that are stabilised by intramolecular crosslinking [39]. Aside from collagen type II, type 
IX and XI are also important within the ECM. Aggrecan constitutes the major non-
fibrillar component of the ECM; it consists of a protein core, with three globular 
domains, G1, G2 and G3. G1 binds non covalently to hyaluronic acid, stabilised by a 
link protein. Between the G2 and G3 domains there are many glycosaminoglycan 
(GAG) chains including chondroitin sulphate and keratin sulphate [40].  The structures 
of collagen and aggrecan are shown in Figure 1.1 in addition to other components of the 
ECM.  
Aggrecan polymers are maintained in an ordered state by their interaction via the link 
protein with collagen fibres. This network is surrounded by water which is drawn into 
the matrix by the negatively charged aggrecan polymers. The water provides a swelling 
pressure that is constrained by the collagen. Together these molecules provide cartilage 
with its structural properties, allowing it to resist compression and remain firm and 
intact.  
Cartilage can be separated into four zones; the superficial, middle, deep and calcified. 
The superficial zone (representing 10-20% of cartilage thickness) is in contact with the 
synovial fluid and offers a smooth surface for articulation. This zone has the highest 
collagen content and is highly organised, enabling it to withstand shear forces. The 
chondrocytes within this zone are small and flat, primarily expressing proteins for 
lubrication and protection [41]. The middle zone (representing 40-60% of cartilage 
thickness) is less organised as a result of the lower collagen content and the 
chondrocytes are rounder, larger and more sparsely spread. The deep zone (representing 
30% of thickness) has a high proteoglycan content. The chondrocytes in this zone are 
arranged in columns, parallel to the collagen fibres [39]. The tidemark separates the 
deep cartilage zone from the calcified cartilage which lies directly on the subchondral 
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bone [37]. Collagen fibrils extend from the calcified cartilage into the articular cartilage 
providing a strong link between the two zones. The calcified cartilage zone contains 
type X collagen, a marker of chondrocyte hypertrophy, and is a region of active matrix 
turnover.  
Water provides cartilage with its resilient properties and is important in providing 
cartilage with nutrition and lubrication, constituting 65-80% of tissue composition [42]. 
The largest amount of water is found in the superficial zone near the surface of the 
cartilage; as depth increases, the concentration of water decreases. The zonal 
arrangement of the articular cartilage and the arrangement of collagen is shown in 
Figure 1.1. 
1.2.2 Subchondral Bone 
The subchondral bone is composed of two regions, the subchondral bone plate and the 
trabecular bone. The subchondral bone plate separates the calcified cartilage from the 
bone marrow spaces and consists of a thick dense layer of calcified tissue which 
supports cartilage, transmitting load into the trabecular bone beneath. The trabecular 
bone is a network of thin, calcified trabeculae consisting of plates and struts, orientated 
in different directions to form a supportive network with a primarily metabolic function. 
These two differences in function relate to structural differences; a large volume (80-
90%) of the subchondral bone end plate is calcified, enabling a strong support structure 
for load, in comparison to a smaller volume (15-25%) of the trabecular bone [43].  
Blood vessels from the subchondral bone extend into the calcified cartilage layer 
through channels in the subchondral bone plate. These channels serve as a source of 
nutrition for the chondrocytes located in the calcified zone. Both regions of the bone are 
composed of an organic matrix consisting primarily of collagen type I, but also non-
collagenous proteins such as osteocalcin. In addition, both regions are mineralised with 
inorganic crystals of hydroxyapetite. The collagen in the end plate is arranged into 
sheets of parallel fibrils which extend into the lamellae of the trabecular bone. The 
calcified bone matrix is not inert, it contains cells capable of bone formation 
(osteoblasts) and bone resorption (osteoclasts). Most components of the bone matrix are 
synthesised and secreted by osteoblasts, osteoclasts are derived from osteoblast cells 
and are key for growth, bone remodelling and repair [44]. 
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1.2.3 The Joint Capsule and the Synovial Membrane   
The joint capsule is a dense, irregular connective tissue which physically holds adjacent 
bones together, providing support and structure. The synovial membrane lines the inside 
of the capsule and contains two cell types; the type A synovial cell, a macrophage 
protecting against infection, and the type B synovial cell, which secretes synovial fluid.  
These cells are responsible for maintaining homeostasis of the joint. Synovial fluid 
contains both hyaluronic acid and lubricin which reduce friction, absorb shock and 
facilitate the exchange of oxygen and nutrients with carbon dioxide and metabolic waste 
in chondrocytes [45].  Synovial fluid also contains mesenchymal stem cells which are 
present in preparation for repair of damage [46].  
Tendons and ligaments are both connective tissues that attach alongside the capsule to 
the bone. Tendons are composed of predominately type I collagen fibres that connect 
muscle to bone and allow motion of the joint. Ligaments are composed of type I (90%) 
and type III (10%) collagen fibres in addition to a small amount of proteoglycans and 
connect bone to bone to help stabilise the joint [47]. The fat pad acts as a cushion to 
protect the joints and is also a rich source of proinflammatory adipokines and 
mesenchymal progenitor cells capable of differentiation [48].  Finally, the menisci are 
pads of fibrous cartilage that maintain stability of the joints and dissipate load [49].  
All joint tissues, with the exception of articular cartilage, are innervated by nerves 
responsible for proprioception and nociception. Blood vessels penetrate the capsule and 
provide nutrition, whilst lymphatic vessels remove waste [50].  
1.3 Joint Homeostasis 
Joint homeostasis requires a fine balance between the anabolic and catabolic activity of 
chondrocytes. The activity of chondrocytes is influenced by biochemical mediators such 
as growth factors and cytokines, and also mechanical factors such as loading and stress. 
Inflammatory cytokines can mediate the catabolic activity of the cells, whilst anti-
inflammatory cytokines can promote anabolic activity [51]. The most important growth 
factors found to be present within the joint during development include transforming 
growth factor β (TGFβ), bone morphogenetic proteins (BMPs), cartilage-derived 
morphogenetic proteins (CDMPs), connective tissue growth factor (CTGF), insulin-like 
growth factors (IGFs), hepatocyte growth factor (HGF) and fibroblast growth factor 
(FGF) [37].  
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Matrix metalloproteinases are the enzymes responsible for the breakdown of cartilage 
components. These proteases are divided into groups based on the substrates that they 
cleave and their location within the cell and include: collagenases (MMP 1, 8 and 13), 
membrane type MMP (MT-MMP), stromelysins (MMP 3, 10 and 11), gelatinases 
(MMP 9 and 2) and adamalysin (ADAM and the subgroup ADAMTS) [37]. Multiple 
members of the MMP family act by cleaving collagen whereas aggrecan is cleaved by 
both MMPs and aggrecanases (ADAMTS-4 and 5 in OA cartilage) [52]. These factors 
are important for cartilage homeostasis and mediate processes such as repair and 
remodelling of the joint. However, they have also been found to contribute to the 
pathology of joint disease [53, 54]. 
MMPs are potent catabolic enzymes and as such their activity must be regulated. MMPs 
are produced in a pro-enzyme form that requires the removal of an N-terminal fragment 
for activation. Pro-MMPs can be cleaved by a number of factors including activated 
MMPs, plasmin and reactive oxygen species (ROS) [55]. Further control of the MMPs 
is achieved through the synthesis of tissue inhibitors of metalloproteinases (TIMPs). 
TIMPs are synthesised in connective tissue cells and their expression is regulated by 
growth factors. They inhibit MMPs by two mechanisms, firstly by binding to them and 
blocking MMPs substrate cleavage and secondly by inhibiting the cleavage of pro-
MMPs, and thus their activation [56].  
In addition to changes to the cartilage, bone remodelling occurs in a coordinated 
sequence to replace old bone with new bone, enabling the shape, architecture or density 
of the skeleton to be changed. Bone formation occurs once bone resorption has taken 
place in an activation-resorption-formation sequence. This sequence ensures that in non 
disease states there is an equal amount of bone resorption and bone formation to 
maintain bone mass [43].  
1.4 Development of the Joint 
The epiphyses are the regions at the end of long bones, the diaphysis is the hollow 
portion in the middle of bone and the metaphysis is the transition zone between them 
(Figure 1.2). The epiphyses is derived from a different ossification centre to the 
metaphysis and diaphysis and during development these two regions are separated by a 
layer of cartilage, known as the epiphysis cartilage (growth plate). This region of 
cartilage matrix enables the growth of long bones until the end of the growth period. 
Bone development occurs through two distinct processes, intramembranous and 
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endochondral ossification. In the first, mesenchymal cells differentiate directly into 
osteoblasts which synthesise a woven bone matrix. Blood vessels are incorporated 
between the woven trabecular bone and form bone marrow. At a later stage, this woven 
bone is replaced with mature lamellar bone. This process does not involve the presence 
of cartilage [43].  
Endochondral ossification is a two step process involving the differentiation of 
mesenchymal stem cells into chondrocytes, which create the cartilage matrix in a 
process known as chondrogenesis, followed by the formation of bone by osteoblasts.  
Chondrogenesis begins with the recruitment, migration and proliferation of 
mesenchymal stem cells. These cells aggregate into pre-cartilage condensations and 
start to produce the cartilaginous matrix for the developing limbs. This matrix consists 
mainly of collagen type II. In the centre of the cartilage model, chondrocytes proliferate 
and become hypertrophic at a region forming the primary ossification centre. The 
differentiation of chondrocytes is controlled by a number of factors; parathyroid 
hormone related peptide (PTHrP) is found in prehypertrophic chondrocytes and 
maintains these cells in a proliferative state. PTHrP expression and chondrocyte 
differentiation is also regulated by other factors such as Indian hedgehog (IHH), 
Fibroblast growth factor (FGF) and bone morphogenetic proteins (BMPs) [57]. The 
transcription factors Sox9 and Runx2 in addition to factors of the wnt signalling 
pathway control the differentiation of the chondrocytes within the chondrocyte lineage 
[58-60].  
A ring of woven bone called the bone collar is formed at the periphery of the mid zone 
area, which following calcification is penetrated by blood vessels and osteoclasts which 
enter into the primary ossification centre.  The blood vessels allow seeding of the 
hematopoietic bone marrow. The osteoclasts resorb calcified cartilage and allow 
osteoblasts to form woven bone. Secondary ossification centres begin to form at the 
epiphysis and form trabecular bone in a similar process. Between these two ossification 
centres, the epiphyseal cartilage remains until growth has finished in adulthood [43].  
From the epiphysis to the metaphysis, the growth plate demonstrates the different stages 
of chondrocyte differentiation; firstly, the proliferative zone in which chondrocytes are 
synthesising cartilage matrix, secondly, the hypertophic chondrocytes which deposit a 
mineralised matrix, and lastly, after calcification of matrix the chondrocytes undergo 
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programmed cell death (apoptosis) allowing for the formation of bone by osteoblasts 
[43]. The process of endochondral ossification is shown in Figure 1.2.  
 
Figure 1.2  
The process of endochondral ossification: Mesenchymal stem cells aggregate and 
differentiate into chondrocytes. The chondrocytes form the cartilage model by 
proliferating and secreting extracellular matrix (ECM) components. A ring of woven 
bone is formed called the bone collar at the periphery of the mid zone area following the 
secretion of osteoid by osteoblasts serving as a support for the new bone. Chondrocytes 
continue to proliferate, stop secreting ECM components and start to become hypertropic 
at the primary ossification centre which following calcification is penetrated by blood 
vessels. Chondrocytes undergo apoptosis, leaving cavities in the bone. Osteoblasts form 
the trabecular bone using the calcified matrix as a scaffold.  Secondary ossification 
centres begin to form at the epiphysis (ends of long bones). The growth plate is 
epiphyseal cartilage that remains until growth has ended in adulthood. Figure taken 
from [43].  
 
1.5 Pathology of OA 
OA is not solely a disease of the articular cartilage, pathological changes can be seen in 
all tissues of the joint [61]. Although there are notable changes in the articular cartilage 
in the early phases of the disease, the bone, ligament and synovium also show evidence 
of damage. It is unclear as to where the initial pathological changes occur; some argue 
that the subchondral bone is the primary source of damage, although others argue that 
changes in the articular cartilage precede this [62].  As the disease progresses, 
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pathological changes occur in a number of tissues of the joint, including tendons, 
muscle and the nervous system, either as a direct effect or indirectly [63, 64]. The 
pathological changes that occur are the consequence of a number of different 
aetiological factors and are dependent on the stage of the disease.  
1.5.1 Articular Cartilage 
There are two mechanisms by which damage can occur to the articular cartilage, the 
first is the abnormal loading on normal cartilage, whereby an excessive load can 
damage the structure of the ECM.  The second is the result of normal loading on 
abnormal cartilage and the risk factors associated with the development of abnormal 
cartilage are discussed further below [65]. In either case, the end result is structural 
damage to the cartilage and the inability to reform the complex structure of the ECM.  
The pathological changes that occur in the articular cartilage during OA progression are 
striking. The normal smooth, elastic, layered cartilage texture following insult can 
become rough, fragmented and thinned or can be absent all together in the late stages of 
the disease.  Macroscopically, cartilage changes in OA are observed as fibrillation 
(discontinuities in the cartilage surface), which can extend to become fissures (splits), 
chondromalacia (softening), erosion of cartilage and ulceration. Other histological 
changes include changes in cartilage thickness, the formation of cartilage clefts and a 
duplication of the tidemark between non calcified and calcified cartilage. Tidemark 
duplication and vascular invasion of vessels penetrating into the cartilage from the 
subchondral bone further decreases the thickness of the articular cartilage [39]. In areas 
where cartilage is absent, the bone is exposed and undergoes sclerosis, a process known 
as eburnation due to its shiny ivory like appearance [22]. 
Biochemically, the major components of the ECM are altered, changing the content, 
composition and structure of the matrix. The two key components of the ECM, collagen 
and aggrecan, are affected; cleavage of type II collagen and local loss of proteoglycans 
occurs initially at the cartilage surface resulting in an increased permeability of the 
matrix. Although there is an increase in the water content of the ECM, this increase in 
permeability results in a decrease in hydrostatic pressure, causing softening of the 
cartilage. The tensile strength of the cartilage is decreased and it becomes stiffer. A 
higher percentage of proteoglycans are present in the non aggregated form, unbound to 
hylauronate, and the chain length of proteoglycans is reduced. With disease progression, 
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there is a rapid loss of proteoglycan content relative to the amount of collagen. 
Furthermore, the organisation of collagen is affected [39].  
Changes to the chondrocytes can also be observed; in the early stages of the disease, 
chondrocytes located in the superficial zone proliferate to form aggregates, believed to 
be replicative clones. As the disease progresses, the chondrocyte clusters increase in 
size and can be seen deeper into the cartilage zones. In addition, there are areas of 
decreased cellularity where chondrocytes have undergone cell death [66].  
The reasons for these changes in the composition of articular cartilage are a result of 
chondrocyte activation; in normal cartilage, chondrocytes remain in a quiescent state, 
exhibiting a very low metabolic activity. In response to load or injury, chondrocytes 
become ‘activated’, characterised by proliferation and increased production of catabolic 
and anabolic factors. An increase in catabolic activity, fuelled by increases in pro-
inflammatory cytokines and proteases, leads to a failure of the chondrocyte to maintain 
its environment. Levels of the collagenases MMP1 and MMP13 have been found to be 
increased in OA cartilage and are responsible for the degradation of type II collagen 
[67]. Furthermore, MMP3 and ADAMTS-4 degrade proteoglyans. There is an 
imbalance in the levels of MMPs compared with TIMPs in OA tissues resulting in 
destruction of the ECM and the release of matrix fragments [68]. Chondrocytes and 
synoviocytes respond by releasing growth factors in an attempt to initiate 
developmental pathways to remodel the matrix. The phenotypic changes in OA 
chondrocytes vary according to their location; chondrocytes at the superficial zone 
exhibit an osteoblastic phenotype, cells in the middle and deep zones however exhibit a 
hypertropic phenotype [69]. Overall, the chondrocytes are unable to maintain an 
adequate level of anabolic activity and cannot replicate the ordered structure of the 
matrix formed during development, leading to destruction and eventually complete loss 
of the articular cartilage [70].    
1.5.2 Subchondral Bone 
Pathological changes can be observed in the subchondral bone during the OA disease 
process.  These changes include sclerosis, the development of osteophytes and the 
formation of bone cysts. Sclerosis of the trabecular bone can occur due to increased 
stress on the bone which causes remodelling, in turn increasing the trabecular bone 
volume. The increased volume is due to an increase in trabeculae number and thickness, 
reducing the space between trabeculae, thus altering the organisation of the structure 
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and the biomechanical properties of the bone. Furthermore, there is evidence of 
thickening of the subchondral bone plate [71]. Osteophytes arise at the joint margins, 
mainly located in non weight bearing areas of the joint, and form due to increased bone 
formation. It is still a debate as to whether osteophytes are damaging to the joint, some 
believe that they add to joint pathology, contributing to OA pain, whereas other 
researchers suggest that they help to stabilise the joint and redistribute load [72]. The 
absence of osteophytes in the hip joint of OA patients has been shown to increase 
disease progression [72]. Clinical studies have however positively correlated the extent 
of osteophyte formation with cartilage destruction [73]. In the advanced stages of the 
disease, subchondral bone cysts usually form in areas where cartilage has been 
completely lost. These are cavities within the bone and are formed due to the action of 
osteoclasts [74]. 
1.5.3 Synovium 
OA is not classically known as an inflammatory disease, although mild synovial 
inflammation is common in the disease [75]. Signs and symptoms of inflammation such 
as joint pain, swelling and stiffness occur in early and advanced OA. Changes are 
confined to the synovium and include synovial hyperplasia, fibrosis and inflammatory 
cell infiltration. Inflammation is mediated by synovial mast cells and chondrocytes in 
addition to infiltrating macrophages, B and T cells. In contrast to rheumatoid arthritis, 
this inflammation is a secondary effect, a result of pathological changes within the joint 
[76]. 
The release of inflammatory mediators is usually in response to the release of 
degradation products such as proteoglycan fragments and type II collagen peptides into 
the synovium and the subarticular bone which elicit an inflammatory response. 
Synovioctes become activated, proliferate and secrete MMPs and cytokines which 
promote a catabolic response. Cytokines such as IL-1β, TNFα, oncostatin M (OSM) and 
interleukins 6, 17 and 18 can all affect the metabolic activities of chondrocytes, 
promoting an increase in the synthesis of degradative enzymes including MMPs and 
aggrecanases [37, 77]. IL-1β also induces other pro-inflammatory cytokines and 
chemokines and suppresses the expression of anabolic factors. Many of the catabolic 
factors synergise with each other promoting further catabolism, favouring catabolic 
changes over anabolic changes, resulting in significant and irreversible damage to the 
ECM [78].  
16 
 
1.5.4 Other tissues of the Joint 
There are also changes in other tissues of the OA joint, although these have been less 
well studied in comparison to the aforementioned tissues. The meniscus can show 
degenerative changes such as horizontal cleavages, complex tears or destruction. In 
advanced stages of the disease, calcification within the menisci is common [79]. 
Thickening and fibrotic shortening of the capsule have also been reported in OA 
pathology and are associated with symptoms of pain [80].  Degenerative changes may 
occur  at the site where the ligaments insert into bone and additionally muscle atrophy 
(mainly in the quadriceps) can occur [81, 82].  
1.6 Risk Factors for OA 
The major risk factor for OA is age, with prevalence of the disease rising with 
increasing age. Other important risk factors include genetics, obesity, gender, 
race/ethnicity, nutrition, bone metabolism in addition to joint specific risk factors 
including mechanical injury or trauma, bone density, muscle strength, leg length 
inequality (LLI), joint morphology/alignment, occupation and sporting activities [3]. 
These can be separated into those that promote the formation of abnormal cartilage, and 
thus predispose to the development of OA, and those that increase susceptibility to OA 
based on injury risk or trauma to the cartilage.  
Whilst age is one of the primary risk factors for the development of OA, it is important 
to note that although changes in the ECM structure and function with increasing age are 
inevitable, the development of OA is not. Not all elderly people develop OA, it is 
therefore clear that there must be other important factors affecting susceptibility. With 
increasing age, the articular cartilage becomes softer and there is a decrease in the 
strength of the ECM, making it more susceptible to injury. There are changes in the key 
components of the ECM with increasing age, but these are distinct from the changes 
observed in OA pathology [65]. With increasing age, the size and number of aggrecan 
molecules is decreased, a result of decreased aggrecan synthesis or increased 
degradation, and this also leads to a decrease in the number of chondroitin sulphate 
chains [83]. Crosslinking of collagen molecules in both the bone and cartilage is 
increased with age [84, 85]. This is in contrast to the changes observed in OA cartilage, 
which as mentioned previously include increased levels of non aggregated aggrecan, 
and an alteration of the organisation of collagen [39]. 
With increasing age, there is also an increase in the accumulation of advanced glycation 
end products (AGEs) and their receptor RAGE. AGEs are the end products of a process 
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called non-enzymatic glycation.  Their accumulation with age can affect the activity of 
the chondrocytes, and trigger the expression of cytokines and MMPs and the release of 
ROS [65, 86].  
In addition to changes in the structure and composition of the ECM, the anabolic 
capacity of the chondrocyte is reduced with age, with chondrocytes being less 
responsive to growth factors [86]. This is known as senescence; senescent chondrocytes 
display aberrant expression of catabolic factors and are more responsive to cytokines 
[87]. Overall, the risk of OA is increased with ageing because the altered composition of 
the matrix renders the cartilage more sensitive to load/trauma and the ability of the 
chondrocytes to maintain cartilage homeostasis and repair following injury becomes 
compromised.  
Female sex is associated with both higher prevalence and increased severity of OA [88].  
The increased prevalence of OA at the time of the menopause led to the hypothesis that 
oestrogen levels may affect OA susceptibility. However, the results from clinical trials 
assessing the effect of oestrogen replacement therapy on the development of OA have 
been conflicting [89-91]. An MRI study investigating sex differences for prevelance for 
OA suggested that women may have thinner cartilage than men but it is not yet clear if 
cartilage loss is accelerated [92].  
Loading can also affect the homeostatic balance within the ECM; chondrocytes respond 
to load by either up-regulating the synthesis of matrix components or increasing the 
levels of inflammatory mediators responsible for cartilage breakdown. Static 
compression has been found to cause degradation of matrix components; conversely, 
dynamic compression stimulates the synthesis of these components [93].  
Obesity is a risk factor for the development of OA, with overweight or obese patients 
being 3 times more at risk of incident knee OA compared to normal weight individuals. 
Furthermore, risk rises with increasing body mass index (BMI) [94, 95]. Women who 
reduced their BMI by 2 or more units over a 10 year period decreased their risk of 
developing OA by 50% [96]. However, there is an increased incidence of obesity with 
hand OA; this association prompted further investigations as this suggests that the effect 
is not primarily a result of increased loading on the joint, but may be the result of 
metabolic or inflammatory factors [97]. Adipokines can be released from chondrocytes 
and directly affect cartilage homeostasis, acting locally to increase catabolic activity. 
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Inflammatory mediators increase the expression of adipokines such as leptin which then 
promotes further catabolic effects by increasing the expression of MMPs [98].  
The effects of dietary factors on OA susceptibility have been conflicting. Increasing 
intake of vitamins C, D, E and K have all been tested and the results have been 
inconsistent [99]. Furthermore, bone mineral density (BMD) has been associated with 
OA risk, such that increased BMD increases OA susceptibility. However, this 
association is not understood; it is unclear if it is related to changes in bone remodelling 
or to increased load rather than a direct association of the BMD [100].  
Joint specific risk factors, include occupation, injury and physical activity. Repeated use 
of the joint such as for squatting, an occupation involving kneeling or lifting or repeated 
physical activity can increase susceptibility to OA [101]. In addition, muscle strength 
may be a predisposing factor, although it is not clear as to whether muscle atrophy is a 
determinant of OA or a consequence of OA related disuse [102]. Structural properties of 
the joint can also affect susceptibility to OA. The alignment of the joint is a key 
example, whereby misalignment of the joint can result in abnormal load distribution and 
thus altered cartilage morphology [103]. In addition, LLI can affect susceptibility, such 
that a LLI of more than 2cm can alter the biomechanics of the lower extremities [104]. 
Lastly, joint morphology is also a predisposing factor, altered anatomy of the shape of 
the joint can affect load distribution and therefore render the joint susceptible to damage 
following loading [105].  
Race and ethnic differences have been shown to impact upon OA prevalence. A cross 
sectional study observed racial differences in hip OA between Caucasians and African 
Americans in the Johnston County OA project, with an increased incidence of hip OA 
in African Americans [106]. In addition, a Chinese cohort was found to be less 
susceptible to hand and hip OA compared to a Caucasian population. However, knee 
OA was more prevalent among Chinese females compared to Caucasian females [107-
109].  
1.7 Genetics of OA 
1.7.1 Family Aggregation Studies 
Epidemiological studies have provided evidence that OA has a genetic component. The 
first of these studies, highlighting the familial clustering of OA, was in the 1940s and 
involved a family aggregation study. These studies investigate the genetic contribution 
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to a disease by looking at relative risks for a family member of an affected individual 
(for example a sibling) and comparing this risk to that of the general population. This 
first study identified that mothers and sisters of patients with Herberden’s nodes (a sign 
of OA in the hands) were disproportionately affected by the same boney swelling [110] 
. Further studies have investigated the familial clustering of OA, confirming a genetic 
influence in hand OA and at other sites including the knee, hip and spine [111-117]. 
Family aggregation studies have provided a good basis for evaluating the genetic 
influence in OA risk, however they do not allow for the separation of clustering that is 
due to shared environmental factors from genetic factors. Factors such as diet and 
exercise may cluster in families, and it is therefore difficult to account for this within 
such studies [118]. 
1.7.2 Twin Studies  
The investigation of disease clustering in monozygotic (MZ) and dizygotic (DZ) twins 
allows for the separation of environmental factors from genetic factors. MZ twins have 
identical genomes, meaning that any variation between pairs is a result of environmental 
influences, whereas DZ twins share on average about 50% of their genes, and so 
variation may be accounted for by environmental or genetic factors. Comparing the 
concordance of disease in these twin pairs therefore allows for the quantification of 
genetic and environmental contributions to disease [118]. The relative contribution of 
genetic and environmental factors in hand and knee OA was assessed in female MZ and 
DZ twins, identifying the influence of genetic factors as between 39-65% [119]. 
Furthermore, a longitudinal twin study has identified that prevalence of progression of 
knee OA was higher in MZ compared to DZ twins. The concordances for osteophyte 
formation and joint space narrowing were also higher in MZ compared to DZ twins, 
with heritability estimates of 69% and 80% respectively [120]. The influence of genetic 
factors in hip OA has also been investigated, with greater concordance in MZ compared 
to DZ female twins translating to heritability estimates of 58% for hip OA overall and 
64% for joint space narrowing [121]. Furthermore, in a male twin pair study, the 
concordance levels of  radiographic disease was higher in MZ compared to DZ twins 
[122].  Heritability of OA in the spine has also been investigated, with a study looking 
at disc degeneration in twins using MRI. Overall, the heritability was 74% at the lumbar 
spine and 73% at the cervical spine [123].  These studies have highlighted that OA is 
not a disease that is mediated by fully penetrant risk alleles. Conversely, polymorphisms 
within a number of genes are responsible for increasing an individual’s risk of 
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developing OA. One allele may therefore only contribute to a fraction of the overall risk 
of OA, but in addition to other alleles and in combination with environmental factors, 
OA susceptibility is increased. Genetic factors account for at least half of the variation 
in susceptibility to disease. Furthermore, there is heterogeneity between different joint 
sites and between sexes, adding to the complex nature of the disease. 
1.7.3 Candidate Gene Studies 
Following the studies confirming that hereditary factors contribute to OA susceptibility, 
investigators then started to interrogate the molecular genetic nature of the disease, with 
the hope of identifying loci that harbour OA susceptibility. The first approach was to 
investigate candidate genes that are thought to be involved in OA pathology based on 
their expression, protein function or association with a related disease. Genes encoding 
structural components of the ECM such as COL2A1 represented reasonable candidates 
given their function within the development of the joint, and considering  that when 
mutated they are associated with developmental abnormalities such as 
chondrodysplasias [124]. Association and linkage studies within these genes have 
however been inconclusive or negative, suggesting that structural genes are unlikely to 
be conferring OA susceptibility, and instead are associated with rare monogenic 
disorders. Furthermore, genes encoding proteins that regulate bone density were 
predicted to affect OA susceptibility and the VDR gene encoding the Vitamin D 
receptor was investigated and produced mixed results [125-127].   
Aside from structural components of the ECM, candidate genes involved in cartilage 
development and signalling have also been investigated. A variable number tandem 
repeat polymorphism in the Asporin (ASPN) gene was identified by a Japanese group 
and was found to inhibit chondrogenesis and to increase susceptibility to OA. ASPN 
was investigated as it is a member of the small leucine-rich proteoglycan (SLRP) 
family. SLRPs function as structural organisers, interacting with components of the 
ECM and modulating growth factors by binding to TGFβ [128]. The D14 allele (14 
aspartic acid repeats) showed an increased frequency in cases and the D13 allele (13 
aspartic acid repeats) showed an increased frequency in controls in an Asian cohort. 
However, this effect was not consistently observed in replication studies using samples 
from the UK, Greece, Spain and China. A meta analysis combining all five studies 
reported an association of the D14 allele in OA cases [129-132]. Significant 
heterogeneity was observed and it was evident that the effect of the D14 allele is much 
stronger in Asians in comparison with Europeans [133].  
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 The same group also identified a functional polymorphism rs143383 within the growth 
differentiation factor 5 gene (GDF5), which to date still remains the most compelling 
candidate OA association signal.  In this study, it was found to be associated with knee 
and hip OA in a Japanese population [134]. This protein was investigated as it is a 
member of the TGFβ superfamily and is involved in the formation of the joint and its 
mutation results in a number of human dysplasias. GDF5 is discussed further in 
Introduction section 1.9. 
Although there have been significant positive findings using the candidate gene 
approach, this approach is limited to our understanding of the disease, and important 
genes conferring OA risk may be missed due to incomplete knowledge of the OA 
disease process. Research has thus moved away from the hypothesis-led candidate gene 
approach towards a hypothesis-free genome wide approach [135]. Regions of the 
genome that harbour OA susceptibility loci can be identified using genome-wide 
linkage scans and genome-wide association scans (GWAS). 
1.7.4 Linkage Studies 
The aim of the linkage studies is to pinpoint areas of the genome that co-segregate with 
a disease phenotype such as OA. In these studies, the genomes of affected sibling pairs 
(ASP) are compared in order to look for regions that overlap. The first OA genome 
wide linkage scan was performed by a group in Oxford using patients ascertained by 
total hip or knee replacement. Linkages to chromosomes 2 and 11 were identified 
concordant for hip OA [136, 137]. These results were then stratified according to sex 
and by joint type which uncovered additional linkages on chromosome 4, chromosome 
6 and chromosome 16 [138] . As the linkage intervals in the genome scan were 
relatively large, these loci were then subjected to finer linkage mapping [139-142]. The 
linkage region on chromosome 6 encompassed two candidates, COL9A1 and BMP5, 
however subsequent studies failed to provide an association for single nucleotide 
polymorphisms (SNPs) within these genes [141].  
Further investigation of the chromosome 2 region revealed an association with a 
functional non synonymous SNP in the FRZB gene with female hip OA [143]. FRZB 
encodes secreted frizzled-related protein 3 (sFRP3) which is a soluble antagonist of wnt 
signalling, shown to possess chondrogenic activity in vivo [144]. The SNP resulted in an 
arginine to glycine substitution, resulting in the diminished ability of sFRP3 to 
antagonise wnt signalling. A study of differential allelic expression (DAE) of FRZB 
22 
 
revealed that only a small number of patients had allelic expression differences and 
these did not correlate with genotype at five selected SNPs [145]. A number of 
replication studies have been performed, with association to knee OA in women being 
reported and a meta analysis confirming a strong association with the FRZB G allele 
[146]. However, a number of studies have been unable to replicate this association, 
including a large scale meta analysis  [147, 148] and this locus was not found to be 
associated with radiographic osteoarthritic outcomes [149]. More recent studies have 
reported mixed associations of FRZB with hip morphology [150, 151]. Although the 
meta analysis results did not confirm a role for FRZB in susceptibility to common OA, 
this may be a result of the different criteria used for the definition of OA cases in these 
studies. A standardised approach for grading OA severe cases and identifying the 
presence of mild OA in controls has been suggested to progress research at this locus 
[148]. Functional studies of frzb knockout mice have supported a role for this factor in 
the development of the joint and have implicated FRZB in OA pathology; the mice 
showed increased cartilage proteoglycan loss, increased cortical bone thickness with 
increased stiffness and an increase in bone formation following loading [152].  
Following the publication of the UK genome linkage scan, further scans followed. The 
first of these was performed using 27 Finnish families and investigated distal 
interphalangeal joint OA [153]. The linkage regions mapped to chromosomes 2 and 4, 
with the region on chromosome 2 encompassing the IL-1 receptor and ligand cluster at 
2q12-q13. This region on chromosome 2 was distinct from that identified in the Oxford 
study. Considering the role of IL-1 in cartilage homeostasis as a catabolic cytokine, 
further studies investigated this association. Some have provided supporting evidence of 
the association at this locus in the knee, hip and hand [153-159], however some studies 
in different ethnic populations have been negative [160, 161].  
A third scan was performed on an Icelandic family who suffered with severe hip OA 
necessitating joint replacement [162]. The strongest evidence for linkage occurred at 
chromosome 16, which overlaps with the region identified in the Oxford study. 
Following further study, the IL-4 gene, located within this region was found to 
predispose to hip OA in female Caucasians [163]. 
Further genome wide linkage scans have focussed on hand and spine OA with a number 
of loci on different chromosomes showing segregation with disease [164, 165]. In the 
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Framingham study, two regions that have been previously identified showed linkage, 
one on chromosome 7 [153] and the second on chromosome 11 [136, 142]. 
1.7.5 Genome Wide Association Scans  
GWAS are now more widely used in comparison with linkage studies due to their 
ability to resolve with greater accuracy areas harbouring susceptibility loci. GWAS 
compare the SNPs within a cohort of disease cases with a cohort of controls. By 
exploiting linkage disequilibrium, the fact that genetic variance at one locus can predict 
with high probability genetic variance at another locus, means that the number of SNPs 
that need to be genotyped in a GWAS (100,000-500,000) is considerably less than the 
total number of SNPs in the human genome. Upon identification of a number of SNPs 
more prevalent in cases compared to controls, each polymorphism within this region is 
interrogated with the aim of identifying the associated SNP. The completion of the 
human genome sequencing project (HGSP) and data from the International Human 
HapMap project have made the GWAS approach possible [166, 167].  
There have been three large scale OA GWAS performed by Dutch, Japanese and UK 
groups. The Dutch GWAS involved a Rotterdam cohort, followed by replication in 
Europeans and North Americans [168]. The overall numbers combined were 14938 
cases and 39000 controls. A highly significant signal (P value less than 8 x 10
-8
) was 
reported to a region of chromosome 7q22. An analysis of additional cohorts in a meta 
analysis increased the significance of the association [169]. The 7q22 locus is 
particularly relevant to knee OA and contains at least six known genes, PRKAR2B, 
HBP1, COG5, GPR22, DUS4L and BCAP29. None of these genes appeared to be 
obvious OA candidates, although GPR22 was found to harbour an expression 
quantitative trait loci (eQTL). However this eQTL was discovered in transformed 
lymphoblast cells and so it’s relevance to OA pathology is unclear. Further investigation 
of this locus consisted of expression studies performed in joint tissues from OA 
patients, in tissues from a mouse model of OA and in zebrafish embryos. In patient 
tissues all of the genes showed a universal pattern of expression except for GPR22 
which could not be detected in any of the joint tissues. There was a lower level of 
expression of the 5 genes in OA cartilage compared to control cartilage. Further analysis 
found that HBP1 and DUS4L demonstrated DAE, with carriers of the associated allele 
demonstrating a significantly different HBP1 DAE compared to non-carriers [170]. 
GPR22 was also absent in normal mouse articular cartilage and synovium. However, 
GPR22 positive chondrocytes were found in mice with papain induced arthritis and in 
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chondrocyte like cells present within osteophytes, taken from animals with instability 
induced OA [168].  
The Japanese GWAS involved Japanese cases and controls, followed by replication in 
both Japanese and European populations [171]. Two SNPs located on chromosome 6 
within the region of the human leukocyte antigen (HLA) locus were associated with 
knee OA with P values of less than 7 x 10
-8
. Neither of the SNPs showed an association 
in the European cohort and this association failed to replicate in an independent Han 
Chinese cohort [172].  
The UK GWAS, known as the arcOGEN study, initially involved cases and controls 
from the UK, with replication in samples from Europe and North America [173]. The 
combined numbers were 13768 cases and 53286 controls. No signal exceeded the 
genome wide significance threshold of P less than 5 x 10
-8
, however a number of SNPs 
produced strong signals, one of which, located in MICAL3 had a P value of 2.7 x 10
-5
 
for knee and/or hip OA. For knee OA, the strongest signal was located in C6orf130 and 
for hip OA the strongest signal was in COL11A1. Further analysis of MICAL3, 
BCL2L13 and BID, the latter two genes being located within the GWAS signal, failed to 
observe an association between the OA associated SNP rs227783 and any changes in 
gene expression [174]. Further analysis into the association signal in COL11A1 has been 
performed and is awaiting publication (Emma Raine, personal communication).  
The next phase of the arcOGEN study included 7410 cases and 11009 controls from the 
UK and the most promising signals were subsequently replicated in 7473 cases and 
42938 controls from samples from Iceland, Estonia, the Netherlands and the UK [175]. 
Five genome wide significant loci were identified as being associated to OA, with a 
further three loci just below the threshold. The strongest of these is within the GNL3 
gene. Other loci were found on chromosome 9 close to ASTN2, chromosome 6 between 
FILIP1 and SENP6 and on chromosome 12, within close proximity to KLHDC5 and 
PTHLH. Another region within chromosome 12, close to CHST11, was also identified. 
Current research is interrogating each of these signals further by gene expression 
analysis and DAE analysis to establish the cause of these association signals. A genome 
wide expression profiling study also highlighted CHST11, and reported significantly 
higher levels of expression of this gene in OA cartilage compared to normal donor 
cartilage [176]. CHST11 encodes a carbohydrate sulfotransferase enzyme that catalyses 
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the transfer of sulphate to chondroitin, a proteoglycan important in the cartilage ECM 
[177]. CHST11 therefore represents an interesting susceptibility locus for OA.   
Overall, GWAS has provided us with a few compelling OA association signals, and the 
signals most recently identified need to be investigated in order to identify which genes 
harbour the susceptibility, enabling the start of functional studies. The signals so far 
identified from the GWAS have had low odds ratios and this is a reflection of the 
polygenic nature of the disease, with a few loci that mediate a moderate impact on OA 
susceptibility. Future studies may focus on phenotypic stratification, which could enable 
the identification of new loci associated with different subsets of OA or with OA 
severity.  
1.8 Bone Morphogenetic Proteins 
BMPs are a group of multi-functional growth factors belonging to the transforming 
growth factor β (TGFβ) superfamily.  BMPs are involved in the formation of cartilage 
and bone and were first discovered following the observation that injection of 
demineralised bone matrix minerals into muscle formed bone [178]. This BMP activity 
was mediated by a mixture of BMPs and TGFβ family members, two of which were 
identified subsequently; BMP3 was identified following purification and sequencing 
and BMP2 by cloning [179-181]. Further research has led to the identification of more 
than 20 BMPs with a diverse range of functions and subgroups: osteogenic proteins 
(Ops), cartilage derived morphogenetic proteins (CDMPs) and growth and 
differentiation factors (GDFs). In addition to having a vital role in the formation of 
cartilage and bone during the development of the limbs, they are involved in a number 
of non-osteogenic developmental processes such as cardiac, kidney and vascular 
development [182-185]. Most mature BMP molecules consist of two monomers that are 
linked covalently via a disulphide bond. Two molecules can be derived from the same 
BMP member, forming a homodimer, or from two different BMP molecules forming a 
heterodimer [186].  
1.8.1 BMP Signalling 
BMPs signal through serine/threonine kinase receptors, composed of two subtypes, type 
I and II. There are three type I receptors that BMPs bind to, type IA and IB BMP 
receptors and type IA activin receptor. There are also three type II receptors, the type II 
BMP receptor, and type II and IIB activin receptors. Activin receptors bind both BMPs 
and activins, whereas BMP receptors are specific to BMPs. The expression pattern of 
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these BMP receptors differs among cell types. After ligand binding, the receptors form a 
heterotetrameric activated complex which consists of two pairs of type I and two pairs 
of type II receptors [187]. Specifically, BMPs bind to BMP receptor II, promoting 
phosphorylation of receptor I, which in turn phosphorylates SMADs 1, 5 and 8. These 
then translocate to the nucleus in combination with SMAD4 (co-SMAD). This SMAD 
complex relays the BMP signal from the receptor to the nucleus and activates the 
transcription of target genes. Activated SMADs regulate the expression of transcription 
factors such as RUNX2 [188]. In addition to the SMAD signalling cascade, BMP 
binding to the BMP receptor complex can stimulate SMAD independent pathways, 
resulting in the activation of ERK, P38α and JNK [189-191].  
BMPs exert a diverse range of functions, but signalling is mediated through a limited 
number of receptors. There are several explanations for the ability of a small number of 
receptors to mediate versatile responses from a number of BMPs; receptor expression 
patterns in different cells, affinity of the different receptors for certain ligands and 
oligomerisation pattern of the receptor (i.e. homodimeric BMP6 has a high affinity for 
type I and low affinity for type II receptors and in contrast, heterodimeric BMP2/6 has a 
high affinity for both type I and II receptors) [192, 193]. The lateral mobility of 
receptors within the membrane has also been reported to determine which signalling 
cascade is activated, highlighting the complexity of this signalling pathway [194]. 
1.8.2 BMP Inhibitors  
Considering the importance of BMPs during development it is not surprising that their 
activities are controlled by inhibitors, such as noggin, chordin and follistatin that bind to 
BMPs to prevent them binding to their receptors [195, 196]. The expression of these 
extracellular antagonists can be up-regulated in response to BMPs, providing a negative 
feedback mechanism in order to control their effects. In addition, there is regulation of 
the signalling pathways of BMPs; SMAD6 binds to BMP receptor I and prevents the 
activation of SMADs 1,5 and 8 [197]. Additionally, SMAD7 is an inhibitory SMAD. 
Tob interacts specifically with SMAD proteins and inhibits signalling [198]. Smurf1, an 
E3 ubiquitin ligase, regulates BMP signalling on a number of levels; it interacts with 
and mediates the degradation of SMAD 1 and 5, mediates Runx2 degradation and forms 
a complex with SMAD6 and targets the type I BMP receptors for degradation [199-
201]. The importance of these inhibitors can be assessed following their over expression 
or depletion; noggin homozygous knock-out mice die at birth and have abnormalities in 
the ribs, vertebrae and limbs [202]. In contrast, the over expression of noggin in mature 
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mice osteoblasts causes osteoporosis [203].  Furthermore, noggin haploinsufficiency 
provided protection to articular cartilage against destruction in a mouse arthritis model, 
and over expression of the antagonist rendered cartilage more vulnerable to damage 
[204]. Mutations within the NOG gene in humans produce joint fusions, emphasising 
the vital role of the regulation of BMPs during the development of the joints [205]. 
Furthermore, over expression of SMAD6 delays the differentiation and maturation of 
chondrocytes [206].  Tob null mutant mice have increased BMP signalling and thus 
increased bone formation, whilst Smurf1 over expression in osteoblasts inhibits 
postnatal bone formation [207, 208].  
1.9 GDF5 
GDF5 was first discovered through its association with brachypodism mice; in 1952, a 
mutation was discovered in a number of Swiss albino mice causing growth 
abnormalities. Due to the decreased size of their paws compared to control mice, these 
mice were named brachypodism mice (bp) [209]. It was suggested that the 
abnormalities were a result of the defective formation of mesenchymal condensations. It 
was not demonstrated until 1994 that a frameshift mutation, leading to a premature stop 
codon and thus a functional null mutation within the GDF5 gene, was responsible for 
this phenotype. These mice have shorter length long bones and smaller feet in 
comparison to control mice, a result of altered patterning of the segments in the digits. 
The length of metacarpals and metatarsals is also altered, with a disorganisation noted 
in the carpals and tarsals. However, the axial skeleton is unaffected. These defects are 
first noted at day 12 of gestation. The digit condensations are slow to initiate 
chondrogenesis and are malformed and the mesenchyme show reduced ability to form 
aggregates [210]. These findings are distinctly different from those observed in BMP5 
mutant mice, which present with altered shape and size of the ears, sternum and ribs 
with the absence of any changes in limb bone length or the morphology of the digits 
[211]. These studies therefore highlight the distinct roles of different BMPs during the 
formation of the skeleton. Aside from the skeleton, GDF5 transcripts were found to be 
present in a number of tissues in the adult mice, however the brachypod mice are fertile 
and do not appear to show any other abnormalities [210].  
GDF5 is a member of the TGFβ superfamily, and structurally, is closely related to the 
BMPs [212].  GDF5 is classified within the growth differentiation factor family, which 
consists of 15 proteins. GDF5 is closely related to GDF6 and GDF7, sharing 74-92% of 
their mature signalling region in the C-terminus [210].  
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1.9.1 Examination of the GDF5 gene 
The human GDF5 gene is located on chromosome 20 and consists of two coding exons. 
It is highly homologous to its murine equivalent, with the mature region of the protein 
differing by only one amino acid [213].  
Figure 1.3 shows exon 1 and the flanking intronic sequence of the GDF5 gene. The 
location of two polymorphisms, rs143383 and rs143384, are highlighted in addition to 
the ATG translation start site. There is no TATA binding sequence or CCAAT box 
upstream of exon 1.  
Three mRNA transcripts for GDF5 have been identified (UCSC genome browser, 
http://genome.ucsc.edu/); our research laboratory has identified the presence of only one 
of these transcripts within a number of relevant tissues corresponding to the shorter of 
the two GDF5 transcripts, the GDF5 O/S transcript has only been identified in testis 
tissue (unpublished data). RNA sequencing data identified the expression of GDF5 
within cartilage tissue from NOF patients (control cartilage tissue) and in OA cartilage 
tissue samples (Yaobo Xu, personal communication and unpublished observations). In 
this data GDF5 is expressed at a higher level in OA than NOF and this data has 
confirmed the presence of only one primary transcript in these tissues, suggesting the 
absence of alternative splice variants.  
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-105 ACTGGAAAGGATTCAAAACTAGGGGGAAAAAAAAACTGGAGCACACAGGCAGCATTACGC  
- 45 CATTCTTCCTTCTTGGAAAAATCCCTCAGCCTTATACAAGCCTCCTTCAAGCCCTCAGTC   
- 16 AGTTGTGCAGGAGAAAGGGGGCGGTYGGCTTTCTCCTTTCAAGAACGAGTTATTTTCAGC  
  76 TGCTGACTGGAGACGGTGCACGTCTGGATACGAGAGCATTTCCACTATGGGACTGGATAC 
 136 AAACACACACCCGGCAGACTTCAAGAGTCTCAGACTGAGGAGAAAGCCTTTCCTTCTGCT 
 196 GCTACTGCTGCTGCCGCTGCTTTTGAAAGTCCACTCCTTTCATGGTTTTTCCTGCCAAAC 
 256 CAGAGGCACCTTYGCTGCTGCCGCTGTTCTCTTTGGTGTCATTCAGCGGCTGGCCAGAGG  
 316 ATGAGACTCCCCAAACTCCTCACTTTCTTGCTTTGGTACCTGGCTTGGCTGGACCTGGAA 
 376 TTCATCTGCACTGTGTTGGGTGCCCCTGACTTGGGCCAGAGACCCCAGGGGACCAGGCCA 
 436 GGATTGGCCAAAGCAGAGGCCAAGGAGAGGCCCCCCCTGGCCCGGAACGTCTTCAGGCCA 
 496 GGGGGTCACAGCTATGGTGGGGGGGCCACCAATGCCAATGCCAGGGCAAAGGGAGGCACC 
 556 GGGCAGACAGGAGGCCTGACACAGCCCAAGAAGGATGAACCCAAAAAGCTGCCCCCCAGA 
 616 CCGGGCGGCCCTGAACCCAAGCCAGGACACCCTCCCCAAACAAGGCAGGCTACAGCCCGG 
 676 ACTGTGACCCCAAAAGGACAGCTTCCCGGAGGCAAGGCACCCCCAAAAGCAGGATCTGTC 
 736 CCCAGCTCCTTCCTGCTGAAGAAGGCCAGGGAGCCCGGGCCCCCACGAGAGCCCAAGGAG 
 796 CCGTTTCGCCCACCCCCCATCACACCCCACGAGTACATGCTCTCGCTGTACAGGACGCTG 
 856 TCCGATGCTGACAGAAAGGGAGGCAACAGCAGCGTGAAGTTGGAGGCTGGCCTGGCCAAC 
 916 ACCATCACCAGCTTTATTGACAAAGGGCAAGGTGAGGGGGCGGGGTGGCAGGGGCACGG 
Figure 1.3 
The sequence of a section of the GDF5 gene: Exon 1 (highlighted in red) and flanking 
sequence of the GDF5 gene. Numbering is relative to the transcription start site. The 
two polymorphisms rs143383 (+41bp) and rs143384 (+268bp) are highlighted in green 
and blue respectively, Y, C/T. The ATG methionine start codon is highlighted in yellow 
and underlined.  
 
1.9.2 Mode of Action of GDF5 
As for most BMPs, GDF5 is an intermolecular disulphide-bonded protein dimer, and 
features seven highly conserved cysteine residues in the carboxy-terminal region. Six of 
these conserved cysteines are present in the core of the monomer protein forming a 
cysteine knot, a seventh cysteine forms an intermolecular disulphide bond with the 
corresponding cysteine in the second monomer [214]. Once assembled, the large 
dimeric precursor protein (consisting of a 495 amino acid protein, preceding an 120 
amino acid mature C terminal polypeptide) is then cleaved at an RXXR site (Arg, X, X, 
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Arg) by a protein from the pro-protein convertase family. The biologically active 
mature dimer is secreted and signals through its mature domain [215].   
GDF5 binds to BMP receptors as described earlier for BMPs (section 1.8). GDF5 
signals specifically through a heteromeric complex of BMP receptor II and BMP 
receptor IB (Alk 6). ActR-II may also serve as a type II receptor for GDF5 in some cell 
types [216]. GDF5 binds first to the type II receptor, which phosphorylates the type I 
receptor and subsequently transduces the signal by phosphorylating and thus activating 
signalling cascades such as SMAD and MAPK signalling pathways. GDF5 activates the 
transcription of genes involved in the formation of cartilage and bone, such as COL2A1 
(encoding collagen type II), AGC1 (encoding aggrecan) and SOX9 (encoding the 
transcription factor SOX-9) [217] (Figure 1.4). 
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Figure 1.4  
A schematic diagram of the GDF5 signalling cascade: The GDF5 gene region is shown 
and contains two exons. GDF5 protein forms homodimers which bind to the BMP 
receptor II and BMP receptor IB. Binding promotes receptor phosphorylation which 
subsequently leads to the phosphorylation and thus activation of SMAD signalling. 
SMADs 1, 5 and 8 in combination with SMAD4 relay the signal to the nucleus where 
the transcription of target genes such as COL2A1 (collagen type II), ACAN (aggrecan) 
and COL10A1 (collagen type X) is activated. Figure modified from [218].  
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The binding profiles of GDF5 were found to be limited in comparison to BMP2, BMP4 
and BMP7, suggesting that GDF5 has different biological functions compared to a 
number of the previously identified BMPs. Furthermore, the expression profile of the 
BMP receptor IB is more limited compared to that of BMP receptor IA, suggesting a 
more restrictive function of GDF5 during development [216]. 
1.9.3 Role of GDF5 during Development   
GDF5 is essential for the formation of cartilaginous tissues during early limb 
development [210, 219, 220]. During joint specification GDF5 can be used as a marker 
for the site of joint formation due to its early presence within the joint space [212]. 
GDF5 is expressed in the condensing mesenchyme prior to joint development and later 
in development it can be detected in the early perichondral layer around the cartilage 
elements and in the joint interzone. The expression of GDF5 is down-regulated as the 
joint cavitates [221]. GDF5 expression can be detected in early postnatal cartilage and 
has been detected in adult bovine and in healthy and osteoarthritic adult human articular 
cartilage [219, 220, 222].  
GDF5 increases the numbers of mesenchymal cell condensations and mesenchymal 
aggregation, and increases cartilaginous nodules in mouse and rat embryonic limb bud 
mesenchymal cells [215, 221]. In chick limb bud, the over expression of GDF5 
increased the size of the early cartilage condensation, increased chondrocyte 
proliferation in the later stages of skeletal development and, overall, increased the 
length of the skeletal elements [221]. Furthermore, using adult bone marrow derived 
MSCs it has been shown that treatment of cells in vitro with recombinant GDF5 
promotes increased expression of collagen type II and sulphated glycosaminoglycans 
(GAGs), indicating enhanced chondrogenic differentiation. Additionally, there were 
increased levels of phosphorylated SMADs 1, 5 and 8 [223].  These gain of function 
studies have provided an insight into the key role of GDF5 during two distinct stages of 
development, first to control mesencyhmal cell recruitment and condensation and 
secondly in the joint interzone to control the growth of adjacent skeletal elements by 
controlling chondrocyte proliferation.  
In addition to effects on chondrogenesis and synovial joint formation, GDF5 also affects 
endochondral ossification, with GDF5 deficiency in the bp mice resulting in shortened 
long bones, and the absence of GDF5 has been suggested to affect the duration of the 
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chondrocytes hypertrophic phase. Furthermore, GDF5 deficient bones are significantly 
weaker than control bones and  more compliant when tested to failure in torsion [224]. 
GDF5, GDF6 and GDF7 have also been suggested to play a role in tendon and ligament 
formation [225]. GDF5 has been found to induce the osteogenic differentiation of 
human ligament cells through the activation of ERK1/2 and p38 MAPK. It is present at 
ossified sites, and treatment with recombinant GDF5 increases the expression of 
alkaline phosphatase and osteocalcin [226]. However, this effect on osteogenic factors 
appears to be more discrete when compared with BMP7 or BMP2. In the osteoblastic 
MC3T3-E1 cell line, in contrast to the positive effect of BMP2, GDF5 did not increase 
alkaline phosphatase activity [215]. 
In human mesenchymal stem cells GDF5 treatment was shown to enhance osteogenesis 
in vitro and in vivo, upregulating COL1A1 (Collagen type 1A1), ALPL ( alkaline 
phosphatase), and OSTCN (osteocalcin) mRNA [227]. Another study found that GDF5 
stimulated early osteoblastic differentiation, enhancing expression of the homeobox 
proteins MSX1 and MSX2 in addition to Runx2 and osteocalcin [228]. GDF5 has also 
been shown to enhance angiogenesis in both chick chorioallantoic membrane and rabbit 
cornea assays [229].  
1.9.4 Human Conditions Associated with GDF5 
The importance of GDF5 during the development of the joints is evident from the 
phenotypes associated with mutation of GDF5, its receptors or within the antagonists 
controlling its function. Mutations within the GDF5 gene have been associated with a 
spectrum of human conditions including Hunter-Thompson and Grebe type 
acromesomelic chondrodysplasias and DuPan syndrome, in addition to brachydactyly 
type C (BDC).  
Hunter Thompson type acromesomelic chondrodysplasia is characterised by skeletal 
abnormalities that are restricted to the limbs and has a similar phenotype to the bp 
mutation. A frameshift mutation within the GDF5 gene was found to be the cause of the 
phenotype and represented the first mutation found in a TGFβ family member causing a 
human disorder [230]. Grebe type acromesomelic chondrodysplasia (GCD) is a severe 
autosomal recessive condition characterised by limb shortening and appendicular bone 
dysmorphogenesis. Several mutations in GDF5 have been associated with this 
condition; an insertion of a C nucleotide at position 297 in the coding sequence of 
GDF5 was found in a cohort of patients, an insertion of a G at position 206 was found 
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in an affected boy and a novel four base insertion was found in an affected family. All 
three mutations caused a shift in the reading frame and premature termination resulting 
in total loss of function [231-233].  
Du-Pan syndrome is an autosomal recessive trait that is characterised by fibular 
hypoplasia and complex brachydacyly. Affected individuals have reductions in the size 
of or absence of limb bones and appendicular bone dysmorphogenesis. Hunter-
Thompson and Grebe type chondrodysplasias are phenotypically similar to Du-Pan 
syndrome and thus the GDF5 gene was investigated as a possible source of the Du-Pan 
causative mutation. A mutation within the GDF5 gene, causing a substitution in the 
mature domain of the protein was found. This mutation resulted in a conformational 
change in the protein structure and thus affected protein function. Individuals 
heterozygous for this mutation were unaffected [234].  
The condition brachydactyly is characterised by a shortness of the fingers and toes. A 
number of mutations within GDF5 have been associated with bracydactyly. Its 
association was first discovered through the investigation of a family with 
brachydactyly type A2 (BDA2), characterised by a shortening of the phalanges of the 
index finger and second toes.  A genetic analysis revealed that these individuals had a 
mutation within the processing site of GDF5. The effect of this mutation, consisting of 
an arginine to glutamine substitution, was investigated in chicken micromass cultures. 
The mutation was found to interfere with the processing of the pro-protein, thus 
significantly reducing the amount of biologically active GDF5 [235]. Furthermore, a 
missense mutation within the coding region of GDF5, Arg388Cys, has been found to 
cause brachydactyly type A1 (BDA1). This mutation is semidominant, with patients 
who are heterozygous for this polymorphism being mildly affected, however those who 
are homozygous present with severe brachydactyly [236] .  
Brachydactyly type C (BDC), characterised by shortening of the middle phalanges of 
the index, middle and little finger has been associated with mutations within GDF5 
[237, 238]. A novel missense mutation has been identified within the pro-domain 
region of the gene resulting in the BDC phenotype, a mild shortening of the metacarpals 
was observed in heterozygous carriers demonstrating the semidominant nature of this 
mutation [239].  
Mutations within the BMP receptor IB receptor are commonly associated with BDA2, 
but have been associated with BDC and a symphalangism-like phenotype [240, 241]. 
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Furthermore, a mutation within the GDF5 gene causing inhibition of the ligand-BMP 
receptor IB interaction resulted in a BDA2 phenotype [242]. A mutation in GDF5 
within the BMP receptor II interaction site was identified in patients who were suffering 
from multiple synostosis syndrome (SYNS), an autosomal dominant disorder 
characterised by progressive symphalangism, deafness and mild facial dysmorphism. 
This mutation caused impaired binding to the receptor but also resulted in resistance to 
Noggin, causing enhanced GDF5 action [243].  
Mutations within the BMP inhibitor Noggin have previously been found in patients with 
SYNS and brachydacyly type B (BDB), characterised by terminal deficiency of the 
fingers and toes [244]. Activating mutations in GDF5 have now also been associated 
with SYNS. These mutations disrupt noggin binding, leading to noggin resistance and 
altered signalling, causing an increase in chondrogenic activity and an induction of 
cartilage formation in an in vivo chick model [242, 245, 246]. These studies 
demonstrate that both decreased and increased expression of GDF5 can lead to 
abnormal joint development and thus regulation of the expression of this factor is vital. 
1.9.5 Mouse Models of gdf5 Mutation 
As described, mutations within GDF5 have been reported to be the cause of a number 
of skeletal conditions in humans. In mice however, far fewer mutations have been found 
within gdf5. The loss of function bp mouse was described previously, and presents with 
abnormalities of the digits and reduced length of long bones. Transgenic mice have also 
been investigated, with the gdf5 gene under the control of the type II collagen promoter. 
These mice exhibited chondrodysplasia, with expanded cartilage consisting of a reduced 
proliferative and increased hypertrophic zone of chondrocytes [247].  
Further investigations sought to investigate in more depth the role of gdf5 in 
development. The first of these studies used the chemical N-ethyl-N-nitrosourea (ENU) 
to induce mutations randomly in genomic DNA [248]. Following this treatment, mice 
were then screened for abnormal limb phenotypes transmitted as dominant traits and a 
mutant line that exhibited a brachypodism phenotype was identified. The mutation was 
within gdf5 and was present in the BMP receptor I interaction domain. The protein 
dimerised and was secreted normally, but was unable to activate SMAD signalling, and 
acted in a dominant negative manner through hetero-dimerisation with wild type gdf5 
[248] . These aforementioned studies have focused on the effects of loss of gdf5 activity 
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in mice and are therefore comparable with the conditions in humans associated with the 
loss of GDF5 activity. ` 
A second study examined the effect of gdf5 hypomorphism in mice heterozygous for the 
bp mutation and examined susceptibility of these mice to developing an OA like 
phenotype [249]. These mice show no apparent skeletal abnormalities and grow 
normally, and the length of their long bones is comparable with the wild type (WT) 
mice. Additionally, there were no differences in BMD or bone area, although a 
significantly decreased trabecular area was observed in the long bones of the 
heterozygous mice compared to the WT mice. The effect of gdf5 haploinsufficiency on 
the development of OA was assessed using four different mouse models: collagen 
induced arthritis (CIA), treadmill model, meniscus destabilisation model and papain-
induced arthritis. Although no difference in cartilage damage between the WT and 
heterozygous mice was observed in the collagenase injected knees, the contralateral 
knees of the heterozygotes showed increases in synovial hyperplasia, capsule fibrosis 
and the number of osteophytes. These effects were thought to be secondary effects, a 
result of increased load of the unchallenged knee. Furthermore, in the treadmill model a 
significantly increased score for synovial hyperplasia was found in the heterozygous 
mice compared to the WT mice, and an increase in capsule fibrosis was also noted. No 
differences between WT and heterozygous mice were observed in the other two models 
tested. Gait analysis revealed that heterozygous mice had a decreased stride length 
compared to WT mice suggesting that joint stability may be mediating changes in load 
on the joint. A reduction in gdf5 expression in these mice therefore appeared to mediate 
increased susceptibility to OA like changes in the CIA and running model, a result of 
altered gait and loading. Furthermore, changes in the subchondral bone and collagen 
fibre orientation were observed in heterozygous mice [249].  
Other studies have examined the effect of gdf5 mutation on the development of tendons 
and ligaments; bp mice show anterior dislocation, hypoplastic condyles and absence of 
intra-articular ligaments. These changes may be a result of excessive mesenchymal cell 
death that was observed in the future knee joint of these mice [250].  Furthermore, gdf5 
deficiency was shown to alter the ultrastructure, mechanical properties and composition 
of the Achilles tendon compared with heterozygous littermates. The tendons in the 
deficient mice were structurally weaker, contained less collagen and had a smaller 
diameter. These findings suggested that joint dislocations that are associated with GDF5 
deficiency may be due to changes in tendon and ligament laxity [251]. Mice deficient in 
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gdf5 have also been reported to show delayed fracture healing in the early phases of 
bone repair compared with WT mice, although long term fracture healing was 
unaffected [252].  
1.9.6 Therapeutic Use of GDF5 
Considering the vital role of GDF5 during the formation of the joint, its use 
therapeutically has been considered. Chondrocytes derived from both human adult 
healthy and osteoarthritic cartilage were responsive to GDF5; GDF5 stimulated the 
metabolic activity of chondrocytes, increasing proteoglycan synthesis in a cartilage 
explant model [222]. 
Models of animal injury have been used to investigate the use of GDF5 therapeutically. 
The first of these investigated the use of GDF5 following injury to tendons and 
ligaments; GDF5 treated tendon tissue specimens were thicker, with a higher strength 
and had increased collagen type II expression [253]. Additionally, another study 
examined the cellular and molecular response to GDF5 on Achilles tendon fibroblasts 
following recombinant GDF5 treatment; glycosaminoglycan (GAG), hydroxyproline 
(HYP) and total DNA content were increased. GDF5 treatment increased cell 
proliferation and ECM synthesis as well as the expression of a number of genes [254, 
255].  The effect of GDF5 on tendon healing was enhanced when GDF5 was added 
alongside bone marrow derived stem cells [256]. 
GDF5 was also found to have early beneficial effects on flexor tendon repair in a rabbit 
model, with a higher histological scoring of collagen in the GDF5 treated animals [257]. 
Furthermore, the combined use of bFGF and GDF5 enhances the healing of medial 
collateral ligament injury by increasing proliferation and expression of COL1A1 in 
rabbits [258].  
Due to the success of these experiments, researchers are now moving on to identify new 
methods for delivery of growth factors to sites in need of repair. Dines et al. have 
developed a method of suture coating in order to provide the delivery vehicle for the 
growth factor and have had success in coating sutures with recombinant GDF5 [255]. 
Cell migration, cell proliferation and collagen synthesis were all stimulated on treatment 
with recombinant GDF5 in rat tendon fibroblasts [255]. Additionally, stimulation with 
GDF5 can modulate primary adipose derived stem cells on an electrospun scaffold that 
mimics collagen fibre bundles in tendon tissue; GDF5 up-regulated the expression of 
genes encoding the major tendon ECM proteins and a neotendon marker [259]. 
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Aside from tendon and ligament healing properties, GDF5 expression has been 
demonstrated in non-degenerate and degenerate human inverterbral discs. Treatment of 
nucleus pulposus cells with GDF5 showed an increase in ACAN and COL2A1 gene 
expression and increased production of GAGs [260]. A recombinant human GDF5-
coated β-tricalcium phosphate graft has been shown to enhance bone formation in 
maxillary sinus lift augmentation procedures [261]. Finally, the use of GDF5 in spinal 
fusion models and in periodontal wound healing has also been investigated [262-265]. 
When considering the use of GDF5 therapeutically, the importance of controlled 
expression of GDF5 must be taken into account. GDF5 must be regulated both spatially 
and temporally for the correct development of the joint, with joint fusions being 
observed as a result of the injection of GDF5 into the joint space [266].  
1.10 rs143383 
Table 1.1 shows the population data available for the SNP. The T allele is the common 
allele in Caucasians and the two Asian populations shown, whilst CC homozygotes are 
uncommon in Caucasians and Asians. In the West African population however, the C 
allele only is present.  
Group Genotype Alleles 
CC CT TT C T 
European 0.117 0.433 0.450 0.333 0.667 
Han Chinese 0.047 0.349 0.605 0.221 0.779 
Japanese  0.023 0.442 0.535 0.244 0.756 
West African 1   1  
Table 1.1 
Genotype frequencies of rs143383: Frequencies of the rs143383 CC, CT and TT 
genotypes in addition to the C and T allelic frequency within different population 
groups. Population frequency information obtained from dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/).  
 
rs143383 is a C/T polymorphism within the 5ʹUTR of GDF5. As noted earlier, this 
polymorphism was first reported to be associated with OA in 2007 when it was 
demonstrated in a Japanese population to show significant association with hip OA. 
This association was reported as part of a  study that involved the sequencing of GDF5 
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in 24 individuals with hip OA [134]. Fifty two polymorphisms were identified and 31 
SNPs were chosen for further analysis based on minor allele frequencies of >0.10. The 
most significant association was observed for rs143383 (p= 3.1 x 10
-11
), with allelic 
frequencies of 83.6% (hip OA) and 74% (control) for the T allele. The odds ratio for the 
susceptibility allele was 1.79 and this effect was apparent following correction for 
confounding factors. This association was also replicated in a Japanese cohort with knee 
OA (718 knee OA patients and 861 controls), with an odds ratio of 1.3 (p = 0.00021), 
and subsequently in a Han Chinese cohort with knee OA (313 knee OA and 485 
controls), with an odds ratio of 1.54 (p = 0.00028),. The promoter activity of GDF5 was 
mapped to a 162 base pair region encompassing the polymorphism and it was therefore 
hypothesised that this SNP may affect transcription [134]. Further investigation 
demonstrated that the polymorphism was functional, with the susceptibility T allele 
showing a lower level of transcriptional activity compared to the C allele in three 
independent cell lines using luciferase reporter experiments. This study therefore 
suggested that a reduction in the expression of GDF5 can increase susceptibility to OA 
[134].  
A number of other groups replicated this association in different ethnic populations and 
further investigated the functional effect of the T allele. The association was first 
replicated at the genotype level, allele level and when carriers were combined (TT + 
CT) in a European cohort in 2007. This analysis was performed using 2487 cases with 
knee, hip and hand OA and 2018 controls, from both the UK and Spain [267]. In the T 
allele carrier analysis, the knee, hip, and knee and hip cases were all significant 
(p<0.05) with odds ratios greater than 1, whereas cases of hand OA were not 
significantly associated. The unstratified odds ratios were not as high as those observed 
in the Asian study (1.10 compared to 1.79). This suggests that the rs143383 SNP is not 
as major a susceptibility locus in Europeans, and that differences between ethnic groups 
may impact on the effect of the risk allele [267].  
The functional effect of the SNP was further assessed in this study using in vivo allelic 
expression analysis. This analysis used RNA extracted from the cartilage of OA patients 
and enabled the quantification of the expression of the two alleles in heterozygotes. The 
two alleles were normalised to an assumed genomic DNA ratio of 1:1. It was discovered 
that the T allele showed a reduction in the expression of GDF5 in comparison to the C 
allele. The average allelic difference observed in these patients was a 27% reduction in 
the expression of the T allele relative to the C allele. This alteration in gene expression 
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is found in patients with severe disease undergoing joint replacement surgery. Although 
only a small change is observed, over a prolonged period of time this reduced 
expression may render individuals more susceptible to developing OA [267]. 
A Greek study however reported no association of the rs143383 T allele with OA 
following the genotyping of 519 Greek Caucasian cases and controls (p>0.05) [268]. 
There are two possible explanations for this result: firstly, and as just touched on, this 
polymorphism may have differential effects in different populations and secondly it 
may be a result of the small sample size used. In this regard it is worth noting that 
within the original European study, alone the UK and Spanish cohorts did not detect 
significant associations between  rs143383 genotype and OA, however when combined, 
these two cohorts showed a significant association. A meta analysis combining the data 
from the Asian and European studies with new data from the UK and the Netherlands 
provided strong evidence of this polymorphisms association with knee OA, implying 
the second explanation may be the reason for the lack of association in the Greek cohort 
(p = 0.0004 for the allele frequency model) [269]. 
rs143383 was not directly targeted by the GWAS, however, a recent study that directly 
targeted rs143383 has demonstrated an association of the T allele with knee OA with 
genome wide statistical significance (p=6.2 x 10
-11
): 6861 knee OA cases and 10103 
controls of European descent and 718 cases and 1844 controls of Asian descent were 
combined and the T allele was shown to be associated with a 17% increased risk of knee 
OA (OR 1.17).  There was no significant heterogeneity seen between studies [270].  
The importance of this locus as a risk factor for knee OA has been reproducibly 
demonstrated, however, for hip and hand OA a significant association has not been 
demonstrated (statistical significance was borderline for OA of the hip and absent for 
hand OA) with a large amount of inter-study heterogeneity being observed [148].  It has 
been noted that extremely large sample sizes are needed in order to assess the 
association of common genetic variants with multifactorial diseases, which may only 
mediate modest effects, as with OA. Furthermore, as I previously discussed, a 
standardised approach for grading OA radiographically is needed as differences in the 
radiographic assessment of OA in these studies may introduce heterogeneity [148]. 
 In order to assess whether rs143383 is associated with increased severity of OA of the 
knee, cases of knee OA were genotyped for rs143383 and their tibiofemoral K/L grade 
and patellofemoral grade was assessed following adjustments for age, gender and BMI. 
41 
 
The T risk allele is associated with a significantly higher tibiofemoral K/L grade 
suggesting that reduced expression of this chondroprotective factor influences the extent 
of radiographic damage. This effect could be a result of GDF5 influencing biological 
processes involved in joint damage, repair or the age of onset of the disease [271].  
Following the discovery that the rs143383 T allele mediated a reduction in the 
expression of GDF5 relative to the C allele in vivo in patient cartilage samples, our 
research group further assessed the extent of this differential allelic expression. OA is 
characterised by changes in a number of tissues of the joint, thus allelic expression 
analysis was performed using rs143383 on a variety of tissues taken from the knee and 
hip joints of OA patients. The effect of this polymorphism was found not just to be 
restricted to cartilage, but a reduced expression of the T allele was evident joint wide in 
the synovium, meniscus, ligament, tendon and fat pad of patients with OA [272].  
1.10.1 rs143383 and Other Conditions 
In addition to being associated with OA, the rs143383 T allele also correlates with 
reduced height in both males and females [273]. This study highlights that the 
functional effect of rs143383 is not only evident in adult life, predisposing individuals 
to OA, but its effect is also apparent in development, leading to variation in height. A 
reduction in the expression of GDF5 may influence cartilage composition, limb 
proportions or joint angles, which may therefore affect stature in addition to 
susceptibility to OA. Furthermore, the CC homozygotes had a larger hip axis length and 
were at increased risk of developing non vertebral fractures in comparison to CT 
heterozygotes or TT homozygotes, suggesting that there may be differences in bone 
composition between genotype groups, although no effect on bone mineral density was 
reported [274].  
The T allele of rs143383 has also been found to increase susceptibility to other 
musculoskeletal disorders including Achilles tendon pathology, congenital hip dysplasia 
and lumbar disc disease. Genotyping of 171 cases and 235 controls revealed that 
individuals with a TT genotype at this locus have twice the risk of developing Achilles 
tendon pathology, with an odds ratio of 2.24  [275]. This condition occurs as a result of 
excess mechanical loading or repetitive loading leading to damage of the Achilles 
tendon. Additionally, in GDF5 deficient mice, tendons were found to contain less 
collagen and were much weaker [251]. CDH is a common congenital skeletal 
abnormality, characterised by abnormal positioning of the femoral head in the 
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acetabulum.  [276].   CDH is a strong risk factor for the development of hip OA and has 
been shown to have a large genetic component. Some patients with BDC also present 
with dysplasia of the hip, hence the investigation of GDF5 as a candidate gene for 
CDH. 960 cases and 622 controls of Han Chinese origin were genotyped for rs143383, 
revealing an association of the T allele with CDH in women, with an odds ratio of 1.4. 
This association was not significant in males. Furthermore, when stratified by severity, 
a significant increasing linear trend was observed when comparing the T allele 
frequency with worsening CDH severity [276].  
Lumbar disc disease (LDD) is a major cause of back pain via the development of 
degenerate discs. LDD is known to have a genetic component and a number of loci have 
been tested for association using a candidate gene approach. An association with the T 
allele of rs143383 and LDD in women was reported, with an odds ratio of 1.72 
following genotyping of five Northern European cohorts [277]. This increased risk of 
LDD development in T allele carriers is thought to be mediated either directly by 
affecting the disc itself or indirectly by affecting periarticular structures [277].  
Overall, these studies suggest that GDF5 is crucial during development and the presence 
of the rs143383 polymorphism within GDF5, which affects gene function, can 
predispose individuals to a variety of skeletal abnormalities. They also highlight the 
pleiotropic nature of rs143383; the T allele has been associated with several different 
phenotypes, owing to the fact that GDF5 has a number of functions and is expressed in 
different cell types at various stages of development.  
1.11 Transcription 
Transcription is the production of RNA in a DNA dependent manner, this process is 
carried out by RNA polymerases. Three different types of this enzyme exist in 
eukaryotes and act on different sets of genes. RNA polymerase II transcribes the genes 
encoding proteins in addition to some of the small nuclear RNAs involved in RNA 
splicing.  
There are a number of proteins involved in transcriptional regulation, including proteins 
that associate with RNA polymerase II during transcriptional activation and these 
proteins are essential for the assembly of the stable transcriptional complex [278, 279]. 
RNA polymerases lack sequence specific recognition ability and thus these additional 
proteins are necessary to form an initiation complex. There are three classes of proteins 
known as general transcription factors that associate with RNA polymerase II to aid 
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transcriptional initiation: TATA binding protein associated factors (TAFs), mediator 
and upstream stimulatory activity (USA) derived cofactors [280]. Additionally, general 
cofactors and site specific transcription factors such as activators and repressors can 
bind and modulate the activity of the polymerase. 
The core promoter of a gene is usually located just upstream of the transcription start 
site and genes can be characterised based on the presence of specific DNA elements 
within the core promoter (core promoter elements). An examples of such a core 
promoter element is the TATA box, an AT rich sequence located just upstream of the 
transcription start site which has a consensus sequence of TATA(A/T)A(A/T)(A/G) 
(genes can be classified as TATA-containing or TATA-less promoters) [281, 282]. In 
genes with promoters that lack the TATA sequence, other core promoter elements such 
as an initiator (Inr), containing a pyrimidine rich sequence can direct transcription 
initiation either alone or in conjunction with other core promoter elements.  
Promoter analysis of the eukaryotic promoter database and the database of human 
transcriptional start sites has found that less than 22% of human genes contain a TATA 
box, 62% of which have an Inr, 24% of which have a downstream promoter element 
(DPE) and 12% have an upstream TFIIB recognition element (BRE
u
). Among the 
TATA less promoters, 45% have an Inr, 25% a DPE and 28% have a BRE
u  
[283]. 
The TATA site is recognised by a subunit of TFIID, which binds first to DNA and is 
facilitated by TFIIA. TFIIA binds to TFIID and stimulates its activity by overcoming 
inhibitory factors;  TFIID is associated with inhibitory factors which prevent its binding 
to DNA [284].  TFIIA also acts as a coactivator by linking DNA bound activators with 
the basal transcription complex.  Following the binding of TFIID and TFIIA, TFIIB 
binds to TFIID. TFIIA and TFIIB help to stabilise promoter bound TFIID. TFIIB also 
binds to RNA polymerase II and so is essential in the formation of the basal complex. 
RNA polymerase II is pre-associated with TFIIF, both of which bind to the complex. 
Finally, the binding of TFIIE, TFIIH and TFIIJ finalises the pre initiation complex 
(PIC) [282]. TFIIH has helicase activity and is therefore involved in unwinding the 
double-stranded DNA ready for transcription creating an open complex. In addition, 
TFIIH has kinase activity and phosphorylates RNA polymerase II at the C terminal 
domain (CTD) initiating transcription. During transcription, TFIIF remains associated 
with RNA polymerase, whilst TFIID and TFIIA remain bound to the promoter enabling 
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repeated rounds of transcription [278]. This sequential binding of factors is known as 
the sequential assembly pathway. 
Transcriptional activity resulting from the binding of general transcription factors alone 
is usually low and is increased following the binding of site specific factors to proximal 
promoter regions. The proximal promoter region is usually located close to the core 
promoter and factors binding to it can help recruit general transcription factors or 
stabilise the PIC. In addition, there are cis acting sequences which regulate gene 
expression from distal regions such as enhancers, silencers and insulators. Enhancer 
elements can further stimulate transcription by binding a multiprotein complex, known 
as the enhanceosome, which activates transcription and can recruit chromatin 
remodelling proteins. Proteins binding to enhancers can also promote looping out of the 
DNA in order to bring transcription factors binding at distal regions within close 
proximity of transcription factors at the core promoter or at another site. Silencing 
elements bind factors that decrease transcriptional activity by either inhibiting RNA 
polymerase activated transcription or by recruiting histone modifying complexes to 
create repressive chromatin structures [278]. In homo sapiens it has been estimated that 
there are between 200-300 general transcription factors that bind to the core promoter 
elements, including the subunits of RNA polymerase II. Additionally, there are 1,400 
factors that bind to DNA in a sequence specific manner, these factors have either very 
broad (present in all or most tissues) or specific (present in one or two tissues) functions 
[285].  
Alterations in gene expression as a result of the aberrant levels or altered structure or 
function of transcription factors underlies the pathology of a number of diseases, with 
genes encoding transcription factors accounting for more than 30% of the genes 
associated with malformation phenotypes [286]. For genes whose expression is highly 
regulated, such as those involved in development or cell cycle progression, aberrant 
expression of transcription factors could cause problems during development and could 
increase susceptibility to diseases such as cancer. The identity of the transcription 
factors binding to and regulating such important genes must therefore be studied to 
expand our understanding of gene regulation within both normal and disease states, and 
to provide the potential for the development of novel preventative or treatment 
strategies.  
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1.11.1 Differential Allelic Expression (DAE) 
There are two broad categories of mutation/polymorphisms; in general, rare mutations 
that are highly deleterious cause mendelian diseases, whilst common polymorphisms 
are often associated with complex, multifactorial diseases. SNPs that alter gene 
expression levels are referred to as expression Quantitative Trait Loci (eQTLs) [287]. 
Cis-regulatory variation in humans is extensive, with around 40% of genes in an 
individual estimated to be heterozygous at functional cis-regulatory sites. The 
investigation of SNPs that are located within regulatory regions can be difficult 
compared with investigating SNPs in protein coding regions due to the large size of 
regulatory regions and the variability in their localisation from the transcriptional start 
site [288, 289]. Furthermore, the action of cis-regulatory elements has been shown to be 
context specific, so may be difficult to identify in a single tissue or cell type [290-292]. 
Although this research may be challenging, these sites need to be investigated further as 
it is likely that they are mediating individual’s susceptibility to developing common 
complex disorders.  
In order to assess the effect of a cis-regulatory polymorphism, the allelic output from 
the gene can be measured. The assumption here being that in the absence of a cis-
regulatory polymorphism, both alleles will contribute an equal amount of transcript. 
Where a differential level of expression between the two alleles is seen, the gene is 
described as showing DAE (Figure 1.5).When DAE is present, an individual is likely to 
be heterozygous at a cis-regulatory site that is responsible for the transcription of the 
gene, for the processing of the mRNA (e.g. within a splice site), or for mRNA stability 
[293]. This is the case for the GDF5 rs143383 SNP described previously, where there is 
a lower level of expression of the T allele relative to the C allele. The relative number of 
genomic DNA molecules for each allele is first determined and compared with the 
number of mRNA molecules. It is likely that polymorphisms present within the 
promoter region of a gene may alter expression of the gene by affecting DNA binding 
proteins with a role in transcription, whereas polymorphisms that are present within the 
3ʹUTR of genes are more likely to affect transcript stability. It has been estimated that 
around 20-50% of genes show DAE dependent on the method used for detection [294, 
295].  
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Figure 1.5 
Differential allelic expression. A: A balance of allelic expression, with both the C and T 
allele expressing equal amounts of mRNA transcript. The two alleles have identical 
amplification curves assessed by real time PCR. B: Differential allelic expression, with 
one of the two alleles expressing a differential level of mRNA transcript; there is a 
decreased level of expression of the T allele relative to the C allele. The T allele is 
identified at a higher cycle threshold by real time PCR.  
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Summary 
Osteoarthritis (OA) is a highly prevalent, chronic, complex disease which causes pain 
and significant dysfunction. OA is characterised primarily by a degeneration of articular 
cartilage, however a number of tissues within the synovial joint show disease related 
changes. Current therapeutic options are limited to pain relief and surgery.  
OA occurs as a result of both genetic and non-genetic factors. OA is polygenic; many 
susceptibility alleles contribute to disease aetiology, each with varying individual 
effects. A number of polymorphisms have now been associated with OA through a 
variety of genetic approaches, with one of the most robust to date being rs143383 within 
the 5ʹUTR of GDF5. The T allele of this SNP produces less mRNA transcript in 
comparison with the C allele, and has been found to influence OA susceptibility across 
a range of ethnic groups. 
GDF5 is an important growth factor that has been extensively characterised, revealing 
its many distinct functions within the body. GDF5 is essential in the joint during 
development with mutations causing a range of skeletal phenotypes in both mice and 
humans.  
Functional analysis of OA associated loci will further enhance understanding of the OA 
disease process and could potentially provide targets for disease modifying drugs.  
 
Aims 
 To identify a cell line that expresses GDF5, is heterozygous for rs143383 and 
demonstrates GDF5 DAE to provide a model system for in vitro manipulation.  
 To identify factors binding differentially to the C and T alleles of rs143383.  
 To modulate the expression of the identified factors to assess their regulation of 
GDF5.  
 The overall goal of this research is to identify new targets which can be 
manipulated to normalise the expression of GDF5 within T allele carriers and 
ultimately provide a novel therapeutic strategy to benefit OA patients. 
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Chapter 2: Materials and Methods 
2.1 Cell Line Culture 
For the purposes of this research, three different cell lines were used; the human 
liposarcoma cell line, SW872, initiated from a surgical specimen of a fibrosarcoma 
taken from a 36 year old male Caucasian, the human chondrosarcoma cell line, 
SW1353, taken from the humerus of a 72 year old female Caucasian, and finally the 
human osteoblast cell line, MG63, taken from a 14 year old male Caucasian.  
2.1.1 Method 
The cells were cultured in their respective culture medium (shown below) in vented 
T75cm
2 
flasks (Corning, UK) at 37°C in a 5% (v/v) CO2 atmosphere until they reached 
70-80% confluency.  
2.1.2 Medium 
- SW872: Dulbeccos modified eagles medium: Hams F12 Glutamax medium in a 
3:1 ratio (GIBCO, Invitrogen, Life Technologies, Paisley, UK) containing 5% 
(volume/volume (v/v)) fetal bovine serum (FBS), 100U/ml penicillin and 
100µg/ml streptomycin (Sigma-Aldrich, Dorset, UK). 
- SW1353: Dulbeccos modified eagles medium: Hams F12 medium in a 1:1 ratio 
(GIBCO) containing 10% (v/v) FBS, 100U/ml penicillin, 100µg/ml 
streptomycin and 2mM of L-glutamine (Sigma-Aldrich).  
- MG63: Dulbeccos modified eagles medium (GIBCO) containing 10% (v/v) 
FBS, 100U/ml penicillin, 100µg/ml streptomycin and 2mM of L-glutamine 
(Sigma-Aldrich).  
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2.2 Human Articular Chondrocyte (HAC) Culture  
2.2.1 Cartilage Sample Collection 
Human articular cartilage samples were obtained from patients with osteoarthritis 
undergoing total hip or total knee replacement surgery at the Freeman Hospital, 
Newcastle upon Tyne. Ethical approval and informed consent were obtained prior to 
surgery. Prior to extraction, samples were stored in Hank’s Balanced Salt Solution 
(HBSS) supplemented with Penicillin, Streptomycin and Nyastatin at 4°C.  
2.2.2 Reagents: 
- HBSS containing 200 IU/ml penicillin, 200µg/ml streptomycin and 40 IU/ml 
Nystatin 
- DMEM culture medium containing 10% (v/v) FBS, 2mM L-glutamine, 200 
IU/ml penicillin, 200µg/ml streptomycin and 40 IU/ml Nystatin. 
- Hyaluronidase (1 mg/ml in phosphate-buffered saline (PBS), 5ml/g cartilage) 
- Trypsin (2.5mg/ml in PBS, 5ml/g cartilage) 
- Collagenase (2.5mg/ml in DMEM containing 10% FBS, 3ml/g cartilage) 
 
2.2.3 Digestion and Culture  
After the articular cartilage was removed with a scalpel and cut into small sections, 
articular chondrocytes were extracted from the ECM by the sequential addition of 
digestive enzymes. The cartilage was first incubated in Hyaluronidase (to digest 
hyaluronan) for 15 minutes at 37°C. Following washing in PBS, Trypsin (to digest 
aggrecan) was then added for 30 minutes at 37°C. Finally, following PBS washes, the 
cartilage was incubated with collagenase at 35.5°C overnight. Following digestion, the 
cartilage sample was passed through a 100µm cell strainer (BD Biosciences, Oxford, 
UK) and cells were pelleted using a desktop centrifuge at 130g for 5 minutes. The 
media containing collagenase was removed; the cell pellet was washed in PBS and 
centrifuged as before. Finally, the cell pellet was resuspended in culture media as 
described above. HACs were seeded at a density of 40,000 cells/cm² and when 80-90% 
confluent, cells were harvested for nuclear protein extraction. 
  
50 
 
2.3 Whole Protein Extraction 
2.3.1 Reagents 
Cell Lysis Buffer - 50mM Tris, 10% (v/v) glycerol, 50mM NaF, 1mM EGTA, 1mM 
EDTA, 10mM glycerol phosphate, 1% (v/v) Triton X-100, 1x complete inhibitor 
cocktail, 1µM microcystin-LR and 1mM Na3VO4 
2.3.2 Method 
Cells were harvested at the relevant time points, washed twice and scraped using an 
18cm cell lifter (Corning) into ice cold PBS. The cell lysate was centrifuged at 4°C at 
11,000g for 5 minutes using a microcentrifuge. The cell pellet was resuspended in 30µl 
of cell lysis buffer and left on ice for 20 minutes. Lysates were centrifuged again at 
11,000g at 4°C for 10 minutes and protein supernatants containing whole cell protein 
were stored at -80°C. 
2.4 Nuclear Protein Extraction 
Two buffers were used for the preparation of nuclear extract: 
2.4.1 Hypotonic Buffer 
10mM HEPES, pH 7.6, 1.5mM MgCl2, 10mM KCl, 1mM DTT, 10mM NaF, 1mM 
Na3VO4, 0.1% Tergitol (v/v), 1x complete protease inhibitor cocktail tablet per 50mls 
solution (Roche, Welwyn, UK).   
2.4.2 High Salt Buffer  
20mM HEPES, pH 7.9, 420mM NaCl, 20% glycerol (v/v), 1mM DTT, 10mM NaF, 
1mM Na3VO4, 1x complete protease inhibitor cocktail tablet per 50mls of buffer 
(Roche).  
2.4.3 Method 
Cells were seeded on 500cm
2 
cell culture dishes (Corning), when 70-80% confluent, the 
culture medium was removed and cells were washed in ice cold PBS.  Cells were then 
scraped into 5mls of fresh PBS and centrifuged for 30 seconds at 10,000g at 4°C. The 
cell pellet was resuspended in 1ml of hypotonic buffer and incubated on ice for 15 
minutes. Cells were centrifuged as before and the supernatant containing cytosolic 
proteins was collected, snap-frozen on dry ice, and stored at -80°C. The pellet was 
resuspended in ice cold hypotonic buffer supplemented with 0.25M sucrose (in order to 
fractionate the nuclei). Again, cells were centrifuged and the pellet was resuspended in 
1ml high salt buffer. Following a 30 minute incubation on ice, cells were centrifuged for 
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the final time at 10,000g for 2 minutes at 4°C and the supernatant containing nuclear 
protein was snap-frozen on dry ice and stored at -80°C.  
2.5 Protein Quantification 
Protein quantification was carried out using a Bradford Assay: a standard curve was 
generated by diluting bovine serum albumin (BSA) stock solution (2mg/ml BSA protein 
standard (Pierce & Warriner, Chester, UK)) in the lysis buffer used for extraction. 
Extracted proteins were diluted in lysis buffer and 300µl of Bradford Ultra (Expedeon, 
UK) was added to each sample. Following a 5 minute incubation, protein absorbances 
were read at 595nm using a Tecan sunrise microplate absorbance reader (Tecan, 
Reading, UK).  
2.6 Electrophoretic Mobility Shift Assay (EMSA) 
2.6.1 Reagents 
- Fluorescently labelled (5ʹDY682) oligonucleotides (Eurofins MWG Operon, 
Ebersberg, Germany)  
- EMSA Annealing Buffer - 100mM Tris HCl, 500mM NaCl, 10mM EDTA 
- 5xTBE – 445mM Tris,  445mM Boric Acid, 10mM EDTA pH8.  
- 5% (weight/volume (w/v)) acrylamide gel, prepared using TEMED and 
ammonium persulfate (APS)  
- Odyssey Infrared EMSA kit, containing all buffers and loading dye (LiCor 
Biosciences, Cambridge, UK).  
- rs143383 Optimal Binding Reaction – 1x Binding Buffer, 25mM DTT, 2.5% 
Tween-20, 1μg/μl Poly (dI:dC), 100mM MgCl2, 200fmol annealed 
oligonucleotide and 5μg nuclear extract.  
- rs143384 Optimal Binding Reaction- 1x Binding Buffer, 25mM DTT, 2.5% 
Tween-20, 1μg/μl Poly (dI:dC), 200fmol annealed oligonucleotide and 5μg 
nuclear extract.  
- 5x (1pmol), 10x (2pmol), 25x (5pmol), 50x (10pmol) unlabelled competitor 
oligonucleotide (Competitor sequences are listed in Table 1A and B Appendix).  
- 2μg species matched control or candidate antibody (Table 2, Appendix).  
2.6.2 Method 
PROMO 3.0 (http://alggen.lsi.upc.es/), TESS (http://www.cbil.upenn.edu/cgi-
bin/tess/tess), and TransFac (http://www.gene-regulation.com/pub/databases.html) 
online databases were used to predict protein binding to the C and T-alleles of GDF5. 
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Fluorescently labelled oligonucleotides were resuspended in H20 (Sigma-Aldrich) to a 
concentration of 100pmol/µl, the oligonucleotides were heated to 95°C for 5 minutes 
and then allowed to cool to room temperature for annealing, in a solution containing 
EMSA annealing buffer. Following this incubation, the reaction was allowed to cool to 
room temperature for 2-3 hours to enable annealing of the probes. The native 
acrylamide gel was prepared the day before the EMSA reaction and left to set at 4°C 
overnight. The gel is pre-run for 30 minutes in 0.5x TBE buffer prior to the loading of 
samples in order to remove any traces of APS, to equilibriate ions within the running 
buffer and to ensure constant gel temperature. The binding reaction was prepared as 
described above for rs143383 or rs143384 and incubated at room temperature for 20 
minutes in the dark. When using unlabelled competitor oligonucleotides or antibody to 
confirm the binding of candidates, these are added prior to the addition of the 
fluorescently labelled oligonucleotide. Orange G loading dye is then added (1x final 
concentration) and samples are loaded onto the gel. Electrophoresis is performed at 
100V at 4°C in the dark for approximately 4 hours, or until the dye front has reached the 
end of the gel. Visualisation was carried out using the LiCor Odyssey Infrared Imager 
(LiCor Biosciences).  
2.7 Oligonucleotide Pull Down Assay  
A 212bp region encompassing rs143383 was amplified by the polymerase chain 
reaction (PCR) with a biotinylated 5ʹprimer and unlabelled 3ʹprimer (Sigma-Aldrich) 
(Table 3, Appendix). Two independent PCRs were performed, using homozygous C or 
T template DNA. 40pmol of PCR product was then coupled to 2mgs of Streptavidin 
Dynabeads® (Invitrogen) following manufacturers instructions. A sample containing no 
DNA was used as a control. Beads were then blocked in 500μl BC-100 buffer (20mM 
HEPES pH 7.9, 20% (v/v) glycerol, 100mM KCl, 0.2mM EDTA, 0.5mM PMSF, 
0.5mM DTT) plus 5% (v/v) BSA, 0.1mg/ml salmon sperm DNA (Invitrogen) and 
0.01% (v/v) Triton X-100 for 1 hour at 4°C. Previously extracted SW782 nuclear 
lysates were transferred to a tube for dialysis (Tube-O-dialyzer, VWR, UK), and 
dialyzed in a low salt buffer (20mM HEPES pH 7.9, 20% (v/v) glycerol, 0.1M KCl, 
0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT) for 4 hours at 4°C. The buffer was 
replaced and the lysates were dialysed for a further 16 hours at 4°C. Dialyzed lysates 
were then pre-cleared for 1 hour with 50μl Streptavidin Dynabeads® (Invitrogen). 
DNA-bead complexes were then resuspended in 1mg of the prepared SW872 protein 
extract and incubated for 2 hours at 4°C with rotation. Following this, complexes were 
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washed once with blocking buffer and six times with BC-100 buffer alone. Protein-
DNA complexes were eluted from the beads following incubation at 95°C for 5 minutes 
and isolated following magnetic separation. The samples (CC, TT and no DNA) were 
loaded on to a 12% (w/v) acrylamide gel, and subjected to electrophoresis at 150V for 1 
hour followed by coomassie blue staining.   
2.7.1 Mass Spectrometry 
Quantitative mass spectrometry was performed as previously described [296]. Briefly, 
the gel pieces were destained with 100% acetonitrile, reduced in DTT and cysteines 
were alkylated using idodacetamide. Proteins were then digested, whilst still in the gel, 
overnight using trypsin, washed, and the final volume was reduced by speedvac. The 
three samples (CC, TT and no DNA) were then labelled using a TMT isobaric mass 
tagging kit (Thermo Scientific, Surrey, UK). Labelled samples were mixed prior to off-
gel fractionation of the peptides. High pressure liquid chromatography was performed 
on a Pepmap C18 reversed phase column (Dionex). Mass spectrometry was performed 
on an Orbitrap mass spectrometer. Quantitative analysis was carried out using the 
ProteinExplorer software, version 1.0 (Thermo Scientific) and the search engine 
MASCOT (Matrix Science Company) was used for identification of proteins.  
2.7.2 Analysis 
This experiment was performed three times, however the samples from experiments two 
and three (C, T and no DNA) were combined as a 6-plex and thus processed 
concurrently. In each case, a technical repeat of each experiment was conducted to 
differentiate background artefacts from protein binding differences. 
The combined results from all three experiments were first sorted according to 
background, i.e. proteins identified that were absent in the no DNA control sample were 
ranked highest, proteins that were present in the background sample in one of the three 
experiments were ranked second highest, down to those which were present in the 
background in all three experiments being ranked lowest. We analysed the data 
provided for each protein and defined the most robust hits as those with medium to high 
confidence values (data with low confidence values were excluded), based on the 
identification of more than 2 unique peptide sequences from the protein and the 
coverage of peptides in the protein (i.e. more than two peptides located in different 
regions of the protein. The functions of the proteins identified were determined using 
DAVID pathway analysis functional annotation tool available at 
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http://david.abcc.ncifcrf.gov/.  Proteins known to have a role in transcriptional 
activation or repression were then prioritised for further analysis. 
2.8 Chromatin Immunoprecipitation (ChIP) 
2.8.1 Crosslinking 
ChIP was performed using the EZ Magna ChIP A kit (Millipore, UK), all subsequent 
reagents described were provided with the kit unless otherwise stated. SW872 cells 
were seeded at a density of 15x10
6
 on a 500cm
2
 square cell culture dish (Corning) in 
80mls of SW872 cell media. Formaldehyde (Sigma) was added to crosslink cells at a 
final concentration of 1% and incubated at room temperature for 10 minutes. Glycine 
was added at a final concentration of 0.125M to quench un-reacted formaldehyde. 
Media was discarded and the dish was placed on ice. Cells were washed with 30mls 
PBS and then scraped into 30mls PBS containing 1x Protease Inhibitor Cocktail II. 
Cells were pelleted at 720g at 4°C for 8 minutes using a desktop centrifuge.  
2.8.2 Lysis and Sonication  
The cell pellet was then resuspended in 1.5mls sodium dodecyl sulphate (SDS) cell lysis 
buffer containing 1x protease inhibitor cocktail II and incubated on ice for 20 minutes. 
The lysate was divided into three 1.5ml Eppendorf tubes and sonication was carried out 
using a probe sonicator (Soniprep150, MSE, London, UK), on ice, at 8 microns for 
10x10 second intervals with 20 second rest periods.  Sonicated lysates were then 
centrifuged at 10,000g at 4°C for 10 minutes.  
2.8.3 Immunoprecipitation 
100µg of chromatin was diluted 1 in 10 with ChIP dilution buffer containing 1x 
protease inhibitor cocktail II and pre-cleared using 50µl magnetic protein A beads 
(Millipore). 10µg of primary antibody (Table 2, Appendix) was used for each 
immunoprecipitation, in addition to 40µl protein A magnetic beads. The samples were 
then incubated overnight at 4°C with rotation. The magnetic beads were pelleted using a 
magnetic separator (Millipore) and the supernatant removed. The pellet was then 
washed in low salt immune complex wash, high salt immune complex wash, lithium 
chloride complex wash and finally Tris-EDTA buffer, each for 5 minutes with rotation, 
with beads being separated after each wash and the supernatant discarded. Following 
the final wash, the beads were resuspended in 100µl ChIP elution buffer in addition to 
1µl Proteinase K and incubated at 62°C for 2 hours with shaking for the reversal of 
crosslinks. Following an incubation of 95°C for 10 minutes, samples were cooled to 
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room temperature and the supernatant removed to a new tube following separation 
using the magnetic separator. DNA purification was carried out using the spin columns 
provided in the kit.  
2.8.4 Polymerase Chain Reaction 
DNA was amplified by PCR using primers located in the first exon of GDF5 (Primer 
sequences are listed in Table 3, Appendix). 2μl of immunoprecipitated DNA was added 
to a 13μl PCR mastermix containing 0.5µM forward and reverse primers, PCR buffer 
(50mM KCL, 10mM Tris-HCL pH 8.3), 2mM MgCl2, 0.2mM dNTPs, 0.08 units of 
AmpliTaq Gold DNA polymerase (Applied Biosystems, ABi, Life Technologies, UK) 
and H20. The thermo-cycling conditions included a denaturation stage for 14 minutes at 
94°C, followed by 32 cycles of 94°C for 30 seconds, annealing at 57°C for 30 seconds, 
and extension at 72°C for 30 seconds and a final step of 72°C for 5 minutes.  
2.9 RNA Mediated Interference (RNAi) 
SW872 cells were seeded at a density of 350,000 cells per well in a 6-well culture plate 
(Corning). After 24 hours, cells were transfected using Dharmacon ON-TARGETplus 
Smartpool siRNAs (100nM final concentration) targeted against candidates in addition 
to Dharmafect
TM
 4 lipid reagent (Dharmacon, Thermo Scientific, Surrey, UK). After the 
desired period of incubation (48 hours unless otherwise stated) the cells were harvested, 
nucleic acid and protein isolated and RNA reverse transcribed as described below. 
Depletion of mRNA expression was calculated in comparison to cells transfected with 
the ON-Targetplus Non-Targeting Pool control siRNA (Dharmacon).  
For the combination siRNA experiments examining protein expression (Chapter 8) the 
transfections were carried out as above using 100nM or 200nM final siRNA 
concentrations and 1x or 2x concentrations of Dharmafect
TM
 4 lipid reagent 
(Dharmacon). For the combination siRNA experiments examining gene expression, 
cells were seeded at a density of 10,000 cells per well in a 96-well culture plate, and 
transfected using the same final concentrations as above.  
2.10 Nucleic Acid Extraction 
Genomic DNA, total RNA and total protein were simultaneously extracted from SW872 
cells following siRNA treatment using a spin column extraction kit according to the 
manufacturer’s instructions (Nucleospin Triprep, Macherey-Nagel, supplied by Thermo 
Fisher, UK). Nucleic acids were quantified using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, USA). RNA was diluted to 
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250ng/μl and stored in diethylpyrocarbonate (DEPC)-treated H2O (Invitrogen) at -80°C. 
DNA and protein were stored at -20°C.   
2.11 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
RNA was DNase treated prior to RT-PCR. RT-PCR was completed using the 
SuperScript First-Strand Synthesis System (Invitrogen); 1μg of RNA was DNase treated 
with 2 units of Turbo DNase (Ambion, Life Technologies, UK) and incubated at 37°C 
for 30 minutes. RNA was then mixed with 150ng random primers and 10mM dNTP mix 
(Invitrogen), incubated at 65°C for 5 minutes and placed on ice. 1x reaction buffer 
(50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl2; Invitrogen), 5mM MgCl2 (Applied 
Biosystems), 10mM DTT (Invitrogen) and 40 units RNaseOUT inhibitor (Invitrogen) 
were added and incubated at 25°C for 1 minute. Superscript II enzyme (50 units) 
(Invitrogen) was then added and mixed by pipetting. The final 20 μl reaction was then 
incubated at 25
o
C for 10 minutes, 42
o
C for 50 minutes and finally 70
o
C for 15 minutes. 
Following this, 2 units of RNase H (New England Biolabs (NEB), Hitchin, UK) was 
added and a final incubation of 37°C for 20 minutes was performed. Complementary 
DNA (cDNA) was stored at -20°C prior to Real Time PCR.  
For the combination siRNA experiments performed in 96-well culture dishes, 48 hours 
post transfection cells were lysed using the Cells-to-cDNA II cell lysis buffer (Ambion). 
Samples were heated to 75ºC for 15 minutes and stored at -80ºC prior to cDNA 
synthesis. The samples were then DNase treated (Qiagen) and incubated at 37ºC for 15 
minutes and 75ºC for 5 minutes. 10ng random primers (Invitrogen) and 10mM dNTP 
mix (Invitrogen) were added to 8µl of cell lysate, which was then incubated for 5 
minutes at 70ºC. Following this, 1x reaction buffer (50mM Tris-HCl (pH 8.3), 75mM 
KCl, 3mM MgCl2; Invitrogen), 100 units MMLV reverse transcriptase (Invitrogen) and 
10mM DTT (Invitrogen) was added to the reaction, followed by water to bring the final 
reaction volume to 20µl. The samples were then incubated at 37 °C for 50 minutes and 
75 °C for 15 minutes. Finally, 30µl of water was added and the samples were then 
frozen at -20ºC prior to analysis by Real Time PCR.  
2.12 Polymerase Chain Reaction 
Following synthesis, the integrity of cDNA was investigated by PCR amplification of 
HBP1. The HBP1 primers, located in different exons, are used to distinguish between 
cDNA and any residual genomic DNA (gDNA) contamination (primer sequences listed 
in Table 3, Appendix). A 15µl PCR reaction was performed, as described previously, 
with minor alterations; 0.5µl of cDNA was added to 14.5µl of master-mix, 35 PCR 
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cycles were performed and the annealing temperature was 60°C. Following the PCR, 
products were separated by electrophoresis through a 2% (w/v) agarose gel. 
Visualisation was carried out by ethidium bromide staining using a Syngene gel dock. 
Only cDNA samples containing the correct sized product were taken forward for gene 
expression analysis.  
2.13 Gene Expression Analysis by Real Time PCR 
Two different types of gene expression analysis by Real Time PCR were performed.  
2.13.1 Taqman Real Time PCR  
Gene expression analysis of GDF5 and the expression of depleted candidates following 
RNAi was determined using a Taqman primer-probe based approach by Real Time 
PCR. The probe has a 5ʹ reporter dye and a 3ʹ quencher and when the polymerase 
enzyme cleaves the probe from DNA during extension, the reporter dye is released from 
the quencher and emits fluorescence. 
Gene expression assays were purchased from either Applied Biosystems (Applied 
biosystems; GDF5) or Integrated DNA Technologies (IDT, Belgium). 10μl reactions 
were prepared containing 1x gene expression assay, 1x Taqman Gene Expression 
mastermix (containing AmpliTaq Gold® DNA Polymerase, Uracil-DNA Glycosylase, 
dNTPs with dUTP, Passive Reference 1 and optimized mix components) and cDNA 
(Undiluted for GDF5, diluted 1:20 for all other genes). The Prism 7900HT sequence 
detection system (Applied biosystems) was used for PCR cycling (50°C for 2 minutes, 
95°C for 10 minutes and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute) and 
detection.  A fast mastermix, Taqman Fast Universal Mastermix (Applied biosystems), 
in addition to fast cycling conditions (95°C for 20 seconds followed by 40 cycles of 
95°C for 1 second and 60°C for 20 seconds) were used for the expression analysis of 
Sp1, Sp3, P15, DEAF-1, and the house keeping genes. For analysis, gene expression 
was normalised to the house keeping gene HPRT1 or GAPDH using the delta ct method 
(2
-(ct
 
test gene)-(ct HPRT1)
).  
2.13.2 Allelic Expression Analysis 
Differential Allelic Expression (DAE) analysis, to assess the expression of the C and T 
alleles of rs143383, was performed using a custom SNP genotyping assay (Applied 
biosystems) containing forward and reverse primers and allele specific probes (VIC or 
FAM labelled). A 10μl reaction was prepared with 1x DAE assay, 1x Taqman Universal 
Mastermix II, no UNG (Applied biosystems), and either cDNA diluted 1 in 5 or 20ng 
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DNA. Cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes and 40 cycles 
of 92°C for 15 seconds and 60°C for 1 minute. Analysis was performed using the 
equation (2
^-ct
) for FAM and VIC and the ratio between the two alleles calculated 
(FAM/VIC) for both cDNA and gDNA. The cDNA allelic ratio was normalised to the 
gDNA C/T allelic ratio (representing a 1:1 ratio) for each treatment group.  The 
genotype of cell lines used for this research at rs143383 was also determined using this 
assay, with detection of fluorescence of just one reporter indicating a homozygous 
sample (CC or TT) and fluorescence of both FAM and VIC reporters indicating a 
heterozygote sample (C/T).  
Sequences of all Real Time PCR primers and probes are detailed in Table 4, Appendix.  
2.14 Immunoblotting 
For the assessment of candidate protein depletion and over expression, total protein was 
isolated using the Triprep spin column method or whole protein extraction method 
respectively. Protein was then quantified as described, diluted to 10μg in 1x laemmli 
sample buffer (0.1M Tris-HCL, 0.35M SDS, 20% (v/v) glycerol, 0.01% (v/v) 
bromophenol blue, 5% (v/v) β-mercaptoethanol) and resolved on 10% (w/v) SDS 
polyacrylamide gels. Proteins were then transferred to a Immobilon-P polyvinylidene 
fluoride (PVDF) membrane (Merck Millipore, Nottingham, UK) by electroblotting in a 
Scie-Plas V20-SDB 20x20 semi-dry blotter (Scie-Plas, Cambridge, UK). After transfer, 
the membrane was blocked for non-specific protein binding by incubation in PBS 
containing 5% (v/v) Marvel milk and 0.02% (v/v) Tween-20 at room temperature for 30 
minutes. The membrane was washed and incubated overnight with primary antibodies 
diluted in PBS/Tween-20 containing 5% (v/v) marvel at 4°C. Details of the antibodies 
are shown in Table 2, Appendix. Following antibody incubation, the membranes were 
washed in PBS/Tween-20, before incubation in secondary polyclonal goat anti-rabbit 
(1:2000) or polyclonal goat anti-mouse (1:10000) horseradish peroxidise (HRP) 
conjugated antibodies for 1 hour at room temperature (DAKO, UK). Detection was 
carried out using X-ray film (Kodak Film, Sigma-Aldrich) with ECL, ECL plus and 
ECL Advance detection reagents (GE Healthcare, Little Chalfont, UK).  A monoclonal 
βActin antibody was used as a loading control (Abcam, Cambridge, UK).   
59 
 
2.15 Cloning 
2.15.1 GDF5 Luciferase Vectors 
The GDF5 promoter and part of the 5ʹUTR region spanning -97 to +305 (relative to the 
transcriptional start site of GDF5) was subcloned from the GDF5 pGL3 plasmid [297] 
into the Mlu/BglII sites of the purified pGL3-Enhancer Vector (Promega, UK).  The 
double digestion was performed using 15 units of Mlu1 and 15 units of BglII restriction 
enzymes (New England Biolabs (NEB) UK), in addition to 1x NEB Buffer 3 (50mM 
Tris-HCl, 10mM MgCl2, 100mM NaCl and 1mM DTT, pH 7.9) and 5µg of GDF5 
pGL3 plasmid for 3 hours at 37°C. The pGL3 enhancer vector was also digested in this 
manner. Following digestion, the PCR product, and pGL3 enhancer vector were 
purified using the QIAquick gel extraction kit (Qiagen, Crawley, UK) following 
manufacturers instructions and eluted in H20.  The digested promoter region was ligated 
into the digested pGL3 enhancer vector during a 12 hour incubation at 16°C, using a 
fragment: plasmid ratio of 5:1, in addition to T4 ligase (NEB) (400 units). Plasmid 
DNA was then transformed into MACH1 competent cells (Invitrogen) following 
manufacturers guidelines. Transformed cells were spread onto agar plates supplemented 
with ampicillin (100µg/ml) (Sigma-Aldrich) and incubated overnight at 37°C. Positive 
colonies were added to 3.5mls of LB broth (Sigma-Aldrich) supplemented with 
ampicillin (100µg/ml) and incubated at 37°C with shaking overnight.  Glycerol stocks 
were prepared with the addition of 200µl of bacterial culture to 200µl of glycerol 
(Sigma-Aldrich) in a 1:1 ratio, and stored at -80
o
C.  Plasmid cultures were purified with 
reagents from the Plasmid Maxiprep Kit (Qiagen) using the following miniprep 
protocol; the culture was centrifuged at 10,000g for 3 minutes and the bacterial pellet 
was resuspended in 100µl P1 + RNase A solution (resuspension buffer), followed by the 
addition of 200µl P2 solution (lysis buffer) and the tubes were inverted to mix. After a 2 
minute incubation, 150µl P3 solution (neutralization buffer) was added, mixed and 
centrifuged for 5 minutes at 17,900g. The supernantant was removed and added to 1ml 
of 100% ethanol. Following a 10 minute incubation at -80°C, the supernantant/ethanol 
mixture was centrifuged for 10 minutes at 17,900g. The DNA pellet was air dried for 10 
minutes to remove residual ethanol, resuspended in 30µl H20 (Sigma-Aldrich) and 
stored at -20°C. Successful insertion into the pGL3 enhancer vector and sequence 
verification was assessed following sequencing by Genome Enterprises (Norwich, UK).  
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2.15.2 Over expression Vectors 
The Sp1, Sp3 and P15 open reading frames (ORF) were amplified from cDNA using 
gene specific primers containing either an EcoR1 restriction or a SacII restriction site at 
the 5ʹ end of the primer (Table 5, Appendix). The PCR was performed using Titanium 
taq (1x final concentration; Clontech, Saint-Germaine-en-Laye, France), with the 
reaction containing 1x Titanium Taq Buffer (40mM Tricine-KOH, 16mM KCl, 3.5mM 
MgCl2, 3.75µg/ml BSA), 0.2µM forward and reverse primers, 0.2mM dNTPs with 
cycling conditions of 95
o
C for 1 minute followed by 40 cycles of 95
o
C for 15 seconds, 
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C for 1 minute and 68
o
C for 1 minute 30 seconds and finally 68
o
C for 7 minutes.  
After PCR amplification, the PCR product was purified and eluted in 30µl H20 using the 
QIAquick PCR purification kit following the manufacturer’s instructions (Qiagen).   
The digestion, purification, ligation and transformation reaction of the Sp1, Sp3 and P15 
PCR products and EGFP-N1 Vector (Clontech) was as previously described for the 
GDF5 pGL3 enhancer vector, with the following minor alterations: the restriction 
enzymes EcoR1 and SacII were used, and the antibiotic kanamycin was used for 
resistance at a final concentration of 50µg/ml. The DEAF-1 EGFP-N1 and empty 
EGFP-N1 expression plasmids were kindly donated by C. Garrison Fathman and Linda 
Yip [298]. 
2.15.3 Site Directed Mutagenesis 
To generate the four possible rs143383 and rs143384 haplotypes (C-C, C-T, T-C, T-T), 
the Agilent Quickchange II site directed mutagenesis kit (Agilent, Berkshire, UK) was 
used.  A control reaction containing the pWhitescript control plasmid was performed 
following the manufacturer’s instructions.  The 50µl mutagenesis reactions contained 
50ng of plasmid DNA, 125ng of forward primer, 125ng of reverse primer, 0.01mM 
dNTP mix, 1x reaction buffer and 2.5 units of Pfu Ultra high fidelity DNA polymerase. 
The cycling conditions consisted of 95
o
C for 30 seconds followed by 18 cycles of 
denaturing at 95
o
C for 30 seconds, annealing at 50
o
C for 1 minute and extension at 68
o
C 
for 7 minutes.  The reaction was then placed on ice for 2 minutes. DNA was digested at 
37°C for 1 hour following the addition of 10 units of DpnI. The transformation was 
carried out following manufacturers instructions. Positive colonies were incubated, 
purified by miniprep and sequenced as described above.  
2.15.4 Purification of Plasmid DNA Prior to Transfection by MaxiPrep 
Prior to transfection, large quantities of purified plasmid DNA were prepared. First, 5µl 
of glycerol stock was added to 5mls of LB broth containing ampicillin (100µg/ml) or 
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Kanamycin (50µg/ml) and incubated at 37°C with shaking for 2-3 hours.  This culture 
was then transferred to a large conical flask containing 250mls LB broth supplemented 
with antibiotics and incubated at 37°C with shaking overnight. The cultures were then 
centrifuged at 6,000g for 15 minutes at 4°C. All buffers described are part of the Qiagen 
Maxiprep Kit (Qiagen). Pellets were resuspended in 10mls of P1 + RNase, followed by 
10mls P2, incubated for 5 minutes, and then 10mls chilled P3 and incubated for 20 
minutes on ice. The lysate was then centrifuged at 20,000g for 30 minutes at 4
o
C, and 
the supernatant transferred to a new tube and centrifuged under the same conditions for 
a further 15 minutes.  A QIAGEN-tip 500 gravity column was equilibrated with 10mls 
of Buffer QBT, following this the supernatant was applied to the column. The column 
was subsequently washed twice with 30mls of Buffer QC, and plasmid DNA eluted 
using 15mls of Buffer QF into a fresh centrifuge tube.  DNA was precipitated following 
the addition of 10.5mls of isopropanol and the sample was then centrifuged at 15,000g 
for 30 minutes at 4
o
C.  Once the residual isopropanol had evaporated, the pellet was 
resuspended in 500µl of H2O.  1250µl (2.5x volume) of 100% ethanol was added and 
after mixing was stored at -80
o
C for 15-20 minutes.  Following a final centrifugation of 
17,900g for 10 minutes at room temperature, the pellet containing DNA was air dried 
for  5-10 minutes prior to resuspension in 300µl of H2O (Sigma-Aldrich) and quantified 
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies).  
2.16 Transfection of Cell Lines 
SW1353 cells were seeded at a density of 17,500 cells per well in a 48-well cell culture 
plate (Costar, UK) and cultured for 48 hours prior to transfection.  Cells were 
transfected with 2µg of plasmid DNA (containing 1µg of GDF5 pGL3 enhancer vector 
and several combinations of either 1µg empty pEGFP-N1 vector, 500ng Empty EGFP-
N1 and one of the transcription factor expression plasmids, or 500ng each of two 
transcription factor expression plasmids) in addition to 15ng of pTK-RL Renilla using 
ExGen500 in vitro transfection reagent (Fermentas, York, UK). Four wells were 
transfected per condition and a total of three individual experiments were performed.  
After 24 hours, cells were lysed as described in section 2.17. 
For the examination of protein over expression, 250,000 SW1353 cells per well were 
seeded in 6-well culture dishes and transfected with plasmid vectors and ExGen500 as 
described for the 48-well cell culture plate, but the relative amounts of each were 
increased according to the final culture volume.  After 24 hours, protein was extracted 
as described in section 2.3. 
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For the combination over expression and depletion experiments (Chapter 8), SW1353 
cells were seeded at a density of 17,500 cells per well in a 48-well cell culture plate 
(Costar) and 350,000 cells per well in a 6-well cell culture plate (Costar). Cells were 
cultured for 48 hours prior to transfection. Cells were transfected with siRNA (100nM 
final concentration) or 1µg plasmid DNA or both in combination using Dharmafect
TM
  
Duo transfection reagent (Dharmacon, Thermo Scientific). After 48 hours, cells in the 
48-well plate were lysed as described in section 2.17 and protein was extracted from 
cells in the 6-well culture plate as described in section 2.3. 
2.16.1 DEAF-1 EGFP Transfections 
For the over expression of DEAF-1 EGFP prior to ChIP, SW872 cells were seeded at 
15x10
6
 on a 500cm
2
 plate and cultured for 24 hours. Cells were transfected with DEAF-
1 EGFP plasmid DNA using Fugene HD transfection reagent (Promega) in a 1:3 ratio. 
After 24 hours the cells were taken forward for ChIP.  
For the over expression of DEAF-1 EGFP prior to immunoblotting, SW872 cells were 
seeded at 250,000 cells per well in a 6-well culture dish. After 24 hours, cells were 
untransfected, transfected with DEAF-1 EGFP or transfected with a control plasmid 
H11 using Fugene HD transfection reagent (Promega) in a 1:3 ratio. After 24 hours 
protein was extracted as previously described in section 2.3. 
For over expression of DEAF-1 EGFP followed by DEAF-1 siRNA treatment, cells 
were seeded at a density of 250,000 per well in 6-well culture dishes. After 24 hours, 
cells were transfected with DEAF-1 EGFP using Fugene HD transfection reagent 
(Promega) in a 1:3 ratio. After 6 hours the transfection media was removed and cells 
were transfected with siRNA as previously described in section 2.9. Cells were then 
incubated for 48 hours prior to protein extraction.    
2.17 Luciferase Activity Reading 
Transfected cells were lysed and luciferase and renilla activity measured using the Dual 
Luciferase Assay system (Promega) with the MicroLumat Plus LB96V luminometer 
(Berthold Technologies UK, Harpenden, UK).   
2.18 Immunofluorescence 
For the verification of DEAF-1 depletion by immunofluorescence, cells were seeded at 
a density of 10,000 cells per well of a chamber slide (Nagel Nunc International, USA). 
After 24 hours, cells were either transfected with DEAF-1 siRNA (Dharmacon) 
(100nM) or untreated. After 48 hours, the media was removed and cells were washed in 
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PBS and fixed with 4% (w/v) paraformaldehyde in PBS. Permeabilisation buffer was 
then added (0.5% BSA, 0.2% Fish skin gelatine, 0.5% Triton X-100) and cells were 
incubated in each of the anti-DEAF-1 antibodies overnight at 4°C. Cells were then 
washed and incubated in either secondary Red fluorescent AlexoFluor 594nm or Green 
fluorescent AlexoFluor 488nm goat anti-rabbit IgG antibodies (Invitrogen molecular 
probes, Invitrogen) for 1 hour at room temperature, washed in PBS and mounted using 
vectashield with DAPI (4'6-diamidino-2-phenylindole)(Vector Laboratories, 
Burlingame, CA). Fluorescence was detected using a LEICA DMLB fluorescent 
microscope and a SPOT-RT camera.  
To examine the over expression of EGFP-N1 vectors by immunofluorescence, SW1353 
cells were seeded at a density of 10,000 cells/well in a chamber slide (Nagel Nunc 
International). After 48 hours, cells were transfected with 1µg of each candidate 
plasmid vector using ExGen500. 24 hours post transfection, cells were washed in PBS 
and fixed with 4% (w/v) Paraformaldehyde in PBS for 10 minutes, washed again in 
PBS and mounted and detected as above.  
2.19 Immunoprecipitation 
Cells were seeded at a density of 2.5 million in a 10cm
2
 cell culture dish (Cellstar, 
Greiner Bio-One, Germany). After 24 hours cells were transfected with 5µg DEAF-1 
EGFP plasmid using Fugene HD transfection reagent (Promega). After 24 hours, whole 
protein was extracted as previously described in section 2.3. For the 
immunoprecipitation, 10µg of each DEAF-1 antibody or the IgG control antibody was 
added to 500µg of cell lysate and the sample was incubated at 4ºC with rotation 
overnight. 70µl of protein A magnetic beads (Millipore) were added to the samples and 
incubated at 4ºC for four hours with rotation. The beads were separated using a magnet 
and washed with lysis buffer twice, and PBS once. The beads were then resuspended in 
2x laemmli buffer and incubated at 100ºC for 5 minutes. The beads were once again 
separated using the magnet, and the supernatant collected. Immunoblotting was carried 
out as described in section 2.14 using the anti-EGFP antibody.  
2.20 Statistics 
Pairwise analysis p-values were calculated using the Students two tailed t-test. *p<0.05 
**p<0.01 ***p<0.001. For the comparison of multiple treatments, statistical 
significance was calculated using an ANOVA. *p<0.05 **p<0.01 ***p<0.001.  
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Chapter 3: Establishing the Conditions for Testing DAE 
3.1 Introduction 
The rs143383 SNP is functional; the T allele produces less GDF5 transcript in 
comparison to the C allele both in vitro and in vivo [134, 267]. Carriers of the T allele 
(TT or CT) are more susceptible to developing OA in comparison with C allele carriers, 
with odds ratios ranging from 1.12 in Caucasians to 1.79 in Asians [134, 267]. In order 
to investigate the reason for the differential expression of the two alleles, I first needed 
to design and validate an assay that would enable me to quantify the expression of the 
two alleles relative to one another.  Secondly, I sought to identify a cell line that 
expressed GDF5 and demonstrated a similar allelic expression imbalance to that 
observed previously in patients. Using this cell line and assay, my aim was to identify 
the causes of the allelic expression imbalance and investigate further how the DAE can 
be modulated.  
3.2 Aims 
 To design and characterise an assay to quantify DAE.   
 To identify a cell line in which we can study the rs143383 DAE.  
 
 
 
 
 
 
 
 
 
 
65 
 
3.3 Results 
3.3.1 Identification of a cell line for investigation of rs143383 DAE 
The human cell lines that are available within our research group had been genotyped 
for rs143383 and rs143384 by Athanasia Gravani (research technician) and the 
expression of GDF5 within each cell line has been investigated previously [299]. The 
genotypes of the cell lines that express GDF5 are detailed in Table 3.1. The liposarcoma 
SW872 cell line is compound heterozygous for rs143383 and rs143384, and expresses 
GDF5 and was thus used for the analysis of GDF5 DAE.  
Table 3.1  
The 9 cell line stocks available in my group for GDF5 expression analysis. Modified 
from Reynard et. al 2011.  
 
3.3.2 Design and validation of a rs143383 DAE assay 
A real time PCR assay was designed with primers located in exon 1 of the GDF5 gene 
encompassing rs143383 and with two differently labelled probes able to discriminate 
between the C (FAM label) and T alleles (VIC label) of the SNP, as described in Table 
4,  Appendix. This assay has been designed to enable the amplification of both DNA 
and cDNA.  
I first assessed the ability of the assay to distinguish between C and T alleles of 
rs143383. I used DNA from the heterozygous cell line, SW872, the homozygous CC 
cell line, SW1353 and the homozygous TT cell line, CH8. Additionally, DNA from two 
patients was used, one of whom was homozygous CC and the other homozygous TT. 
Figure 3.1 shows the real time PCR amplification graphs. The CC CH8 cell line and the 
CC patient DNA were amplified efficiently using the real time PCR assay and the FAM 
reporter fluorescence, signifying the C allele probe detected the C allele DNA. Although 
there was a small amount of signal detection from the VIC reporter, this did not pass the 
cycle threshold (set automatically by the real time PCR machine) and was thus 
Cell Line Name Origin rs143383 genotype rs143384 genotype 
CH8 articular chondrocyte TT TT 
HeLa cervix carcinoma CT CT 
HOS-TE85 osteosarcoma CC CC 
MDA-MB-231 breast adenocarcinoma TT TT 
MG63 osteosarcoma TT TT 
SaOS-2 osteosarcoma TT TT 
SW1353 chondrosarcoma CC CC 
SW872 liposarcoma CT CT 
U937 histiocytic lymphoma CC CC 
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undetected. Similarly, the TT SW1353 cell line and the TT patient DNA was detected 
using the assay by the VIC reporter fluorescence, signifying the T allele probe, detected 
the T allele DNA and again, although there was a small amount of detectable FAM 
reporter, this did not pass the cycle threshold. Both FAM and VIC reporter fluorescence 
were detected using the heterozygous SW872 cell line DNA, and both passed the cycle 
threshold, confirming that this assay is able to efficiently genotype the rs143383 SNP.  
 
Figure 3.1 
Real Time RT PCR amplification plots. Detection of both VIC (T) and FAM (C) 
labelled dyes are shown. Cycle number is shown on the x-axis and ΔRn (fluorescence 
emission intensity of the reporter dye/fluorescence emission intensity of the passive 
reference dye) on the y-axis. 20ng of DNA was used for each reaction, including patient 
DNA homozgous CC or TT at rs143383 and cell line DNA from SW1353 (CC), CH8 
(TT) and SW872 (C/T).   
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I then wanted to assess if the assay was able to provide an accurate measurement of the 
amount of both alleles relative to one another. This was assessed by mixing CC and TT 
DNA of known concentration in various ratios. Figure 3.2A shows the 9 ratios used for 
the analysis, the expected T/C value and the observed T/C value. Figure 3.2B shows the 
expected and observed values relative to one another. The observed values are 
consistently higher in all DNA concentrations except for concentration number 6, where 
the observed value is lower than expected. In order to correct for the differences in the 
expected and observed values, the values were plotted against one another as shown in 
Figure 3.2C. The equation y=mx + c was then used to correct for the observed values, 
with y being the corrected value, and substituting the graphical equation: corrected = 
(observed*0.4893) + 0.4931. All real time analysis using the DAE assay was corrected 
for in this manner.  
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Figure 3.2  
Validation of allelic expression assay. A. Table detailing the 9 ratios of TT and CC 
DNA, generated by mixing 20ng CC and TT DNA. The 3rd column shows the T/C 
expected ratio and the fourth column shows the amount of the T allele relative to C 
obtained following Real Time PCR using the assay. B. The expected and observed T/C 
ratios, plotted as ratios 1-9 on the x-axis against VIC (T allele)/ FAM (C allele).    C. 
Observed/Expected T/C ratios: the x-axis shows the observed values, plotted against 
expected values on the y-axis. A linear treadline is shown. The equation generated was 
used to correct for the differences in observed/expected.  
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This assay was then used to assess the level of expression of both the rs143383 C and T 
alleles relative to one another in the heterozygous SW872 cell line as described in 
Materials and Methods section 2.13.2. The expression of the C allele relative to the T 
allele is shown in Figure 3.3. The C allele is expressed at a higher level in comparison 
to the T allele; this cell line is thus exhibiting DAE and as such is recapitulating the 
DAE that is observed in rs143383 heterozygous OA patients. In the SW872 cells, for 
every 1 T, there are 1.5 C transcripts. This cell line could therefore act as a model 
system for investigating DAE.  
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Figure 3.3  
DAE of GDF5 in SW872 cells assessed using rs143383. The C/T allelic ratio for 
genomic DNA (DNA) and complementary DNA (cDNA) are shown. Genomic DNA 
was normalised to 1.0 and then used to compare against the C/T allelic ratio obtained 
for cDNA. Error bars denote the standard error of the mean (SEM). * p<0.05, calculated 
using a Student’s 2 tailed t-test. n=6. 
 
3.4 Discussion 
I have designed and validated an assay that can be used to quantitatively assess the 
expression of the rs143383 C and T alleles relative to one another. Furthermore, I have 
identified a cell line, SW872, that is heterozygous at rs143383, that expresses GDF5 
and which exhibits GDF5 DAE, with the T allele showing a reduction in the expression 
of GDF5 relative to the C allele. This cell line can now be used to dissect the 
mechanism behind the DAE mediated by rs143383.  
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Chapter 4: The Identification of Sp1 and Sp3 as GDF5 Trans-acting 
Factors by EMSA 
4.1 Introduction 
Previous functional research performed on rs143383 used EMSA analysis to investigate 
the binding of proteins to this polymorphic region. They reported a difference in 
mobility of the radioactively labelled C and T allele probes in three cell lines, MG63, 
CH8 and SW872, suggesting a difference in protein binding. Using competition EMSAs 
the T allele was found to be binding a unique complex that was unaffected by C allele 
competition. By searching online databases, a number of factors were identified that 
were predicted to bind in an allele specific manner to rs143383. The group focussed on 
three factors, the Myb protooncogene protein (c-Myb), early growth response protein 1 
(EGR-1) and Deformed epidermal autoregulatory factor 1 (DEAF-1). Using consensus 
competitors for each factor, the binding of proteins to the GDF5 C and T allele probes 
by EMSA was investigated. The DEAF-1 consensus competitor was able to compete the 
binding of the T allele protein complex but not the C allele protein complex. C-Myb and 
EGR-1 competitors did not compete binding of either complex. Furthermore, binding to 
a DEAF-1 consensus labelled probe was competed with unlabelled T allele competitor 
and to a lesser extent to with unlabelled C allele competitor.  
The role of DEAF-1 was investigated further in cotransfection experiments using GDF5 
promoter constructs and a DEAF-1 over expression vector. Over expression of DEAF-1 
repressed the expression of both the C and T allele luciferase constructs and in line with 
the stronger binding of DEAF-1 observed in the EMSA experiments, the T allele was 
significantly more repressed compared to the C allele. DEAF-1 was therefore identified 
as a trans-acting factor predicted to bind differentially to the two alleles of rs143383 
[272]. 
The rs143383 polymorphism is located within the 5ʹUTR of the GDF5 gene at +41bp 
relative to the transcription start site. There is little known with regards to transcription 
factor binding within this region and overall about the transcriptional regulation of 
GDF5. The transcription factor YY1 has been identified as a transcriptional activator 
binding upstream of the polymorphism at -41bp relative to the transcription start site 
and modulates the expression of GDF5 [297, 300]. Due to the fact that a reduction in 
the expression of GDF5 during development in the tissues of the joint could affect 
normal development of the joint and mediate the increased susceptibility to OA, 
knowledge of the factors that regulate this key growth factor could provide us with 
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potential methods for increasing GDF5 expression for therapeutic benefit. Boosting the 
expression of GDF5 above normal levels could be damaging; control of GDF5 
expression is vital for normal joint formation and has been highlighted by studies 
showing that mutations within GDF5 that increase its activity or expression can result in 
fusions of the joint [242, 243]. In order to restore normal GDF5 expression in T allele 
carriers, my approach is to identify the mediator of this DAE, providing us with a 
greater understanding of the regulation of GDF5 and enabling the identification of novel 
therapeutic targets.   
This chapter will therefore examine protein binding to the two rs143383 alleles using 
EMSAs and identify novel factors predicted to bind to the alleles using online database 
search tools. Chapter 6 will continue with the analysis of DEAF-1. The Sp1/Sp3 
competition and antibody EMSAs were carried out with assistance from Dr. Louise 
Reynard.  
4.2 Aims  
 To examine in vitro protein complex binding to the C and T alleles using 
electrophorectic mobility shift assays (EMSAs). 
 To identify trans-acting regulators of GDF5 expression via the use of online 
bioinformatics databases. 
 To interrogate binding of predicted factors through the use of EMSA 
competition assays and antibody supershifts.  
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4.3 Results 
4.3.1 Extraction of Nuclear Protein 
I used EMSAs to assess if there are any differences in protein binding to the C and T 
alleles of rs143383 in the SW872 cell line. Labelled EMSA probes and competitor 
sequences are shown in Table 1A, Appendix.   Nuclear protein was extracted and the 
EMSA reaction performed as described in Materials and Methods sections 2.4 and 2.6 
respectively.  
 
Following the extraction of cytoplasmic and nuclear protein, the purity of each fraction 
was assessed following separation by gel electrophoresis and immunoblotting using two 
antibodies, anti lamin A/C and anti Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Lamins are proteins that are present in the nucleus of the cell and are 
important for cell structure and for transcription. Anti lamin A/C is able to identify both 
the A and C types of lamin. This antibody was used to assess the presence of nuclear 
protein in both the nuclear and cytoplasmic fractions. GAPDH is a key enzyme in 
glycolysis and is mainly present in the cytoplasm of the cell. The anti GAPDH antibody 
was therefore used to assess the presence of cytoplasmic proteins in both fractions. The 
presence of GAPDH and lamin A/C in the cytoplasmic and nuclear fractions following 
extraction is shown in Figure 4.1. There is a small level of GAPDH in the nuclear 
protein fraction (Nuc.), however there is a much larger level of GAPDH in the 
cytoplasmic fraction (Cyt.). Conversely, there is a large level of lamin A/C present in 
the nuclear fraction and a very small level present in the cytoplasmic fraction. I 
considered the purity of the nuclear fraction was sufficient for use.  
 
Figure 4.1 
Optimisation of nuclear protein extraction. Cytoplasmic and nuclear proteins were 
isolated from SW872 cells. The purity of the two extracts (Nuclear – Nuc. and 
Cytoplasmic – Cyt.) was investigated following gel electrophoresis and western blotting 
using an anti-GAPDH antibody, an indicator of cytoplasmic protein content, and an 
anti-Lamin A/C antibody, an indicator of nuclear protein content.  
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4.3.2 Optimisation of the Electrophoretic Mobility Shift Assay (EMSA) 
An optimisation EMSA was performed using 200fmol of C or T allele probe incubated 
with binding buffer, DTT and Poly (dI:dC) alone as shown in Figure 4.2A (lanes 1 and 
2), or with the addition of 5µg of nuclear extract (lanes 3 and 4). Different components 
were also added to a reaction containing 5μg nuclear extract to assess optimal binding 
conditions, these included salmon sperm (lanes 5 and 6), glycerol (lanes 7 and 8), NP40 
(lanes 9 and 10), KCl (lanes 11 and 12), MgCl2 (lanes 13 and 14) and EDTA (lane 15). 
The five protein complexes binding to the two probes are highlighted by arrows. Most 
of the conditions show a similar pattern of binding, however, binding of complex two 
increases the presence of MgCl2, whilst complex four appears to bind most abundantly 
in the presence of KCl. There does not appear to be any proteins binding solely to one 
allele, although there are intensity differences in some complexes between the two 
probes.  
 
Binding to the C allele probe was then assessed for a second time using MgCl2, KCl and 
EDTA and combinations of each of these (Figure 4.2B). Excess amounts of unlabelled 
C allele competitor were added to assess if the binding of these complexes was specific 
to the probe sequence. Complex binding to the probe was weak in the presence of both 
KCl and EDTA, whereas in the presence of MgCl2 there was an abundance of protein 
binding. Furthermore binding of the two complexes indicated by the arrows was 
reduced upon addition of increasing amounts of unlabelled C allele competitor, 
confirming that the binding of these complexes is sequence specific. Of the different 
combination conditions tested, binding in the presence of MgCl2 alone appeared to be 
optimal, thus subsequent EMSAs were performed in the presence of MgCl2.  
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Figure 4.2 
Optimisation of binding conditions of proteins to the C and T allele EMSA probes.              
(A) EMSA analysis optimising the conditions for the binding of proteins using C and T 
allele probes for rs143383 and nuclear extract from SW872 in lanes 3-16. Lanes 1 and 2 
contain C and T allele probes but no nuclear extract. Lanes 5-16 contain salmon sperm 
DNA (SSperm), glycerol, NP40, potassium chloride (KCl), magnesium chloride 
(MgCl2) and in lane 16, EDTA. The arrows indicate protein complexes binding to the 
probes. (B) EMSA analysis using the C allele probe and nuclear extract from SW872 
cells. Increasing concentrations of unlabelled C allele competitor were added to the 
EMSA reaction in each condition of potassium chloride (KCl), magnesium chloride 
(MgCl2), EDTA and combinations of MgCl2 and KCl, EDTA and KCl, EDTA and 
MgCl2, EDTA and KCl and MgCl2. The arrows indicate specific binding complexes.  
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4.3.3 Differential Protein Binding to the rs143383 C and T alleles 
Following optimisation of binding, unlabelled C and T allele competitors were used to 
identify any differences in binding affinity to the two probes (Figure 4.3).  Both of the 
specific complexes binding to the C allele probe (marked by arrows in Figure 4.3) were 
outcompeted with excess unlabelled C and T allele competitor, and vice versa for the T 
allele probe. Higher concentrations of C allele unlabelled competitor were required to 
compete binding of the two complexes to the T allele probe and complex binding was 
competed from the C allele probe at a lower concentration of T allele competitor 
compared to C allele competitor. These results suggest the two protein complexes bind 
more avidly to the T allele, compared to the C allele.  
 
Figure 4.3 
EMSA analysis using C and T allele probes and nuclear extract from SW872. 
Increasing concentrations of unlabelled C and T allele competitor were added to the 
EMSA reaction containing the C and the T allele probes, with the arrows indicating the 
specific complexes binding to the probes. 
The region of binding of the two complexes to GDF5 was then assessed by the addition 
of smaller competitor sequences. Figure 4.4 shows protein binding to the C and T allele 
full sized probes, and competition with three competitors encompassing different 
regions of the full sized probe. The competition assay suggests that protein binding is 
strongest to the full sized probe, suggesting this whole region is necessary for the 
binding of complexes 1 and 2.  There is a small degree of competition from the C and T 
allele probes using the 50x concentration of competitor 1 and also from the T allele 
probe using competitor 2. Competitor 3 did not compete binding to either allele, 
suggesting that the region upstream of the polymorphism may be more important in 
comparison to the downstream region for complex 1 and 2 binding.  
0    5x  10x  25x 50x 0     5x  10x  25x 50x 0     5x  10x  25x 50x0    5x   10x  25x  50x
C Competitor T CompetitorT Competitor C Competitor
C Probe T Probe
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Figure 4.4 
EMSA analysis investigating the region of complex binding to the GDF5 C and T allele 
probes. The EMSA reaction contained the C or T allele labelled probes and nuclear 
extract from SW872. Increasing concentrations of the unlabelled competitors of varying 
sizes (full length competitor, and three shorter competitors) covering different regions 
were added to the EMSA reaction. The sequences of each of the competitors are shown 
below the EMSA, with the rs143383 polymorphism highlighted in bold and underlined. 
4.3.4 The Identification of Sp1 and Sp3 binding to GDF5 by EMSA 
Following the discovery that two protein complexes bind to the GDF5 probe and that 
their binding is modulated by the two alleles of rs143383, three online databases were 
used to identify proteins predicted to bind at this site as described in Materials and 
Methods section 2.6. Table 4.1 lists the transcription factors predicted to bind, the 
consensus sequence of the factors and the database used for identification. Increasing 
concentrations of consensus sequence competitors for each of these factors were added 
to the EMSA reaction and the results of this are shown in Figures 4.5A and 4.5B. Both 
of the complexes binding to the C and T allele probes are competed with increasing 
concentrations of E2F1, EllaEa, IA-1, p53, Sp1/Sp3/ETF (Sp1) and GABP competitors. 
Binding to the C allele probe is competed with the KLF16 competitor (Figure 4.5B).  
 
 
 
 
 
 
 
 
 
T 10x  50x  T 10x  50x   T 10x   50x  T 10x  50x    
Full Size Comp 1 Comp 2 Comp 3
T Allele Competitors
Full Size - GAGAAAGGGGGCGGT[C/T}GGCTTTCTCC
Comp 1 - GAGAAAGGGGGCGGT[C/T]GG
Comp 2 - GGCGGT[C/T]GGCTTT
Comp 3 - GGT[C/T]GGCTTTCTCC
Full Size Comp 1 Comp 2 Comp 3
C 10x  50x  C 10x  50x   C 10x  50x   C 10x 50x    
C Allele Competitors
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Factor  Consensus Sequence (5ʹ-3ʹ) Database  
Sp1/Sp3/ETF GGGGGCGGGG Promo 
3.0/Tess/TransFac 
E2F1 (1) 
E2F1 (2) 
E2F1 (3) 
E2F2 
AGGGCGG 
TCTTTCCCGCCTA 
TAGCCCGCGAAA 
ATTTTTCCCGCCT 
Promo 3.0 
EllaEa GAGGGCG Promo 3.0/Tess 
EGR1 TGTGGGCGGGAGC Promo 3.0 
GCF1 AGCGCGGGCCG Promo 3.0 
RC2 GGTTTA Promo 3.0 
IA-1 TGTAAGGGGGCGA Promo 3.0 
p53 GGGCGGT Promo 3.0 
NF-1 GCCAA Promo 3.0/Tess 
CTF GCGTTTGG Promo 3.0 
DRF1.1 GGCGGTGACT Promo 3.0 
KLF16 GGGGCGGTG Promo 3.0 
c-Myb GGCGGTTG Tess 
GABP (1) 
GABP (2) 
GABP (3) 
GGGGGGTT 
GGCACTTCCGGT 
TCGGGTGTT 
Tess 
CP2 ATTGG Tess 
 
Table 4.1 
Consensus sequence of proteins predicted to bind to rs143383: The trans-acting factors 
predicted to bind to the sequence encompassing rs143383, their consensus sequence and 
the database used for identification.  
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Figure 4.5 
EMSA competition analysis. (A) and (B) The addition of increasing concentrations of 
unlabelled consensus competitors that were predicted to bind to GDF5; c-Myb, E2F1, 
EllaEa, EGR, GCF1, RC2, IA-1, Sp1/Sp3/ETF, NF-1, GABP, CP2, CTF, DRF1.1, 
KLF16.  
 
 
 
 
 
 
c-Myb E2F1(1) EllaEa EGR1       GCF1             RC2          IA-1        p53   Sp1/Sp3/ETF 
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Further assessment of Sp1/Sp3/ETF, E2F1, EllaEa, IA-1 and P53 was carried out, 
involving the addition of a greater range of concentrations of the consensus competitors. 
The Sp1/Sp3/ETF competitor outcompeted binding to both the C and T allele probes in 
a competitor concentration dependent manner (Figure 4.6A). Binding of the lower 
mobility complex to the T allele probe was outcompeted in a concentration dependant 
manner on the addition of increasing concentrations of E2F1 and EllaEa competitors, 
however binding of the higher mobility complex only slightly decreased at the 50x 
competitor concentration (Figure 4.6B). The IA-1 and p53 competitors competed 
protein complex binding to only a limited extent and did not do so in a competitor 
concentration dependent manner (Figure 4.6B). E2F1 is part of a family of E2F 
transcription factors and has three alternative consensus sequence binding sites. All 
three were tested whilst the binding of E2F2 was also assessed. Binding to the T allele 
probe was not affected by addition of the two of the three alternative E2F1 consensus 
competitors; the addition of increasing E2F2 consensus competitor decreased the 
binding of both complexes to the probe (Figure 4.6C). GABP also has three known 
consensus sequences; the two additional consensus competitors did not compete binding 
of either protein complex to the T allele probe (Figure 4.6C).  
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Figure 4.6 
EMSA analysis using additional concentrations of competitors and alternative 
consensus sequences. (A) The addition of increasing concentrations of the Sp1/Sp3/ETF 
unlabelled consensus competitor to the C and T allele probes. (B) The addition of 
increasing concentrations of E2F1, EllaEa, IA-1 and p53 to the EMSA reaction 
containing the T allele probe. (C) The addition of increasing concentrations of three 
E2F1 consensus competitors, an E2F2 competitor and two alternative GABP 
competitors.  
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Addition of the Sp1/Sp3/ETF consensus competitor consistently competed binding to 
both the C and T allele GDF5 probes in a concentration dependent manner, thus the 
binding of Sp1 and Sp3 was investigated further by the addition of antibodies targeting 
the transcription factors. The binding of E2F1 and E2F2 was further assessed using an 
antibody that recognises E2F1 and E2F2. I did not take the analysis of EllaEa any 
further due to the unavailability of an antibody targeting the protein. Additionally, the 
binding IA-1, p53 and GABP was not investigated further because the addition of 
increasing concentrations of consensus competitors did not compete binding to the 
GDF5 probes in a concentration dependent manner.  The binding of KLF16 was 
assessed further by antibody supershift and an antibody against EGR was used as an 
additional species matched control.  
The antibody targeting Sp1 resulted in a supershift of two proteins from the lower 
mobility complex and addition of an antibody targeting Sp3 supershifted both the higher 
mobility complex, and a protein from within the lower mobility complex (arrows in 
Figure 4.7A). These results confirm the binding of Sp1 and Sp3 to the GDF5 sequence 
in vitro in SW872 cells. Binding was also demonstrated by EMSA supershift in two 
additional human cell lines, the chondrosarcoma cell line SW1353, and the 
osteosarcoma cell line MG63, and also in human articular chondrocytes (Figure 4.7B 
and C). No supershifts were observed on the addition of antibodies targeting 
E2F1/E2F2, EGR and KLF16 (Figure 4.8).  
Finally, the binding of the histone deacetylases HDAC1 and HDAC2 was investigated 
as these enzymes have previously been reported to form a repressive complex with Sp1 
and Sp3. The addition of antibodies targeting the two enzymes did not however affect 
protein binding to either C or T allele probes (Figure 4.8).  
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Figure 4.7 
EMSA antibody analysis. (A) Supershift experiment demonstrating the effect of adding 
antibodies targeting Sp1, Sp3 or Sp1 and Sp3 together (1+3), compared to the IgG 
rabbit antibody control (Con) using the C or T allele probe. The arrows indicate the 
supershifted complexes. (B) Supershift experiment demonstrating the effect of adding 
antibodies targeting Sp1 and Sp3 to the EMSA reaction containing the C allele probe, 
compared to the IgG rabbit antibody control (Con). Nuclear extracts from SW872, 
SW1353 and MG63 cell lines and from human articular chondrocytes (HAC) were 
used. The arrows indicate supershifted complexes. (C) Supershift experiment 
demonstrating the effect of adding antibodies targeting Sp1 and Sp3 to the EMSA 
reaction containing the T allele probe, compared to the IgG rabbit antibody control 
(Con). Nuclear extracts from SW872, SW1353 and MG63 cell lines and from human 
articular chondrocytes (HAC) were used. The arrows indicate supershifted complexes.  
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Con  Sp1  Sp3  1+3
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Con  Sp1  Sp3  1+3
C Probe T Probe
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T Probe T Probe
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T Probe
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Figure 4.8 
Supershift experiment: demonstration of the affect of adding antibodies targeting E2F1, 
EGR, HDAC1 (H1), HDAC2 (H2), KLF16 (KLF) using the C and T allele probes, 
compared to the IgG rabbit antibody control (Con) and C or T probe alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C   Con E2F1 EGR H1  H2   KLF  
Antibody
T    Con E2F1 EGR H1  H2  KLF  Sp1
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4.4 Discussion 
Two complexes binding specifically to the C and T alleles of GDF5 were identified by 
EMSA. These two complexes were found to bind differentially to the two alleles, with 
both complexes binding more avidly to the T allele. Considering a lower level of T 
allele transcript is observed, it is likely that the protein complexes binding more avidly 
to the T allele are repressing GDF5 expression. A search of bioinformatics databases 
and the use of EMSA supershifts confirmed the binding of Sp1 and Sp3 to the C and T 
allele GDF5 probes in vitro in the SW872 cells. I then confirmed the binding of Sp1 and 
Sp3 to GDF5 in vitro in SW1353 chondrosarcoma cells, in MG63 osteosarcoma cells 
and in human articular chondrocytes.  
Sp1 and Sp3 are well characterised transcription factors and are members of a family of 
transcription factors, known as Sp1 like proteins or Krϋppel-like factors (KLFs). 
Members of this family contain the same characteristic DNA binding domain, and bind 
to GC rich elements (GC boxes – GGGGCGGGG), in addition to GT boxes 
(GGGTGTGGC), within genes. Sp1 like proteins and KLFs are present in a number of 
species and so far 21 human Sp1/KLF like proteins have been identified. Sp1-Sp6 are 
highly related to Sp1 and form a subgroup of the family [301].  
Sp1 was identified in the early 1980s and was one of the first transcription factors to be 
purified and characterised in mammalian cells [302, 303]. Sp1 was found to bind to the 
GC rich region in the simian virus 40 (SV40) promoter through its characteristic DNA 
binding domain [302]. Sp3 was initially identified as binding to the GT box in the 
promoter of the T-cell antigen receptor alpha gene [304]. Both Sp1 and Sp3 are 
ubiquitously expressed and regulate the expression of a wide variety of genes and are 
involved in a number of cellular processes [305]. Furthermore, there are estimated to be 
over 12,000 Sp1/Sp3 binding sites in the human genome [306]. 
 
Sp1 has been described as one of the most potent transcriptional activators, although it 
has been reported to repress gene expression when binding as part of a repressive 
complex [307, 308]. Many of the Sp proteins interact with co activators and co 
repressors via activation and repression domains. There are a variety of proteins 
reported to bind with Sp1 to modulate gene transcription, including activators such as 
p300 and CBP and other transcription factors such as YY1 and E2F [309, 310]. A co-
factor for Sp1, CFSP is a large protein complex that has been purified and is required 
for Sp1 to mediate transcriptional activation [311]. Sp3 can act as an activator or a 
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repressor and its repression has been reported to be a result of competition with Sp1 for 
occupancy of the GC boxes.  Sp3 was found to repress Sp1 mediated activation in a 
linear dose-dependent manner, and Sp3 with a mutated DNA binding domain did not 
affect Sp1 activation, confirming that it represses Sp1 activation through competition 
for binding to the DNA [312]. Sp3 contains an inhibitory domain and mutations within 
this domain change its repressive function to a strong trans-activator of promoters 
[313]. 
Sp1 and Sp3 have been reported to interact with proteins in the basal transcription 
machinery [314]. In addition, Sp1 with Sp3 can recruit the repressor complex HDAC1, 
HDAC2, RbAp48 to repress gene transcription [308]. Sp1 has also been reported to 
recruit chromatin remodelling proteins such as the SWI/SNF complex to modulate the 
expression of genes via altering chromatin structure [315]. Furthermore, a role for Sp1 
in methylation of the promoters of genes has been proposed; Sp1 sites are critical for the 
maintenance of methylation free CpG islands in the Adenine phospho-ribosyltransferase 
(APRT) gene [316], Sp1 elements protect CpG islands from de novo methylation [316], 
and methylation of CpG sites prevents the binding of Sp1 [317].  
When bound to gene promoters, Sp1 can form a tetramer, serving as a docking site for 
the binding of other proteins to synergistically affect the expression of genes. Sp3 
cannot form homo-multimers and has been reported to have differential transcriptional 
effects depending on the number of Sp sites within promoters; Sp3 activates the 
expression of promoters with a single GC binding site, but responds weakly to or 
inhibits those with multiple binding sites [318].  
Further evidence of the distinct roles of Sp1 and Sp3 is evident when comparing the 
knockout phenotypes in mice. Sp1 knockout mice display a number of abnormalities 
and are growth retarded confirming a key role for Sp1 during development, with 
embryo lethality at around day 11 of gestation. Many target genes of Sp1 however are 
unaffected in these mice and methylation free islands are maintained [319], furthermore 
Sp1 null embryonic stem cells have normal growth characteristics and survival rates. 
Considering the large number of genes that Sp1 is reported to regulate and its 
involvement in a number of cellular processes, it has been suggested that this phenotype 
may be due to the presence of Sp3 [319]. Sp3 deficient mice are growth retarded but 
develop until birth with no gross abnormalities. After birth, the mice die quickly with 
respiratory failure. Sp3 knockout mice also have a pronounced defect in late tooth 
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formation. Furthermore, Sp3 is required for proper skeletal ossification; both 
endochondral and intra-membranous ossification are impaired in Sp3 null embryos. 
This is due to the reduced expression of the osteoblastic specific  marker gene 
osteocalcin [320] . It was concluded therefore that Sp1 and Sp3 have similar, and 
potentially redundant, functions during early development but exert distinct and highly 
specific functions in later developmental stages [321]. 
  
It is clear that both Sp1 and Sp3 have a wide variety of functions and are involved in 
many processes. Further analysis will aim to establish a role for these two ubiquitous 
transcription factors in the transcriptional control of GDF5. It appears from previous 
studies that Sp1 and Sp3 can form a repressive complex alongside other factors, and 
Sp1 can form homodimers enabling the binding of other proteins within the 
transcriptional complex. The next chapter will therefore focus on identifying additional 
novel factors binding to GDF5 using a different methodology.  
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Chapter 5: The Identification by Mass Spectrometry of P15 as a 
GDF5 Trans-acting Factor  
5.1 Introduction 
In addition to the identification of trans-acting factors using online prediction software 
tools and EMSAs, I wanted to find an alternative method to identify differential protein 
binding to the GDF5 gene. An oligonucleotide pull down assay using two regions of 
DNA, one for each rs143383 allele and magnetic beads to enable isolation was 
explored. I identified a method in the literature, whereby the research group had 
combined an oligonucleotide pull down assay with tandem mass spectrometry to enable 
quantitative assessment of protein binding to DNA. Their aim was to identify binding of 
factors to mtk, a gene important for immunity in Drosophila. They compared the 
binding of proteins to a wild-type region of DNA with binding to a mutated region of 
DNA and identified a transcription factor that regulates the expression of this gene 
[322].  
Quantification of proteins within different samples can be carried out simultaneously 
using tandem mass tags (TMTs). TMTs are a set of identical tags that contain a reactive 
group (which binds to peptides on the amino terminus), a reporter ion (which following 
tandem mass spectrometry provides information on the abundance of the peptide) and a 
mass normalisation group (which balances mass differences between tags to ensure the 
same overall mass) [323]. Using an oligonucleotide pull down assay, in addition to 
TMT labelling and tandem mass spectrometry, I was therefore able to identify proteins 
binding to each rs143383 allele, and quantitatively assess if there were any differences 
in binding affinity for the two alleles.   
Achim Treumann and Karen Lowden assisted in the design, data requisition and 
analysis of the TMT mass spectrometry experiment.  
5.2 Aims 
 To isolate proteins binding to the GDF5 gene using an oligonucleotide pull 
down assay. 
 To quantitatively assess differences in protein binding between the rs143383 C 
and T alleles using tandem mass tag labelling and tandem mass spectrometry. 
 To validate proteins identified using RNAi.  
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5.3 Results 
5.3.1 Optimisation of the PCR 
A 212bp region of patient DNA (CC or TT genotype at rs143383) was amplified using a 
5ʹ biotinylated primer and unmodified 3ʹprimer. The PCR was first optimised by testing 
seven annealing temperatures ranging from 50-64.7°C and MgCl2 at a final 
concentration of 1mM and 2mM. The 212bp DNA region is amplified optimally at 
2mM MgCl2 and a temperature of 54.2°C was chosen for the annealing (Figure 5.2). 
Following optimisation of the PCR, the concentration of DNA required for the pull 
down assay was determined. The DNA was quantified and the CC and TT DNA 
samples diluted to equal concentrations. 4μg of each DNA sample was used for a serial 
dilution and compared by agarose gel electrophoresis to verify that equal proportions of 
C and T allele DNA were present. The binding capacity of 1mg of magnetic beads is 
20pmol DNA, thus an excess concentration of 30pmol of biotinylated template was 
added to the reaction in order to ensure the saturation of the streptavidin coated 
magnetic beads and minimise non specific protein binding to the beads. 
 
 
Figure 5.1 
Optimisation of PCR reactions. These were performed using either 1mM or 2mM 
MgCl2 and annealing temperatures ranging from 50-64.7°C. Following the PCR, the 
PCR products were analysed by agarose gel electrophoresis. The 212bp PCR product is 
shown.  
 
5.3.2 Optimisation of the Binding Conditions 
The purity of nuclear extract using the nuclear extraction protocol described in 
Materials and Methods section 2.4 has been previously discussed in Chapter 4.3.1. 
Following the extraction of nuclear protein, I assessed if the salt concentration of the 
nuclear lysate impacted upon protein binding to the GDF5 DNA region. Following 
extraction, the nuclear protein buffer contained a high level of salt, I dialysed half of 
this sample into a low salt buffer as described in Materials and Methods section 2.7 and 
compared protein binding in the two buffers by completing concurrent pull downs using 
50       51.2   54.2    58.9    62.7     64.7               50      51.2   54.2    58.9    62.7    64.7             
1mM                                                                    2mM
Annealing 
Temperature ( C)
Magnesium
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the two extracts. Samples that contained no DNA were used as a control. The forward 
and reverse PCR oligonucleotides contain an EcoR1 restriction enzyme site enabling the 
isolation of protein/DNA complexes from the magnetic beads following an EcoR1 
digestion. Protein samples and the isolated bead samples were separately 
electrophoresed and detected by coomasssie staining (Figure 5.2). Lanes 2-5 show 
binding of proteins in low salt conditions. Lanes 2 and 3 do not contain DNA and no 
protein is detected in these samples. Lanes 4 and 5 contain proteins that bound to DNA, 
lane 4 showing protein present bound to the beads, and lane 5 showing proteins that 
were separated from the beads following the digestion. Lanes 6-9 show binding of 
proteins in high salt conditions. Lanes 8 and 9 clearly have fewer bound proteins than 
lanes 4 and 5, demonstrating that there are a greater number of proteins binding under 
the low salt binding conditions. In subsequent pull down assays therefore, the proteins 
were dialysed into a low salt buffer prior to incubation with DNA to maximise protein 
binding. Additionally, there appears to be a greater number of proteins present in the 
bead samples (lanes 4 and 8) in comparison to isolated proteins following the EcoR1 
digest (lanes 5 and 9). This could be because a greater number of proteins are binding to 
the beads non specifically compared to the number binding to the DNA or because the 
EcoR1 digest is not efficiently releasing the DNA/protein complexes from the beads. 
The latter appears more likely considering the similarity in the pattern of binding 
between the two lanes. In subsequent pull down assays therefore, I isolated proteins 
from the beads by heating to 95°C and using a magnetic separator. Although this new 
approach resulted in proteins that bind non specifically to the beads being present within 
the sample for analysis, the use of a beads only (no DNA) control sample enabled me to 
identify non specific binding proteins.  
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Figure 5.2 
Optimisation of the binding of proteins to a region of GDF5 DNA. Lane 1 contains a 
protein sizing ladder. Lanes 2-5 contain proteins that bound to the DNA under low salt 
conditions. Lanes 2 and 3 are control samples with no DNA. Lane 4 contains proteins 
present in the sample containing beads and lane 5 contains proteins isolated that were 
bound to DNA. Lanes 6-9 contain proteins bound under high salt conditions, lanes 6 
and 7 have no DNA, lane 8 contains proteins present in the sample containing beads and 
lane 9 contains proteins bound to DNA.  
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5.3.3 Gels for Quantification 
The three repeat oligonucleotide pull down assay gels that were taken forward for 
analysis by quantitative tandem mass spectrometry are shown in Figure 5.3. The pattern 
of protein binding to the two alleles in the three experiments is similar.  
 
Figure 5.3 
The three oligonucleotide repeat experiments taken forward for analysis by tandem 
mass spectrometry. (A) Oligonucleotide pull down repeat 1: Lane 2 has no DNA, lanes 
3 and 4 contain proteins binding to the C and T alleles respectively. Lane 1 contains a 
protein sizing ladder (B) Oligonucleotide pull downs 2 and 3. Lane 1 and lane 5 have no 
DNA. Lanes 2 and 6 and lanes 3 and 7 contain proteins binding to the T and C alleles 
respectively. Lanes 4 and 8 contain a protein sizing ladder.  
5.3.4 Mass Spectrometry data analysis 
The data was analysed by DAVID pathway analysis functional annotation tool available 
at http://david.abcc.ncifcrf.gov/. The functional classifications of the proteins identified 
in each mass spectrometry experiment were listed according to a calculated P-value, 
which represents the enrichment of the proteins identified in the functional categories. 
For example, common functions of proteins that showed high enrichment common to all 
three experiments was acetylation, nuclear proteins, ribonucleoproteins, 
phosphoproteins, RNA binding proteins and mRNA processing proteins. Proteins with a 
known role in transcription, including activators, repressors, coactivators, proteins 
associated with RNA polymerase II and proteins involved in transcriptional regulation 
were also identified.  
In order to compare the data obtained from the three repeat experiments, I first removed 
proteins from the analysis that were identified in the control (no DNA) sample in each 
of the three experiments. I then sorted the results according to their relative abundance 
in the C allele DNA sample compared with the T allele DNA sample (C/T ratio). The 
1              2               3      4             5               6               7      8               Lane
No DNA         TT               CCNo DNA     TT             CC
Lane 1          2                     3                   4                
No DNA               CC TT
A: Oligonucleotide pull down 1 B: Oligonucleotide pull downs 2 and 3
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results obtained in each of the three experiments are shown in Figure 5.4. In experiment 
one, in total, 352 proteins were identified, with C/T ratios ranging from 8 to 0.126. In 
experiment two, 88 proteins were identified, with C/T ratios ranging from 6.2 to 0.384. 
In experiment three, 127 proteins were identified with C/T ratios ranging from 8.9 to 
0.164. The number of proteins identified in experiments two and three is similar, whilst 
far more proteins were identified in experiment one. This may be a result of the time 
periods between experiments; experiments two and three were performed within weeks 
of one another and analysed concurrently by tandem mass spectrometry, whilst the first 
experiment was performed and subject to tandem mass spectrometry a few months prior 
to this which could result in experimental variability. Aside from protein number, the 
spread of C/T values is similar in all three experiments. 
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Figure 5.4 
Comparison of the three repeat mass spectrometry experiments. Proteins were sorted 
according to their abundance in the C allele DNA sample in comparison with the T 
allele DNA sample (Ratio C/T). The proteins were then numbered, with protein 1 
having the largest C/T ratio, and the highest number protein having the smallest C/T 
ratio.  
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Each experiment was first analysed independently and for each I identified proteins with 
a known role in transcription. Table 5.1 shows the transcription associated proteins that 
were identified in all three or in two of the three repeat experiments. The next stage of 
analysis involved sorting results based on C/T ratio to obtain a comparison of the 
abundance of proteins present within each sample. The results of each repeat were 
colour coded and combined, then sorted alphabetically. Any proteins that were present 
in the background sample were highlighted bold. Proteins present in all three 
experiments and absent in the background samples were ranked highest. Proteins 
present in all three experiments, and present in the background in one of the 
experiments were ranked second highest, continuing downwards in a tiered analysis, 
shown in Document 1, Appendix. The unmodified mass spectrometry data can be found 
on the excel file on the supplementary disc attached to this thesis (Document 2, 
Appendix). 
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Table 5.1   
The transcription related proteins that were identified in two or more of the quantitative 
mass spectrometry experiments.  
Following this analysis, there were three factors that were present in the top three 
groups that had a role in transcription and all these proteins were present in higher 
abundance in the T allele DNA sample compared to the C allele DNA sample. These 
factors were Poly(ADP-Ribose) polymerase I (PARP1), POLR2H and Activated RNA 
polymerase II transcriptional coactivator P15 (P15). After studying the published 
research into each of these factors, I prioritised P15 for further analysis, due to its dual 
function as a transcriptional activator and repressor. PARP1 on the other hand is 
predominantly known for its involvement in DNA repair and POLR2H is a component 
of the general transcription machinery.  
Protein Identified  Identified by Repeat 
Number 
RNA binding motif protein 14 All 3 
Activated RNA polymerase II transcriptional 
coactivator P15 
All 3 
Poly (ADP-ribose) polymerase 1 All 3 
Similar to RNA binding motif protein 39 All 3 
Thyroid hormone receptor associated protein 3 All 3 
Ubiquitin-like with PHD and ring finger 
domains 1 
All 3 
YLP motif containing 1 2 and 3 
Non-POU domain containing, octamer binding 2 and 3 
Replication factor C 2 and 3 
Splicing factor proline/glutamine-rich 1 and 2 
Hairy and enhancer of split 7 1 and 3 
Upstream binding transcription factor 1 and 3 
RuvB-like 1 1 and 2 
DEAH (Asp-Glu-Ala-His) box polypeptide 9 1 and 2 
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5.3.5 Further analysis of P15 
In order to verify if P15 is involved in GDF5 transcription and if its activity is affected 
by genotype at rs143383, I first depleted the expression of P15 by using siRNA. The 
optimal conditions for target protein knockdown using siRNA within this cell line were 
determined during my Master of Research project and the conditions used are described 
in Materials and Methods section 2.9 and the siRNA details are given in Table 6, 
Appendix. The depletion of P15 mRNA was confirmed by real time RT-PCR (Figure 
5.5A). The overall expression of GDF5 was increased, with a significant fold change 
(p<0.01) observed upon P15 knockdown (Figure 5.5B).  I then used allele specific real 
time PCR to assess if P15 differentially affects the two alleles of rs143383, and as such 
could contribute to the DAE mediated by this SNP. Depletion of P15 significantly 
(p<0.05) attenuated the DAE from a C/T allelic ratio of 1.5 in the control (NTsiRNA) to 
1.26 (P15 siRNA) (Figure 5.5C).  
 
 
 
97 
 
 
Figure 5.5 
P15 depletion by RNAi (A) Expression of P15 mRNA, shown as a percentage of the 
control non-targeting siRNA (NTsiRNA) treated cells following P15 siRNA 
knockdown. Error bars denote the standard error of the mean (SEM). *** p<0.001, 
calculated relative to the NTsiRNA value using a Student’s 2 tailed t-test. (B) Fold 
change in GDF5 expression following P15 siRNA knockdown and shown relative to 
the NTsiRNA control. Error bars denote SEM. ** P<0.01, calculated using a Student’s 
2 tailed t-test. (C) The rs143383 C/T allelic ratio is shown following P15 siRNA 
knockdown and compared against treatment with the NTsiRNA control. Allelic ratios 
were normalised to genomic DNA (gDNA). Error bars denote SEM. *p<0.05, 
calculated using a Student’s 2 tailed t-test. Three replicates were performed.  
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5.3.6 EMSA analysis of P15 
P15 does not have a known binding consensus sequence and I was therefore not able to 
use an EMSA to investigate competition for binding to the fluorescently labelled 
rs143383 C and T allele probes. On the addition of an antibody targeting P15 to the 
EMSA reaction, I observed a decrease in the two specific protein complexes binding to 
the two probes (Figure 5.6A).  This effect was replicated using nuclear extracts from the 
chondrosarcoma cell line SW1353 and the osteosarcoma cell line MG63, and using 
nuclear extract from human articular chondrocytes (HACs; Figure 5.6B).  
 
Figure 5.6 
Demonstration of the effect of adding P15 antibody to the EMSA reaction compared to 
the IgG rabbit antibody control (Con). (A) The EMSA reaction contains C and T allele 
probes and SW872 nuclear extract. The arrows indicate the affected complexes. (B) The 
EMSA reaction contains C and T allele probes and extract from SW1353 and MG63 
cells in addition to extract from human articular chondrocytes (HAC). The arrows 
indicate the affected complexes. 
 
 
 
 
C Probe T Probe C Probe T Probe C Probe T Probe
Con   P15 Con   P15 Con   P15 Con   P15 Con   P15 Con    P15
SW1353 MG63 HAC
Antibody Antibody
B: Addition of P15 antibody to the EMSA using nuclear extracts from SW1353, MG63 and HAC
C Probe T Probe
Con  P15 Con  P15
SW872
A: Addition of P15 antibody to the EMSA using nuclear extracts from SW872
Antibody
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5.4 Discussion 
I was able to isolate protein binding to the two alleles of rs143383 using an 
oligonucleotide pull down assay and identify and quantify the abundance of each of 
these proteins in the C and T allele DNA samples following tandem mass tag labelling 
and tandem mass spectrometry. After completing three repeat experiments, the data was 
analysed and candidates were prioritised based on their absence in the control (no DNA) 
sample, and their known functional involvement in transcription. P15 was identified as 
a transcription factor that was more abundant in the T allele DNA sample in comparison 
with the C allele DNA sample.  
There are differences in the number of proteins identified as binding to GDF5 in the 
three repeat experiments, and slight variability in the spread of C/T ratios observed. 
Unavoidable variability amongst the experiments may account for these differences, in 
particular the difference in number of proteins identified in the first repeat compared to 
the final two repeats may be a result of the time period between these experiments and 
potential variability in the tandem mass spectrometry process. This variability was not 
considered important since only proteins that were identified in all three or in two of the 
three experiments, and which showed consistent values in each repeat experiment, were 
considered further.  
Depletion of P15 mRNA increased the expression of GDF5 and significantly attenuated 
the DAE. I was unable to investigate the binding of P15 to the rs143383 C and T allele 
probes using competition EMSAs. However, on the addition of an antibody targeting 
P15 to the EMSA reaction I observed a decrease in the binding of the two specific 
binding complexes, suggesting that P15 may be present within the complex binding to 
the two GDF5 probes. Observing a decrease in the intensity of complexes binding to the 
EMSA probes on the addition of an antibody, rather than a supershifted complex, 
implies that the antibody is binding to the region of the protein that binds to the DNA, 
thereby leading to a reduction in the amount of protein-DNA complex observed [324]. 
This effect was also observed using nuclear extract from two further cell lines, SW1353 
and MG63 and when using nuclear protein extracted from human articular 
chondrocytes.  
P15 is also known as positive cofactor 4 (PC4). Positive cofactors (PC1-PC6) and 
negative cofactors (NC1, NC2) are a class of general cofactors that positively or 
negatively regulate transcription by mediating interactions between the basal 
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transcription machinery and gene specific transcription factors. These cofactors were 
identified following the fractionation of HeLa cell nuclear extracts to identify proteins 
stimulating activator dependent transcription [325]. Furthermore, they have a dual role 
in transcription; in the presence of activators, the positive cofactors increase promoter 
activity, in the absence of activators however, these cofactors are capable of repressing 
basal transcription [325]. They are distinct from other general transcription factors in 
that they are dispensable for basal-level transcription and distinct from activators as 
most do not bind to DNA or DNA binding is not sequence dependent.  
P15 is a 15kDa protein and like other positive cofactors, when activators are absent, P15 
can function as a repressor protein, repressing basal transcription by stabilizing a 
minimally transcriptionally active PIC. In the presence of activators however, P15 can 
interact with components of the basal transcriptional machinery and stimulate 
transcription; a large (up to 90 fold) induction of transcription was mediated by P15 in 
the presence of activators. Compared to the other positive cofactors, P15 mediates the 
greatest effect on transcriptional activation and the gene that encodes P15 (SUB1) is 
highly conserved between different species [326].  
P15 is abundantly expressed and performs a diverse range of functions. Upon P15 
knockdown, 128 genes were up regulated and 49 down regulated. Furthermore, P15 has 
been reported to interact with a number of proteins containing different activation 
domains, including the acidic activation domain of VP16, the proline-rich activation 
domain of CTF, and the glutamine-rich activation domain of Sp1 [326]. P15 can bind to 
components of the basal transcription machinery including TFIIA, TFIIH and RNA 
polymerase II and serves as a bridging molecule between the PIC and coactivators. 
Furthermore P15 can enhance DNA binding of some activators, or enhance PIC 
formation or RNA polymerase II elongation. Recombinant P15 protein has been shown 
to enhance AP-2, NF-κB and Sp1 mediated gene activation [327, 328].   
P15 has also been reported to associate with chromatin and can efficiently pull down all 
the core histones and preferentially binds to histones H3 and H2B. In addition, P15 
induces chromatin condensation, suggesting a role in gene repression via chromatin 
remodelling. Knocking down expression of P15 was found to alter chromatin 
organisation, leading to alteration in the higher ordered chromatin structure [329].  
P15 knockout mice show embryonic lethality at the pre-implantation stage, indicating 
the vital role of P15 in mouse embryonic development. P15 embryos were smaller and 
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disorganised at E6.5 when gastrulation starts, indicating that the major cause of lethality 
was due to impaired cellular proliferation. Heterozygous P15 mice however did not 
exhibit developmental problems, suggesting that reduced amounts of P15 may be 
sufficient for normal development [330].  
P15 appears to be a valid trans-acting factor candidate that may be binding 
differentially to the alleles of rs143383 and which may modulate the DAE at this locus. 
The role of P15, in addition to Sp1 and Sp3 is further assessed in Chapter 7.  
Aside from P15, many other factors were identified that are binding differentially to the 
two rs143383 alleles. PARP1 in particular may be worthy of further investigation, but 
was not taken further in the scope of this thesis.  PARP1 catalyses poly(ADP-
ribosyl)ation, a process that involves the transfer of ADP ribose from nicotinamide 
adenine dinucleotide (NAD+ donor protein) to an acceptor protein [331]. Although 
primarily known for its role in DNA repair, PARP1 is also involved in nucleic acid 
metabolism and in the maintenance of chromatin structure, where it modifies target 
proteins by poly(ADP-ribosyl)ation. In addition to these functions, PARP1 also 
modifies transcription components such as PC3, histones, components of the basal 
transcriptional machinery such as TBP, RNA polymerase II, p53, YY1, E2F and Sp1 
[332, 333]. Poly(ADP-ribosyl)lation of DNA binding proteins such as P53, YY1 and 
Sp1 prevents their binding to DNA. Furthermore, PARP1 can also mediate repressive 
effects on transcription through incorportation into chromatin, promoting the formation 
of highly condensed chromatin, through incorporation into a corepressor complex or by 
inhibiting ligand dependent transcription [334-336]. PARP1 can thereby act as a switch, 
either mediating repression or converting transcriptionally silent  genes into an active 
state by dissociating from a co repressor complex and recruiting chromatin modifying 
enzymes and activators. Although it is unlikely considering the known functions of 
PARP1 that it is binding differentially to the two rs143383 alleles, it could be 
interacting in some way with factors that are binding to the DNA and potentially 
mediating a repressive effect on GDF5 transcription. 
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Chapter 6: Investigating DEAF-1 binding to GDF5 using five DEAF-
1 antibodies 
6.1 Introduction 
Chapter 4 examined protein binding to the two rs143383 alleles using EMSAs and 
identified the binding of Sp1 and Sp3 to the alleles. This Chapter will continue with the 
analysis of DEAF-1.  
Following the findings by Egli et al. that the GDF5 rs143383 differential allelic 
expression is apparent in all tissues of the joint, this group sought to further characterise 
the function of rs143383 by identifying trans-acting factors that are binding to this locus 
[272]. As described in Chapter 4 (4.1) they first assessed binding to the two alleles by 
EMSA and found that the C and T allele probes had differing mobilities, suggesting 
differences in protein binding. The T allele was found to bind a unique protein that was 
unresponsive to increasing concentrations of C allele competitor. 
Using three online prediction sites Egli et al. identified several transcription factors that 
were predicted to bind to rs143383 in an allele specific manner and three were chosen 
for further analysis; the Myb protooncogene protein (c-Myb), early growth response 
protein 1 (EGR1) and deformed epidermal auto-regulatory factor 1 (DEAF-1). On the 
addition of consensus competitor sequences against each of these factors, only the 
DEAF-1 competitor competed binding to the GDF5 probe. Specifically, complex 
binding to the T allele probe was competed [272]. The role of DEAF-1 was therefore 
assessed further by Egli et al. using luciferase experiments. A DEAF-1 expression 
vector was co-transfected into cells in addition to GDF5 C and T allele promoter 
luciferase constructs. DEAF-1 repressed the expression of the C and T allele GDF5 
luciferase constructs, but in accordance with the EMSA competition experiments, 
DEAF-1 repressed the T allele more significantly than the C allele [272]. This study 
highlighted DEAF-1 as a repressive factor that appears to be differentially modulating 
the expression of GDF5. 
DEAF-1 was first discovered and identified as a nonhomeodomain protein in 
Drosophila Melanogaster that interacts, in addition to other factors, with the deformed 
protein at the HOM-C gene cluster [337]. Precise expression and interaction of 
transcription factors is required for the regulation of ‘selector’ or HOM-C/Hox genes 
that determine the morphological characteristics of an organism. In drosophila, such 
genes are encoded within the HOM-C gene cluster and govern the anterior to posterior 
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patterning of developing fly embryos [338]. In vertebrates there are four Hox gene 
clusters that show homology to the HOM-C cluster in drosophila. Mutations within 
these genes result in substitution of one body part for another. All of the proteins 
encoded within this gene cluster share a region of homology in their DNA binding 
domain known as the homeodomain, and have similar binding specificities [339, 340]. 
Deformed is a homeodomain protein that is expressed in drosophila and is required for 
the segmental expression patterns established during development [341]. Specificity in 
binding to target genes is achieved through binding with co-factors, such as DEAF-1, 
that enhance the binding of homeodomain proteins [342].  
Mutations within DEAF-1 that improved binding in vitro increased the expression of 
deformed target genes. DEAF-1 was shown to bind to the human HOXD4 promoter, a 
mammalian homolog gene of deformed, suggesting that a mammalian homolog of 
DEAF-1 may exist and may modulate the expression of Hox genes [343].  
A mammalian homolog of DEAF-1 was then discovered by its affinity for the retinoic 
acid response element of target genes. Retinoic acid receptors (RARs) are nuclear 
transcription factors that bind, in addition to the retinoid-X-receptors (RXRs), to the 
retinoic acid response elements within target genes and mediate developmental effects 
such as cellular differentiation and embryogenesis [344]. DEAF-1 was identified as a 
transcription factor that interacts with RAR/RXR dimers and activates the transcription 
of the human proenkephalin promoter, a gene that is expressed in many reproductive 
and neuroendocrine tissues.  DEAF-1 was found to be expressed in many of these 
rapidly dividing tissues and is expressed at high levels in the foetus, suggesting an 
important role for this protein during development [345].  
This protein has been extensively characterised, the gene is found on human 
chromosome 11, and a number of different molecular weight proteins have been found 
in several tissues such as testis (72kDa), muscle (45kDa), brain (60kDa) and heart 
(47KDa). All tissues show the presence of DEAF-1 mRNA, DEAF-1 protein is however 
thought to be unstable in most tissues and is mainly found to be expressed in rapidly 
dividing cells [345].  
DEAF-1 knockout mice display skeletal abnormalities including rib cage defects, with a 
large proportion of the animals suffering from defective neural tube closure that causes 
death shortly after birth [346].  
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During my Master of Research project, I used siRNA to deplete the expression of 
DEAF-1 and assessed the impact of DEAF-1 depletion on the overall expression of 
GDF5. Upon DEAF-1 knockdown, I observed a significant increase in the overall 
expression of GDF5. These experiments further highlighted the importance of DEAF-1 
in modulating the expression of GDF5. The core consensus sequence for DEAF-1 is 
TCGG, the GDF5 sequence surrounding rs143383 (shown here in bold) is 
GGTCGGCT, and therefore contains the DEAF-1 consensus sequence (underscored). 
The T allele changes the sequence to GGTTGGCT and therefore no longer contains the 
DEAF-1 core consensus sequence. This single base change may result in the differential 
binding of this trans-acting factor, and thus could account for differential GDF5 
expression.   
In this chapter I sought to confirm the binding of DEAF-1 to GDF5, firstly in vitro 
using EMSAs and secondly in vivo using chromatin immunoprecipitation (ChIP). 
Furthermore, I have tested five different DEAF-1 antibodies and characterised each to 
assess their binding specificity. 
6.2 Aims 
 To assess the binding of DEAF-1 to GDF5 in vitro using EMSAs.  
 To assess the binding of DEAF-1 to GDF5 in vivo using ChIP.  
 To identify a specific antibody that targets DEAF-1.  
6.3 Results 
6.3.1 Investigating DEAF-1 binding by EMSA 
DEAF-1 was not identified as a protein binding to the rs143383 sequence by the 
database search that I performed in Chapter 4 (using the databases Promo 3.0, TESS 
and TransFac) however Egli et al. had identified DEAF-1 using three databases, two of 
which are distinct from those that I used (TESS, TFsearch and MatInspector) [272]. The 
core consensus sequence for DEAF-1 is TCGG, which encompasses rs143383. 
Following the identification of the complexes binding to the two rs143383 alleles in 
Chapter 4 by EMSA (Figure 4.6, Chapter 4), I used competition EMSAs to assess if 
DEAF-1 was binding to GDF5 in vitro using SW872 cell nuclear extract, see Materials 
and Methods section 2.6. Figure 6.1A shows the addition of three different consensus 
DEAF-1 competitors (the first identified by Promo 3.0 online software tool, the second 
by Huggenvik et al. [345] and the third by Egli et al.[272]) to the EMSA reaction 
containing the rs143383 T allele probe. The two specific complexes that were found to 
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bind to the C and T allele probes in Chapter 4 are shown and were not competed on the 
addition of increasing concentrations of any of the DEAF-1 consensus competitors 
(Figure 6.1A).  
There is an abundance of Sp1 and Sp3 protein binding to the GDF5 probe (identified 
previously in Chapter 4), thus I hypothesised that the binding of DEAF-1 may be 
masked by these two proteins. I therefore used DEAF-1 recombinant protein instead of 
the SW872 nuclear extract to further investigate DEAF-1 binding to the GDF5 probes. 
Unlabelled competitors for the C and T alleles and for DEAF-1 were added to the 
reaction; however, no binding to the probe was observed (Figure 6.1B). 
Poly (dI:dC) has been used previously in the EMSA reaction to reduce non specific 
protein binding [347]. In order to verify that the addition of Poly (dI:dC) was not 
preventing the binding of DEAF-1 to the probe, I investigated if removing it from the 
EMSA reaction would enable DEAF-1 binding to the probe to be detected. 
Furthermore, I tested two different concentrations of DEAF-1 recombinant protein and 
added the Sp1 antibody to supershift the abundant Sp1 complex to verify that the 
binding of DEAF-1 was not masked by Sp1. There was however no binding to the 
probe observed in any of these modifications (Figure 6.1C).  
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Figure 6.1 
DEAF-1 competition EMSA analysis. (A) Increasing concentrations of three different 
unlabelled DEAF-1 competitors were added to the EMSA reaction containing the 
rs143383 T allele probe and SW872 nuclear extract. The sequences of each of these 
competitors are shown below. (B) EMSA analysis using the T allele probe and DEAF-1 
recombinant protein. 25x C and T allele unlabelled competitors were added to the 
reaction. An antibody targeting DEAF-1 was added to the reaction (D1) both alone and 
in addition to 25x DEAF-1 competitor 1 and compared with the control IgG antibody 
(Con). (C) EMSA analysis using the T allele probe and both SW872 nuclear extract (T) 
and two different concentrations of DEAF-1 recombinant protein (0.05 and 0.1μg, 
containing no Poly (dI:dC)). The Sp1 antibody was also added to the reaction (+Sp1).   
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To further assess the binding of DEAF-1 to the GDF5 EMSA probes, an antibody was 
added to the EMSA reaction (DEAF-1 antibody 4, Figure 6.2A, antibodies listed in 
Table 2, Appendix). A supershifted complex was observed on the addition of the 
DEAF-1 antibody. In addition to an antibody targeting DEAF-1, an antibody targeting 
Sp1 was added to the reaction to try and identify where the supershifted complex had 
shifted from. However, there was no apparent reduction in the intensities of any the 
complexes binding to the probe (Figure 6.2A). The supershift was confirmed using 
nuclear extract from human articular chondrocytes, with protein complexes binding to 
the C and T allele probes being less intense than those observed in the SW872 cells 
(Figure 6.2B). Further concentrations of the DEAF-1 antibody were added to the EMSA 
reaction containing SW872 nuclear extract; however, there was no increase in the 
intensity of the supershifted complex with increasing antibody concentration. A 
supershifted complex was also observed in the EMSA reaction containing the C allele 
on addition of the DEAF-1 antibody. The intensity of this supershifted complex was 
lower compared with the T allele supershifted complex (Figure 6.2C). An alternative 
DEAF-1 antibody (DEAF-1 antibody five) was then added to the EMSA reaction. This 
antibody did not affect the protein complexes binding to the GDF5 T allele probe. 
Antibodies targeting Sp1 and Sp3 were used as positive control antibodies and were 
also added in addition to the DEAF-1 antibody (DEAF-1 antibody five), however 
complex binding to the T allele probe was unaffected (Figure 6.2D).  
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Figure 6.2 
DEAF-1 antibody EMSA analysis. (A) Supershift experiment demonstrating the effect 
of adding an antibody targeting DEAF-1 alone or in addition to an antibody targeting 
Sp1 to the EMSA reaction containing SW872 nuclear extract. This EMSA reaction was 
performed using the T allele probe and was compared with the control IgG antibody 
(Con). The DEAF-1 supershifted complex is highlighted by an arrow. (B) Supershift 
experiment demonstrating the effect of adding an antibody targeting DEAF-1 to the 
EMSA reaction containing nuclear extract from human articular chondrocytes. This 
EMSA reaction was performed using the C and T allele probes and was compared with 
the control IgG antibody (Con). The DEAF-1 supershifted complex is highlighted by an 
arrow. (C) Supershift experiment demonstrating the effect of adding increasing 
concentrations of DEAF-1 antibody to an EMSA reaction containing the T or C allele 
probes. The effect was compared with the addition of increasing concentrations of the 
control IgG antibody (Con). The supershifted complex is highlighted by an arrow. (C) 
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Supershift experiment demonstrating the effect of adding antibodies to the EMSA 
reaction targeting Sp1 and Sp3 alone and in combination (Sp1 + Sp3), a different 
DEAF-1 antibody to that used previously (D1*), both alone and in combination with 
Sp1 and Sp1 in addition to Sp3. 25x DEAF-1 competitor 1 was added in addition to an 
antibody targeting Sp1 (Sp1 + 25xD1). 
To summarise, protein binding to the GDF5 C and T allele probes was not competed on 
the addition of three different DEAF-1 consensus competitor sequences. Furthermore, 
no binding to the probes was observed on the addition of DEAF-1 recombinant protein. 
However a supershifted complex was observed on the addition of one of the DEAF-1 
antibodies to the EMSA reaction. I have therefore not been able to conclude from these 
EMSA experiments if DEAF-1 is binding to GDF5 in vitro.  
6.3.2 Investigation of DEAF-1 binding by ChIP 
6.3.2.1 Optimisation of DNA fragmentation by sonication 
I next sought to assess the binding of DEAF-1 in vivo to GDF5 by ChIP in SW872 
cells, Materials and Methods section 2.8. In order to accurately identify the region in 
which a protein of interest binds to a gene, it is necessary to first sonicate genomic DNA 
into smaller pieces. Fragments of length 200-1000bp of DNA are recommended for 
ChIP (based on manufacturers instructions of the ChIP kit used, manufactured by 
Millipore). Figure 6.3A shows the DNA fragments produced following sonication using 
a probe sonicator (at amplitude five) for three different time periods. DNA was purified 
by phenol-chloroform extraction and electrophoresed through an agarose gel. A 
decrease in fragment size can be seen with increasing sonication time.  
Sonication of SW872 cell DNA was then compared with sonication of DNA from 
JURKAT cells, an immortalized T-lymphocyte cell line; fragmentation of JURKAT 
DNA by sonication using a waterbath has been successfully performed previously in 
our laboratory and was therefore used for comparison of sonication conditions. I 
compared two different methods of sonication, the above probe sonicator and two 
sonicating waterbaths (Figure 6.3B). The probe sonicator (at amplitude five) produced 
SW872 DNA fragments within the desired size range at all of the time points studied. 
Both waterbaths fragmented SW872 cell DNA to the desired size range after 4x5 
minute intervals (20 minutes total). JURKAT DNA however was not fragmented during 
the time periods studied using either waterbath (Figure 6.3B).  
Further test sonications on SW872 DNA were carried out using the probe sonicator, 
assessing different time periods and amplitudes. Sonication for a total of 15 minutes 
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(30x10 second intervals) at amplitude five gave optimal lengths of DNA fragments, 
whilst sonicating at amplitude 10 for 15 minutes produced smaller fragments, of 100-
400bp (Figure 6.3C).  
From these optimisations, I concluded that a shorter sonication time of five minutes 
(10x10 second sonication intervals, with 20 seconds rest periods between sonications) 
would be optimal. A shorter time period also ensured that the DNA was kept at a low 
temperature to avoid degradation. Amplitude eight was chosen to ensure that there was 
sufficient fragmentation. Figure 6.3D shows DNA following sonication under these 
chosen conditions.  
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Figure 6.3 
The optimisation of the conditions for fragmenting DNA by sonication. (A) DNA was 
sonicated using the probe sonicator at amplitude 5 for periods of 10 seconds, followed 
by 20 seconds rest (either 5 times (2.5 minutes total), 10 times (5 minutes total) or 20 
times (10 minutes total)). The total sonication time (including rest periods) in minutes is 
shown beneath the image. DNA was purified by phenol-chloroform extraction. (B) Two 
different cell lines were used for the optimisation of the sonication method, JURKAT 
and SW872. The probe sonicator, and two sonicating water baths were tested. Using the 
probe, DNA was sonicated at amplitude 5 for periods of 10 seconds, followed by 20 
seconds rest, for total periods of 5, 10 or 20 minutes. Using the two sonicating 
waterbaths, DNA was sonicated for periods of 5 minutes, followed by 5 minutes on ice, 
for a total of 5, 10 or 20 minutes. DNA was purified using the spin column method. (C) 
The probe sonicator was used to sonicate DNA, two different amplitudes were tested, 
amplitude 5 (Amp.5) and amplitude 10 (Amp.10) for 10 second periods, with 20 
seconds rest for a total duration of 5 or 15 minutes. DNA was purified using the spin 
column method. (D) The probe sonicator was used to sonicate DNA at amplitude 8 
(Amp.8) for 10 second periods, with 20 seconds rest for a total duration of 5 minutes. 
DNA was purified using the spin column method.  A 100bp DNA sizing ladder is 
shown in the first lane of each image.  
Probe Sonicating Waterbath 1 Sonicating Waterbath 2
5  10  20 5  10  20        5  10  20        5  10  20        5  10  20
SW872 SW872 SW872JURKAT JURKAT
B: Optimisation of Sonication Method
C: Optimisation of Sonication Duration
15         5          15
Amp.5 Amp.10
D: Optimisation of Sonication Duration 2
Amp.8
5
2.5   5    10
Amp.5
A: Sonication Test
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6.3.2.2 Assessment of five DEAF-1 antibodies 
DEAF-1 immunoprecipitation was performed using five different DEAF-1 antibodies 
(Table 2, Appendix). Following each ChIP the DNA that was isolated was purified and 
subsequently analysed by PCR as described in Materials and Methods section 2.8.4. The 
region amplified included the GDF5 exon 1 region (-315 to -167 relative to the 
transcription start site and encompassing rs143383). The enrichment of GDF5 DNA 
was assessed following electrophoresis of the samples through an agarose gel. Anti-
acetyl histone H3 antibody was used as a positive control for the ChIP protocol, with 
enrichment signifying GDF5 is an actively transcribed gene, whilst a species matched 
IgG antibody was used as a negative control. Chromatin that has not been subject to 
immunoprecipitation was used  to provide a comparison for the amount of DNA present 
in each sample and was referred to as the Input (10% of the pre-immunoprecipitated 
DNA was used). The first ChIP experiment was performed using DEAF-1 antibody 1 
(Figure 6.4A). There was enrichment of GDF5 DNA following ChIP with the Histone 
H3 positive antibody and a moderate amplification of DNA following ChIP with the 
IgG negative antibody, most likely an indication of the incomplete removal of unbound 
DNA during the washing stages of the protocol. There was an enrichment of GDF5 
DNA following ChIP with the anti-DEAF-1 antibody relative to the negative antibody. 
The GAPDH gene was then used to assess DEAF-1 binding to a negative control 
region; however, there was also an enrichment of GAPDH DNA following ChIP using 
the anti-DEAF-1 antibody. These results indicate that either DEAF-1 is binding to the 
GADPH gene in addition to the GDF5 gene, or that DEAF-1 antibody 1 is binding non 
specifically. 
DEAF-1 antibody 2 was next tested. There was however no enrichment of GDF5 DNA 
following ChIP with this antibody (Figure 6.4B). DEAF-1 has been reported previously 
to bind to its own promoter to self regulate its expression [348]. In order to examine 
further the negative result obtained for antibody 2, I assessed by PCR the enrichment of 
a region of the DEAF-1 promoter following ChIP with this antibody. DEAF-1 binding 
to this region however was also negative, with no enrichment of DEAF-1 DNA 
observed (Figure 6.4B). The negative binding to GDF5 observed with antibody 2 could 
therefore not be verified. DEAF-1 antibody 3 was therefore next tested. The same result 
was obtained for this antibody as was seen for antibody 2; there was no enrichment of 
GDF5 DNA or DEAF-1 DNA following ChIP (Figure 6.4C). For both antibody 2 and 3 
there was amplification of GDF5 and DEAF-1 DNA following ChIP with the positive 
control antibody, indicating the protocol was successful.  
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Finally, antibodies 4 and 5 were tested. As above, there was no enrichment of GDF5 
DNA following ChIP with these antibodies (Figure 6.5 A and B). 
 
Figure 6.4 
ChIP analysis of DEAF-1 using antibodies 1, 2 and 3. (A) Sheared genomic DNA was 
immunoprecipitated with DEAF-1 antibody 1 (D1(1)), rabbit polyclonal IgG control 
(negative) and anti-acetyl histone H3 control (positive) antibodies and then PCR 
amplified across either GDF5 or GAPDH. (B) Sheared genomic DNA was 
immunoprecipitated with DEAF-1 antibody 2 (D1(2)), rabbit polyclonal IgG control 
(negative) and anti-acetyl histone H3 control (positive) antibodies and then PCR 
amplified across either GDF5 or DEAF-1. (C) Sheared genomic DNA was 
immunoprecipitated with DEAF-1 antibody 3 (D1(3)), rabbit polyclonal IgG control 
(negative) and anti-acetyl histone H3 control (positive) antibodies and then PCR 
amplified across either GDF5 or DEAF-1. The input represents 10% of the non-
immunoprecipitated sheared genomic DNA. A PCR containing no DNA was used as a 
control (PCR Blank). 
 
PCR Blank                     Negative  Positive   DEAF-1  10%Input
PCR Blank      Negative             Positive            DEAF-1         10%Input
PCR Blank     Negative           Positive            DEAF-1          10%Input
GDF5 
DEAF-1 Promoter 
D1(3)
D1(2)
PCR   Negative  Positive DEAF-1 10%Input
Blank
D1(1)
GDF5 
GDF5 
DEAF-1 Promoter 
GAPDH 
A
B
C
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Figure 6.5 
ChIP analysis of DEAF-1 using antibodies 4 and 5. (A) Sheared genomic DNA was 
immunoprecipitated with DEAF-1 antibody 4 (D1(4)), rabbit polyclonal IgG control 
(negative) and anti-acetyl histone H3 control (positive) antibodies and then PCR 
amplified across GDF5. (B) Sheared genomic DNA was immunoprecipitated with 
DEAF-1 antibody 5 (D1(5)), rabbit polyclonal IgG control (negative) and anti-acetyl 
histone H3 control (positive) antibodies and then PCR amplified across GDF5. The 
input represents 10% of the non-immunoprecipitated sheared genomic DNA. A PCR 
containing no DNA was used as a control (PCR Blank). 
6.3.3 Characterisation of the DEAF-1 Antibodies 
Four of the five antibodies targeting DEAF-1 yielded negative ChIP results suggesting 
that DEAF-1 does not bind to the region of GDF5 examined. Antibodies 2 and 3 were 
however also tested for binding to the DEAF-1 promoter and binding at this region was 
also negative. As DEAF-1 has previously been reported to bind to its own promoter, 
these negative results call into question the specificity of the antibodies. I therefore 
sought to characterise each of the five antibodies, assessing their specificities.  
6.3.3.1 Knockdown of DEAF-1 and Immunofluorescence 
The ability of the five antibodies to recognise endogenous DEAF-1 protein was first 
assessed by immunofluorescence (Figure 6.6; details of the antibodies used are provided 
in Table 2, Appendix). SW872 cells were untreated or treated with DEAF-1 siRNA 
(Details of DEAF-1 siRNA are given in Table 6, Appendix). Nuclei are stained blue 
with DAPI, as shown in the first row. The localisation of antibody binding is shown in 
the second row. The final row shows the merged DAPI and antibody images. Antibody 
1 (D1(1)) appears to be binding to a protein that is abundant outside of the nucleus 
(Figure 6.6A).  Furthermore, the amount of antibody binding does not appear to be 
reduced upon treatment with DEAF-1 siRNA when compared with the untreated cells. 
Antibody 2 is binding to a protein that is localised within the nucleus; the co localisation 
of DAPI with the antibody is shown in the merged image (Figure 6.6B). The amount of 
PCR Blank  Negative      Positive       DEAF-1      10%Input
D1(4)
GDF5 
PCR Blank  Negative      Positive       DEAF-1      10%Input
D1(5)
GDF5 
A
B
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antibody binding however does not appear to be reduced upon treatment with DEAF-1 
siRNA in comparison with the untreated cells.  Antibody 3 also appears to be binding to 
a protein that is located within the nucleus, but as with antibody 2, the amount of 
binding is not reduced upon treatment with DEAF-1 siRNA (Figure 6.6C). Antibody 4 
is recognising a protein that is primarily located within the nucleus, with a small amount 
of binding in the cytoplasm. The amount of antibody binding appears to be reduced 
upon treatment with DEAF-1 siRNA; there is a lower intensity of immunofluorescence 
observed in the DEAF-1 siRNA treated cells when compared with the untreated control 
cells (Figure 6.6D). Lastly, antibody 5 also appears to be binding a protein that is 
localised within the nucleus, however the antibody binding is not reduced upon 
treatment with DEAF-1 siRNA when compared with the untreated cells (Figure 6.6E).  
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DAPI
Antibody
D1(1)Control siRNA
Merge
DAPI
Antibody
D1(2)Control siRNA
Merge
A B
DAPI
Antibody
Control siRNA
Merge
DAPI
Antibody
Control siRNA
Merge
D1(3) D1(4)
C D
DAPI
Antibody
Control siRNA
Merge
E
D1(5) Figure 6.6 
Characterisation of the DEAF-1 
antibodies by immunofluorescence.  
(A-E) Visualisation of DEAF-1 
using antibodies 1 to 5 (D1(1) to 
D1(5)). Cells were untreated 
(Control) and treated with DEAF-1 
siRNA (siRNA). Nuclei are stained 
blue with DAPI and shown in the 
first row of each panel A-E. 
DEAF-1 antibody binding is shown 
in the second row (Antibody). The 
final row shows the merged DAPI 
and antibody images (Merge).  
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6.3.3.2 Addition of Recombinant Protein 
Antibodies 2-5 are recognising a nuclear protein, and antibody 4 is binding to a protein 
that appears to be reduced upon treatment with DEAF-1 siRNA. However, when used 
for ChIP, these four antibodies yielded negative results. I therefore further tested the 
ability of each of these four antibodies to recognise DEAF-1 protein and DEAF-1 
recombinant protein (tagged with glutathione S-transferase (GST), which is 
approximately 26kDa in size) by immunoblotting. DEAF-1 protein levels were assessed 
in SW872 cells following no treatment (cells), following treatment with a control non 
targeting siRNA (NTsiRNA) and following DEAF-1 siRNA treatment (D1 siRNA). 
Figure 6.7A is an immunoblot, probed for DEAF-1 using antibody 2. It is unclear from 
the immunoblot which protein is DEAF-1; there is no obvious reduction in the intensity 
of any of the proteins upon DEAF-1 siRNA treatment at either time point. The antibody 
appears to recognise DEAF-1 recombinant protein, as indicated by the arrow in Figure 
6.7A. Using antibody 3, as with antibody 2 it is unclear which protein is DEAF-1 and 
there is no apparent reduction in intensity of the proteins upon DEAF-1 siRNA 
treatment. This antibody does not detect recombinant DEAF-1 protein. For antibody 4, 
there is a reduction in the intensity of one of the proteins upon treatment with DEAF-1 
siRNA at 96 hours, indicated by the arrow in Figure 6.7C.  Furthermore, this antibody 
appears to be able to detect recombinant DEAF-1 protein, as indicated by the second 
arrow. With DEAF-1 antibody 5, there is no apparent reduction in any of the protein 
upon DEAF-1 siRNA treatment at either time point. This antibody does not detect 
DEAF-1 recombinant protein.  
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Figure 6.7 
Characterisation of the DEAF-1 antibodies by immunoblotting. (A-D) Immunoblots 
demonstrating the effect of DEAF-1 siRNA treatment after two different incubation 
periods (48 and 96 hours). Protein extracted from cells treated with the NTsiRNA 
control was used for basal protein expression and cells are untreated protein samples. β-
Actin was used as a loading control. GST tagged recombinant DEAF-1 protein (D1) 
was loaded as a positive control. Four of the DEAF-1 antibodies were used for 
immunoblotting (antibodies 2-5, D1(2) – D1(5)). Arrows indicate the identification of 
DEAF-1 recombinant protein (Recombinant D1).  
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6.3.3.3 Optimisation of the Over expression of DEAF-1 
Although antibodies 2 and 4 appear to recognise DEAF-1 recombinant protein, it is still 
unclear if the antibodies are able to recognise endogenous protein within the cells. In 
order to determine if this uncertainty is a result of poor specificity of the antibodies, or 
alternatively if this could be a result of low levels of DEAF-1 protein within the SW872 
cells, I obtained an enhanced green fluorescent protein (EGFP) tagged expression vector 
for DEAF-1 to over express DEAF-1 protein.  
I first optimised the over expression of DEAF-1 EGFP within the SW872 cell line. I 
tested the transfection reagent (Fugene HD) at different transfection reagent: plasmid 
DNA ratios, different cell densities and for 24 and 48 hour transfection periods. The 
optimal conditions that resulted in the highest number of cells being transfected with the 
EGFP tagged plasmid are described in Materials and Methods section 2.16.1. 
6.3.3.4 Over expression of DEAF-1 
Following this optimisation, I assessed the ability antibodies 2-5 to detect over 
expressed DEAF-1. Figure 6.8 depicts the immunoblots following incubation with each 
of the four antibodies. The expression of DEAF-1 was assessed in SW872 nuclear and 
cytoplasmic protein extracts (N and C), in DEAF-1 EGFP transfected cells (D1), and in 
cells transfected with a control EGFP vector (H11). Following transfection of the cells 
with DEAF-1 EGFP and subsequent detection with each of the four antibodies (D1(2), 
D1(3), D1(4), D1(5)), it is clear that there is a protein being over expressed of 
approximately 130kDa in size. This protein is not present within the nuclear or 
cytoplasmic extracts or in the control EGFP vector treated cells. Panel B shows the 
protein levels of β-Actin, which is used as a loading control. Panel C shows the 
expression levels of EGFP. EGFP protein is detected using the EGFP antibody in the 
cells transfected with DEAF-1 EGFP (D1) and corresponds to the same molecular 
weight as the protein detected using the DEAF-1 antibodies. The control EGFP vector 
(H11) also shows an increase in the expression of EGFP protein, which is of lower 
molecular weight to the DEAF-1 EGFP protein. Collectively, these results suggest that 
DEAF-1 antibodies 2-5 can each recognise over expressed DEAF-1 protein.  
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Figure 6.8  
Characterisation of the DEAF-1 antibodies following DEAF-1 EGFP over expression. 
(A) Immunoblots examining the expression of DEAF-1 using four of the DEAF-1 
antibodies (antibodies 2-5, D1(2)-(5)) in SW872 nuclear extract (N), SW872 
cytoplasmic extract (C) and in SW872 nuclear extract following the over expression of 
either DEAF-1 EGFP (D1) or a control vector (H11). Arrows indicate DEAF-1 EGFP 
expression. (B) β-Actin expression, used as a loading control. (C) Detection of the 
protein using an antibody targeting EGFP. The upper arrow indicates DEAF-1 EGFP 
and the lower arrow indicates H11 EGFP.  
 
I have been unable to confirm the protein levels of DEAF-1 following DEAF-1 siRNA 
treatment in the previous experiments (Figure 6.7), I therefore sought to assess if the 
DEAF-1 siRNA is able to successfully deplete DEAF-1 protein. To investigate this, I 
first over expressed DEAF-1 EGFP and then treated  these cells with DEAF-1 siRNA. 
DEAF-1 EGFP over expression can be detected  in the cells transfected with DEAF-1 
EGFP (Figure 6.9). Cells that have been transfected with the DEAF-1 over expression 
vector and DEAF-1 siRNA have reduced levels of DEAF-1 EGFP protein, in 
comparison with cells treated with the non targeting siRNA control (NTsiRNA), 
suggesting that the DEAF-1 siRNA is able to successfully deplete DEAF-1 protein. β-
Actin is used as a loading control. DEAF-1 EGFP expression was assessed using 
DEAF-1 antibody 3 (As Figure 6.8 showed that DEAF-1 antibodies 2-5 could all detect 
DEAF-1 EGFP).   
 
D1(3)D1(2) D1(4) D1(5)
N      C       D1   H11 N     C      D1      H11 N       C     D1    H11 N     C     D1     H11
DEAF-1
β-Actin
EGFP
A
B
C
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Figure 6.9 
Examination of the effect of DEAF-1 siRNA treatment on DEAF-1 EGFP expression. 
Immunoblots demonstrating the effect of over expressing DEAF-1 EGFP (D1 EGFP) 
and the effect of concurrently depleting DEAF-1 expression using siRNA (DEAF-1 
EGFP D1 siRNA). Protein extracted from cells that are over expressing DEAF-1 EGFP 
and have been treated with the NTsiRNA control (D1 EGFP NTsiRNA) were used for 
assessing basal protein expression. β-Actin was used as a loading control. Arrow 
indicates DEAF-1 EGFP expression.  
The final test that I performed using DEAF-1 antibodies 3-5 was to assess their ability 
to immunoprecipitate DEAF-1 EGFP (antibody 2 was not used for this experiment 
because it was provided at a low concentration, making the volume required for the 
immunoprecipitation too high). Nuclear lysate from cells that had been transfected with 
DEAF-1 EGFP were used for the immunoprecipitation, as described in Materials and 
Methods section 2.19.  Figure 6.10 shows the protein detected following 
immunoblotting with the anti-EGFP antibody. The first two lanes are controls, lane one 
containing no antibody and lane two containing a species matched IgG control; binding 
detected within lane two is background and as such the other antibodies were compared 
to this control sample. Immunoprecipitated protein obtained using anti-DEAF-1 
antibodies 3, 4 and 5 is shown in lanes three, four and five respectively. EGFP 
transfected lysate is shown in lane six and represents a positive control enabling the 
migration size of DEAF-1 EGFP to be determined. Proteins of the same molecular 
weight as DEAF-1 EGFP are apparent following immunoprecipitation with DEAF-1 
antibodies 4 and 5. These two antibodies can therefore be used to successfully 
immunoprecipitate over expressed DEAF-1 protein.   
Cells         D1 EGFP   D1 EGFP      D1 EGFP
NTsiRNA D1 siRNA
β-Actin
DEAF-1 EGFP
DEAF-1 
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Figure 6.10 
Immunoprecipitation of DEAF-1 EGFP. Immunoblot demonstrating the expression of 
DEAF-1 following immunoprecipitation using SW872 cell lysates that are over 
expressing DEAF-1 EGFP with three of the DEAF-1 antibodies (antibodies 3-5, D1(3), 
D1(4) and D1(5). EGFP cell lysates were either not treated with antibody (No AB), 
treated with a negative control rabbit IgG antibody or with one of the three DEAF-1 
antibodies. SW872 lysate over expressing DEAF-1 EGFP was used as a positive control 
(EGFP lysate).  Arrow indicates DEAF-1 EGFP.  
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6.3.3.5 DEAF-1 Over expression and ChIP 
As reported above, I have previously used five antibodies targeting DEAF-1 for ChIP, 
four of which yielded negative results. As I have now demonstrated that DEAF-1 EGFP 
can successfully be over expressed and that two of the five antibodies can 
immunoprecipitate DEAF-1 EGFP, I next sought to assess if DEAF-1 binding to GDF5 
could be detected using ChIP following the over expression of DEAF-1. I used antibody 
4 for the ChIP experiments as this antibody has been shown in this chapter to 
specifically bind to DEAF-1. Figure 6.11A shows the enrichment of GDF5 DNA 
following ChIP and PCR at three different cycle numbers. GDF5 DNA is enriched 
following immunoprecipitation with antibody 4 in comparison with the IgG negative 
control antibody (Neg). This enrichment is apparent at all three different cycle numbers. 
Figures 6.11B and C represent an additional two immunoprecipitation experiments 
performed. The second EGFP ChIP experiment was performed using both DEAF-1 
antibody 4 and an anti-EGFP antibody. It is unclear as to whether there is enrichment of 
GDF5 following immunoprecipitation using antibody 4 in comparison with the IgG 
negative antibody control (Neg). GDF5 DNA is enriched following 
immunoprecipitation using the EGFP antibody in comparison with the antisera negative 
antibody control (Neg AS). GDF5 DNA is also enriched following the third 
immunoprecipitation in comparison with the negative antibody control (Figure 6.11C). 
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Figure 6.11 
ChIP analysis of DEAF-1 in cells over expressing DEAF-1 EGFP. (A) Sheared genomic 
DNA was immunoprecipitated with DEAF-1 antibody 4 (DEAF-1) and rabbit 
polyclonal IgG control (Neg) antibody and then PCR amplified for either 27, 30 or 33 
cycles across GDF5 exon 1. (B) A second ChIP using DEAF-1 antibody 4 and an anti-
EGFP antibody. Sheared genomic DNA was immunoprecipitated with antibody 4 
(DEAF-1), rabbit polyclonal IgG control (Neg) and anti-acetyl histone H3 control (Pos) 
antibodies and then PCR amplified across GDF5 exon 1 (upper gel image). Sheared 
genomic DNA was immunoprecipitated with EGFP, rabbit polyclonal IgG control 
(Neg), rabbit antisera (Neg AS) and anti-acetyl histone H3 control (Pos) antibodies and 
then PCR amplified across GDF5 exon 1 (lower gel image). (C) A third ChIP using 
DEAF-1 antibody 4.  Sheared genomic DNA was immunoprecipitated with DEAF-1 
antibody four (DEAF-1), rabbit polyclonal IgG control (Neg) and anti-acetyl histone H3 
control (Pos) antibodies and then PCR amplified across GDF5 exon 1. In all 
experiments the input represents 10% of the non-immunoprecipitated sheared genomic 
DNA. A PCR containing no DNA was used as a control (Blank). 
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In addition to binding to the GDF5 promoter I also assessed by PCR, using several 
different cycle numbers, DEAF-1 binding to its own promoter following over 
expression of DEAF-1 EGFP (Figure 6.12). There is enrichment of DEAF-1 DNA 
following immunoprecipitation with DEAF-1 antibodies 4 and 5 and with the anti-
EGFP antibody (apparent after     PCR cycles) in comparison with their respective 
controls. The IgG negative control antibody (Neg) is used as a comparison for antibody 
4 and the antisera (Neg AS) is used as a negative control for both antibody 5 and the 
anti-EGFP antibody. The highest level of enrichment of DEAF-1 DNA is achieved 
following immunoprecipitation with DEAF-1 antibody 5.  
 
Figure 6.12 
ChIP analysis of DEAF-1 at the DEAF-1 promoter in cells over expressing DEAF-1 
EGFP. Sheared genomic DNA was immunoprecipitated with DEAF-1 antibody 4 
(D1(4)), DEAF-1 antibody 5 (D1(5)), EGFP antibody, rabbit polyclonal IgG control 
(Neg), rabbit antisera (Neg AS) and an anti-acetyl histone H3 control antibody (Pos). 
DNA was PCR amplified for either 29, 31, 33, 35 or 37 cycles across the DEAF-1 
promoter region. The input represents 10% of the non-immunoprecipitated sheared 
genomic DNA. A PCR containing no DNA was used as a control (PCR Blank). 
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6.4 Discussion 
Following on from the functional studies performed by Egli et al., which identified 
DEAF-1 as a trans-acting factor that may be differentially regulating the expression of 
GDF5, and from the siRNA knockdown studies performed during my Master of 
Research project, I sought to further investigate the role of DEAF-1. I first investigated 
DEAF binding to GDF5 in vitro by EMSA. Although the addition of three different 
DEAF-1 competitors did not alter protein complex binding to the C and T allele probes, 
the addition of an antibody targeting DEAF-1 produced a supershifted complex. This 
supershifted complex was more intense in the T allele probe EMSA in comparison to 
the C allele probe EMSA. This supershift was confirmed using nuclear extract from 
human articular chondrocytes. A second DEAF-1 antibody however did not produce a 
supershifted protein complex.  
The Sp1 and Sp3 complexes that were identified as binding to the C and T allele probes 
in Chapter 4 are abundant and could therefore be masking the binding of DEAF-1. To 
test this possibility, I investigated protein binding to the C and T allele probes using 
DEAF-1 recombinant protein. However, no complex binding was observed in the 
different conditions tested. It is therefore not possible from these EMSA experiments to 
determine if DEAF-1 is binding to GDF5 in vitro. Future experiments could use a range 
of DEAF-1 recombinant protein concentrations and test the addition of recombinant 
protein in addition to SW872 nuclear extract; the binding of DEAF-1 may be dependent 
upon the binding of other factors, and thus the use of DEAF-1 recombinant protein 
alone may prevent the binding of DEAF-1 to the probes. Furthermore, Sp1 and Sp3 
could be depleted using siRNA, and the nuclear extract from these siRNA treated cells 
could be used to identify if there is any DEAF-1 binding masked by the abundant 
Sp1/Sp3 protein complexes.  
The expression of DEAF-1 within the SW872 cell line may be low, therefore the 
binding of DEAF-1 may be difficult to detect by EMSA. Furthermore, the conditions 
used for the EMSA experiments may not be optimal for the binding of DEAF-1. A 
previous study has suggested that modest concentrations of the non specific competitor 
Poly (dI:dC) can displace DEAF-1 binding to its target gene. However, Poly (dI:dC) 
was removed from the DEAF-1 recombinant protein EMSA and no binding to the 
probes was observed. It is important to note that the binding of trans-acting factors to 
the 33bp probes in vitro may be different to the in vivo binding to the DNA. Following 
the EMSAs I therefore assessed DEAF-1 binding to GDF5 in vivo using ChIP. Five 
127 
 
different DEAF-1 antibodies were tested, one of which was positive and four of which 
were negative. For antibody 1, which produced a positive result, binding to the control 
gene GAPDH was also positive. For antibodies 2-5, binding to GDF5 was negative. 
However, binding to the DEAF-1 promoter was also negative; in the absence of a 
positive control region for DEAF-1 binding, I am unable therefore to use these results to 
confirm whether DEAF-1 is binding to GDF5 in vivo.  
Following on from this negative ChIP result, I performed several experiments to deduce 
if each antibody was able to specifically recognise DEAF-1 protein. Using 
immunofluorescence I demonstrated that antibodies 2-5 were all recognising proteins 
that are primarily located in the nucleus. Antibody 1 however was binding to a protein 
located in the cytoplasm. DEAF-1 has been shown previously to be located in the 
nucleus, with a small level of expression also found in the cytoplasm [345]. I therefore 
concluded that antibody one was not binding specifically to DEAF-1. Using antibody 4, 
the immunofluorescence was reduced upon treatment with DEAF-1 siRNA, suggesting 
that this antibody may be recognising DEAF-1 protein. Using antibodies 2, 3 and 5, the 
immunofluorescence was not reduced upon treatment with DEAF-1 siRNA suggesting 
that either the siRNA is not able to deplete DEAF-1 protein or these antibodies are not 
specific.  Antibodies 2 and 4 detected DEAF-1 recombinant protein by immunoblotting. 
Only antibody 4 was successful in detecting a decrease in protein following DEAF-1 
siRNA treatment, 96 hours post transfection.  
A number of DEAF-1 proteins of varying molecular mass have been detected [345]. In 
CV-1 (monkey kidney cell lines), JEG-3 cells (human placental choriocarcinoma cell 
line) and in rat testis a 72kDa protein was identified. In muscle, brain and heart tissue 
samples taken from rats lower molecular weight proteins of 59kDa have been detected 
[345]. Furthermore in HEK293 cells (human embryonic kidney cell line) DEAF-1 is 
70kDa [298] .  
DEAF-1 has not been detected previously in SW872 cells, it was therefore difficult to 
predict the size of the protein that is being expressed within these cells. In order to 
assess conclusively if any of the proteins on the immunoblot represent endogenous 
DEAF-1, the sample could be pre-absorbed with the peptide used for the generation of 
the antibody to investigate if any proteins disappear. I did not carry out this experiment 
due to the unavailability of the peptide sequence used for the generation of the 
antibodies.   
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Over expressed DEAF-1 protein (DEAF-1 EGFP) was detected using four of the five 
DEAF-1 antibodies (antibodies 2-5). Furthermore, following the over expression of 
DEAF-1, DEAF-1 siRNA depleted DEAF-1 EGFP. This result suggests that the DEAF-
1 siRNA is working; thus the negative depletion results obtained with the endogenous 
DEAF-1siRNA immunoblots implies that antibodies 2, 3 and 5 are not able to detect 
endogenous DEAF-1 protein. Finally, DEAF-1 EGFP was successfully 
immunoprecipitated using DEAF-1 antibodies 4 and 5.  
Taking into account these antibody characterisation results, I concluded that DEAF-1 
antibody 4 was binding to DEAF-1, as this antibody recognised a nuclear protein that is 
depleted upon DEAF-1 siRNA treatment. Additionally, DEAF-1 recombinant protein 
and DEAF-1 EGFP were detected using this antibody by immunoblotting. Finally, this 
antibody was successfully used to immunoprecipitate DEAF-1 EGFP. DEAF-1 
antibody 4 produced a supershifted band when added to the EMSA reaction suggesting 
DEAF-1 is binding in vitro to GDF5, but produced a negative result for in vivo binding 
assessed by ChIP. In light of the absence of a positive region for DEAF-1 binding in the 
ChIP experiments, the final section of this chapter assessed the in vivo binding of 
DEAF-1 using ChIP following the over expression of DEAF-1 EGFP. In three 
independent ChIP experiments, GDF5 DNA was enriched following 
immunoprecipitation with this antibody compared with the IgG control antibody. 
Furthermore, the binding of DEAF-1 was confirmed at the DEAF-1 promoter by ChIP 
using DEAF-1 antibodies 4, 5 and an EGFP antibody following DEAF-1 over 
expression.  
Correspondence with other researchers who investigate DEAF-1 has confirmed the 
difficulties in detecting endogenous DEAF-1 within both cell lines and tissues (Michael 
Collard, Southern Illinois University and Linda Yip, Stanford University). These 
researchers have suggested that DEAF-1 protein is expressed at a low level in all cell 
types investigated and thus is difficult to detect. When over expressed, ChIP 
experiments suggest that DEAF-1 is binding to GDF5 in vivo, however in untreated 
cells DEAF-1 binding is negative. It is tempting to speculate that DEAF-1 is binding to 
GDF5 in vivo and this can be detected when increasing the amount of DEAF-1 within 
SW872 cells. However, it could be argued that when DEAF-1 protein is over expressed, 
an abundance of the protein within the cell may lead to non specific binding of DEAF-
1. It is therefore not possible to state for certain that DEAF-1 is binding in vivo to GDF5 
under normal cellular conditions.  
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DEAF-1 has been identified as an important transcription factor in regulating the 
expression of the 5HT-1A receptor [349-351].  The 5HT-1A receptor is an auto-receptor 
found in pre-synaptic neurons in the brain, responsible for regulating the levels of the 
neurotransmitter serotonin. Alterations in the levels of serotonin in the brain have been 
associated with depression and the auto-receptor is important for maintaining normal 
physiological levels of this neurotransmitter [352]. In DEAF-1 knockout mice, there 
was increased expression of the 5HT-1A autoreceptor and reduced raphe serotonin 
levels [353] 
A polymorphism (C -1019 G) within the promoter of the 5HT-1A receptor gene was 
found to reduce the repressor activity of DEAF-1 at this locus, promoting increased 
5HT-1A receptor gene expression and affecting response to antidepressant treatment. 
Increased expression of the 5HT-1A receptor  decreases the levels of serotonin in the 
synapse and thus increases susceptibility to depression [349, 354]. This effect however 
was found to be cell type specific, such that DEAF-1 was found to have the opposite 
effect at postsynaptic neuronal cells, where binding of DEAF-1 to the 5HT-1A receptor 
promoter enhanced transcription [350]. This study highlights the importance of DEAF-1 
in the regulation of target genes and the dual repressor and enhancer functions in 
different cell types reveals the complex nature of this transcription factors distinct 
functional roles. Furthermore, this study suggests that a single base change within the 
DNA binding sequence of DEAF-1 can alter its binding affinity and repressive activity. 
As mentioned previously, the core consensus sequence of DEAF-1 is TCGG, which 
resides directly over the GDF5 rs143383 C allele; changing this base to a T allele may 
account for a change in repressive activity, thus could account for an alteration in the 
expression of GDF5.  
Other than the 5HT-1A receptor, other target genes of DEAF-1 include the nuclear 
ribonuclearprotein (RNP) A2/B1 promoter (a potential early biomarker in lung cancer) 
and genes encoding peripheral tissue antigens in the pancreatic lymph nodes [298, 348]. 
Additionally, a study has shown that in patients with type 1 diabetes, lower expression 
of the canonical DEAF-1, and higher expression of an alternatively spliced variant lead 
to a reduction in the expression of peripheral tissues antigens, promoting diabetes 
disease pathogenesis [298]. This is due to the impaired formation of tolerance and the 
survival of auto-reactive T cells that are specific for the tissue antigens [298]. These 
studies highlight that DEAF-1 is an important trans-acting factor, regulating the 
expression of a number of genes.  
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The functional domains of DEAF-1 have been defined and include a SAND (Sp100, 
AIRE-1, NucP41/75 and DEAF-1) domain which contains the nuclear localisation 
signal and confers DNA binding activity and a MYND domain which mediates protein-
protein interactions [343, 355, 356]. DEAF-1 has been suggested to form dimers with 
itself and has been reported to interact with Lim only protein 4 (LMO4) and members of 
the Clim protein family [357]. Furthermore, the C terminal region of DEAF-1 shares 
amino acid homology with the repressor domain of the transcription factor MTG8. 
MTG8 has been reported to interact with a number of repressor proteins such as N-CoR 
and Sin3A. This degree of similarity suggests that the C terminal region of DEAF-1 
may also be involved in protein-protein interactions. Deletion experiments involving the 
removal of parts of the C terminal region of DEAF-1, resulting in a lower level of 
transcriptional repression have confirmed that this region may recruit co repressors 
[348].   
In summary, DEAF-1 is expressed in many neuroendocrine and reproductive tissues 
and is expressed at high levels in the foetus, suggesting an important role during 
development. In addition to binding to and activating or repressing the transcription of 
target genes, it may also form complexes with a number of other proteins and modulate 
their function. Further experiments will be carried out in the following chapters of this 
thesis to study DEAF-1 binding to GDF5 and its effect on the expression of this gene.  
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Chapter 7: The Investigation of the Functional Effects of Sp1, Sp3, 
P15 and DEAF-1 on GDF5 Gene Expression  
7.1 Introduction 
Sp1 and Sp3 were predicted to bind to GDF5 using online prediction tools. Using 
EMSAs I have confirmed the binding of these two factors to GDF5 in vitro. 
Furthermore, the binding of Sp1 and Sp3 is modulated by the genotype at rs143383, 
with both factors binding more avidly to the T allele in comparison with the C allele 
(Chapter 4). P15 was identified as binding to GDF5 DNA in vitro using an 
oligonucleotide pull down assay and tandem mass spectrometry (Chapter 5). P15 was 
found to be more abundant in the T allele DNA sample in comparison with the C allele 
DNA sample. DEAF-1 has previously been suggested to bind to GDF5 at rs143383, and 
on the addition of an antibody to the EMSA reaction I observed a supershifted complex. 
The experiments I have performed to identify in vivo binding of DEAF-1 to GDF5 
however have been inconclusive (Chapter 6).  
All four of these factors are known to be involved in transcriptional regulation. Further 
work in this chapter will assess the extent to which each factor is modulating both the 
overall and allelic expression of GDF5.I will also assess whether manipulating the 
expression of these factors can alter the expression of GDF5.  
The cloning of the Sp1, Sp3 and P15 expression constructs was carried out with 
assistance from Dr. Louise Reynard.  
7.2 Aims 
 To investigate the binding of Sp1, Sp3 and P15 to GDF5 in vivo in SW872 cells 
using chromatin immunoprecipitation (ChIP). 
 To knockdown the expression of Sp1, Sp3, P15 and DEAF-1 using siRNA and 
examine the effect on the overall and the allelic expression of GDF5. 
 To over express the four factors and examine the GDF5 rs143383 C and T allele 
promoter activities using a luciferase reporter assay. 
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7.3 Results 
7.3.1 The Investigation of Sp1, Sp3 and P15 binding to GDF5 in vivo using Chromatin 
Immunoprecipitation (ChIP) 
The sonication conditions for ChIP were previously determined within the SW872 cell 
line in Chapter 6. Following immunoprecipitation using antibodies against Sp1, Sp3, 
P15 and a species matched IgG control, the DNA was purified and amplified by PCR as 
described in Materials and Methods section 2.8. The enrichment of GDF5 DNA was 
assessed following electrophoresis of the samples through an agarose gel. Figure 7.1 
represents four independent experiments. Anti-acetyl histone H3 antibody was used as a 
positive control for the ChIP protocol and a species matched IgG antibody used as a 
negative control. In all four experiments, there is enrichment of GDF5 DNA following 
ChIP with the positive antibody and a moderate amplification of DNA following ChIP 
with the negative antibody, most likely an indication of the incomplete removal of 
unbound DNA during the washing stages of the protocol.  
GDF5 DNA is enriched following ChIP with antibodies targeting Sp3 and P15 relative 
to the negative antibody in all four ChIP experiments, most notably for P15 in 
experiments two, three and four. GDF5 DNA is enriched following ChIP with an 
antibody targeting Sp1, relative to the IgG control, in ChIP experiments one, three and 
four. In experiment two there is less GDF5 DNA following ChIP with an antibody 
targeting Sp1 in comparison to the negative control antibody suggesting a problem may 
have occurred. The DNA present in the 10% input sample is for the most part 
comparable with that present following ChIP with the four antibodies, suggesting that at 
least 10% of the chromatin inputted into the immunoprecipitation is bound by these 
factors. Overall, these results suggest that this region of GDF5 is enriched for Sp1, Sp3 
and P15 binding. 
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Figure 7.1 
ChIP analysis of Sp1, Sp3 and P15. Sheared genomic DNA was immunoprecipitated 
with Sp1, Sp3, P15, rabbit polyclonal IgG (negative control) and anti-acetyl histone H3 
(positive control) antibodies and then PCR amplified across exon 1 of GDF5. The input 
represents 10% of the non-immunoprecipitated sheared genomic DNA.  
 
7.3.2 Investigation of GDF5 expression following Sp1, Sp3, P15 and DEAF-1 depletion 
Following the identification of the binding of Sp1, Sp3 and P15 in vivo by ChIP and the 
binding of DEAF-1 in vitro by EMSA (Chapter 6), I sought to assess if the four factors 
influence the expression of GDF5. Two techniques were used in order to assess the 
impact of each factor upon GDF5 expression. The first, described in this section, 
assessed the effect of Sp1, Sp3, P15 and DEAF-1 depletion by RNAi in SW872 cells. 
The second, described in the following section, assessed the effect of over expressing 
the factors.  
 
As described in Chapter 5, the optimal conditions for the knockdown of target proteins 
using siRNA were determined by me during my Master of Research project. The same 
conditions were used here and can be found in Materials and Methods section 2.9, 
whilst details of the siRNAs used can be found in Table 6, Appendix. The depletion of 
the mRNA for each gene was confirmed by real time RT-PCR. Significant decreases in 
the expression of Sp1, Sp3, P15 and DEAF-1 were observed following siRNA treatment 
in comparison with the non-targeting siRNA (NTsiRNA) control (p<0.05) (Figure 
7.2A). The depletion of target protein was confirmed by immunoblotting. Sp1, Sp3 and 
P15 protein levels were decreased relative to the NTsiRNA (Figure 7.2B). As discussed 
in Chapter 6, it was difficult to assess the depletion of DEAF-1 protein levels due to the 
low level of expression of DEAF-1 within the SW872 cell line (Figure 7.2B). I was 
however able to detect a decrease in the expression of over expressed EGFP tagged 
Negative        Sp1            Sp3            P15        Positive    10% Input
1.
2.
3.
4.
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DEAF-1 using immunofluorescence following DEAF-1 siRNA treatment suggesting 
that the siRNA is able to successfully deplete DEAF-1 protein (Chapter 6, Figure 6.9). 
  
The overall expression of GDF5 was increased following the depletion of each factor 
(Figure 7.2C). Small and non-significant fold changes were seen in GDF5 expression 
following Sp1 (1.37 fold), Sp3 (1.8 fold) and P15 (1.38 fold) knockdown, relative to 
NTsiRNA. A significant fold change (4.6 fold, p<0.001) was observed upon DEAF-1 
knockdown.  
Allele specific real time PCR was then used to assess if the depletion of any of the four 
factors differentially affects the two alleles of rs143383, and as such could contribute to 
the DAE mediated by this SNP. DNA and RNA were extracted from the siRNA 
transfected cells and cDNA synthesis was performed as described in the Materials and 
Methods sections 2.10, 2.11 and 2.12. Depletion of Sp1 and Sp3 resulted in small and 
non-significant increases in the C/T allelic ratio (ratio of 2.1 in the control (NTsiRNA) 
to 2.7 (Sp1 siRNA) or 2.4 (Sp3 siRNA)) whilst P15 depletion did not alter the DAE 
(Figure 7.2D). DEAF-1 depletion increased the DAE from a C/T ratio of 2.1 in the 
control (NTsiRNA) to 4.7 (DEAF-1 siRNA) and this was highly significant (p<0.001, 
Figure 7.2D).  
 
Overall, the data suggest that all four factors are involved in the transcriptional activity 
of GDF5, each repressing GDF5 expression, with DEAF-1 also clearly contributing to 
GDF5 DAE. 
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Figure 7.2 
GDF5 expression following Sp1, Sp3, P15 and DEAF-1 depletion. (A) Expression 
levels of Sp1, Sp3, P15 and DEAF-1 mRNA are shown as a percentage of the control 
non-targeting siRNA (NTsiRNA) treated cells following Sp1, Sp3, P15 and DEAF-1 
siRNA knockdown. Error bars denote the standard error of the mean (SEM). *p<0.05, 
calculated relative to the NTsiRNA value using a Student’s 2 tailed t-test. (B) 
Immunoblots demonstrating Sp1, Sp3, P15 and DEAF-1 (D1) protein depletion 
following siRNA treatment. Protein extracted from cells treated with the NTsiRNA 
control was used for basal protein expression whilst β-Actin was used as a loading 
control. (C) Fold change in GDF5 expression following Sp1, Sp3, P15 and DEAF-1 
siRNA knockdown and shown relative to the NTsiRNA control. Error bars denote the 
SEM. ***p<0.001, calculated using a ANOVA. (D) The rs143383 C/T allelic ratio is 
shown following Sp1, Sp3, P15 and DEAF-1 siRNA knockdown and compared against 
treatment with the NTsiRNA control. Allelic ratios were normalised to genomic DNA 
(gDNA). Error bars denote the SEM. ***p<0.001, calculated using a ANOVA. Each 
siRNA experiment was performed three times and each with three technical repeats. 
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7.3.3 Investigation of GDF5 expression following Sp1, Sp3, P15 and DEAF-1 over 
expression 
The second technique employed to assess the impact of each candidate upon GDF5 
expression was their over expression. A region of GDF5 containing the promoter and 
5ʹUTR sequence encompassing rs143383 was cloned into a luciferase reporter plasmid 
as described in Materials and Methods section 2.15. Two constructs were generated, one 
containing the rs143383 C allele and the second containing the T allele by site directed 
mutagenesis (Materials and Methods section 2.15.3). Furthermore, I cloned the mRNA 
sequence of Sp1, Sp3 and P15 into an expression plasmid containing an enhanced green 
fluorescence protein (EGFP) tag. DEAF-1-EGFP was kindly donated by C. Garrison 
Fathman and Linda Yip. [298]. Details of the primers used to create inserts for cloning 
and those used for sequencing can be found in Table 5, Appendix. The over expression 
of plasmid DNA has been previously tested in the SW872 cell line in our laboratory by 
Andrew Dodd, PhD student, however the transfection efficiency was low. The 
chondrosarcoma cell line, SW1353 was used for the over expression experiments due to 
higher transfection efficiencies being observed.  
 
I first optimised the transfection of the over expression plasmids into the SW1353 cells 
using the empty EGFP vector. I tested different cell confluencies and different 
transfection reagent: DNA ratios. I assessed the transfection efficiency by visualising 
the fluorescence 24 hours post transfection. The conditions chosen for transfection are 
described in Materials and Methods section 2.16. Over expression of Sp1, Sp3, P15 and 
DEAF-1 proteins was confirmed by immunoblotting and immunofluorescence (Figure 
7.3A and B). Each EGFP tagged protein was localised to the nucleus following 
transfection as shown in Figure 7.3B.  
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Figure 7.3 
Over expression of Sp1, Sp3, P15 and DEAF-1. (A) Immunoblots showing Sp1 (Sp1-
EGFP), Sp3 (Sp3-EGFP), P15 (P15-EGFP) and DEAF-1 (DEAF-1 EGFP) protein 
levels following over expression compared to the EGFP/pGL3 combination empty 
vector control (EGFP). Cells are untreated protein samples whilst β-Actin was used as a 
loading control. The arrows indicate basal protein and over expressed protein levels. (B) 
Immunofluorescence images following over expression. Nuclei are stained blue with 
DAPI and shown in the first row. The localisation of the EFGP fusion proteins (Empty 
EGFP, Sp1 EGFP, Sp3 EGFP, P15 EGFP and DEAF-1 EGFP) is shown in the second 
row (EGFP). The final row shows the merged DAPI and EGFP images (Merge).  
 
Following transfection of the GDF5 promoter luciferase constructs into SW1353 cells, I 
first assessed the effect that the C-T single nucleotide change had on luciferase activity. 
I observed that the presence of a T allele at rs143383 significantly reduced the luciferase 
activity in comparison with a C allele at rs143383 (p<0.001). The average C/T allelic 
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ratio was 1.2 (Figure 7.4). This confirms findings previously observed in CH8, SW872 
and MG63 cell lines [272].  
 
Over expression of Sp1 decreased the promoter activity of both C and T allele 
constructs, with a significant repressive effect on the T allele (p<0.05; Figure 4A), 
significantly increasing the C/T ratio to 1.38 (p<0.01). Over expression of Sp3 
decreased the promoter activity of both the C and T allele constructs, and this effect was 
significant with the T allele construct (p<0.001; Figure 4B) significantly increasing the 
allelic ratio to 1.48 (p<0.001). P15 over expression decreased the promoter activity of 
both alleles, however, this repressive effect was not significant (Figure 4C). Finally, 
DEAF-1 over expression significantly repressed the promoter activity of both alleles (C 
and T alleles p<0.001; Figure 4D), but most notably repressed the T allele construct, 
decreasing its activity to near that of the empty control and significantly increasing the 
allelic ratio to 1.37 (p<0.01). These results confirm that all four factors repress GDF5 
expression, and that for Sp1, Sp3 and DEAF-1 this repression is greater for the T allele 
of rs143383.  
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Figure 7.4 
Over expression of the Sp1, Sp3, P15 and DEAF-1 (D1) proteins. (A-D) Promoter 
activity of the C and T GDF5 luciferase vectors is shown relative to Renilla. Values are 
normalised to the luciferase levels of the EGFP/pGL3 empty vector (EMPTY). 
Promoter luciferase levels of both C and T allele vectors are shown in addition to the 
empty EGFP vector (C and T) and following over expression of (A) Sp1 (C+Sp1 and 
T+Sp1), (B) Sp3 (C+Sp3 and T+Sp3), (C) P15 (C+P15 and T+P15) and (D) DEAF-1 
(C+D1 and T+D1). Error bars denote the standard error of the mean (SEM). *p<0.05, 
**p<0.01, ***p<0.001, n/s = not significant, calculated using a Student’s 2 tailed t-test. 
Six replicate experiments were performed, each with four technical repeats.  
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7.4 Discussion 
Following the identification of the binding of Sp1, Sp3 and P15 to GDF5 in vitro, I 
have confirmed the binding of these three factors in vivo in SW872 cells using ChIP. 
GDF5 DNA was enriched following ChIP with antibodies targeting these three factors. 
In order to accurately assess the binding of each of these factors to GDF5 in vivo, the 
next stage would be to use Real Time PCR to quantitatively investigate the fold 
enrichment of GDF5 over the negative control antibody. Using Real Time PCR would 
enable a more accurate assessment of the binding of each factor relative to one another. 
Furthermore, the identification of a region that is negative for the binding of each of 
these factors will confirm that the binding at this locus is specific. 
The depletion of Sp1, Sp3 and P15 resulted in small, non significant increases in the 
overall expression of GDF5. Upon DEAF-1 knockdown, the overall expression of 
GDF5 was significantly increased. The depletion of Sp1, Sp3 and DEAF-1 increased 
the DAE, with the DEAF-1 depletion significantly increasing the C/T allelic ratio. The 
depletion of P15 increased the expression of both the C and T alleles relative to the 
NTsiRNA but did not alter the C/T allelic ratio. In chapter 5 (Figure 5.6), I have 
previously depleted P15 using siRNA and I observed an increase in the overall 
expression of GDF5 and a decrease in the C/T allelic ratio from 1.5 in the control 
(NTsiRNA) to 1.26 (P15 siRNA). This previous experiment was based on data from one 
experiment, with three technical repeats. The experiment completed in this chapter is 
based on three independent experiments, each also with three technical repeats. As the 
differential repressive effect observed in Chapter 5 following P15 depletion has not 
been replicated here with a larger number of samples, I conclude from the depletion 
experiments that P15 is not repressing the C and T alleles differentially.  
Overall, the siRNA knockdown experiments suggest that all four factors are repressing 
the expression of GDF5. Sp1, Sp3 and DEAF-1 are also modulating the DAE observed. 
DEAF-1 appears to be repressing the expression of GDF5 most significantly. However, 
although the mRNA expression of DEAF-1 was decreased following DEAF-1 siRNA 
treatment, I cannot confirm the depletion of DEAF-1 at the protein level. The 
characterisation studies that I performed in Chapter 6 did however suggest that the 
DEAF-1 siRNA is able to deplete DEAF-1 protein and I can therefore deduce from 
these experiments that DEAF-1 protein has been decreased.  
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The difference observed in the promoter activity between the C and T alleles is 
comparable with that reported previously [272], where the presence of a T allele at 
rs143383 was found to mediate a reduction in luciferase activity relative to a C allele. 
Here I examined the extent to which each factor is modulating the allelic expression of 
GDF5 using over expression experiments. These confirmed that each factor is 
repressing GDF5 expression, supporting the findings from my siRNA depletion studies. 
Furthermore, Sp1, Sp3 and DEAF-1 showed a greater repressive effect on the T allele 
promoter construct compared to the C allele promoter construct.  
P15 over expression repressed the two alleles to a minor extent and its depletion led to a 
small and non significant increase in the expression of GDF5. P15 may therefore only 
be mediating a modest repressive effect and be binding as part of a larger repressive 
complex. When depleted, the other factors that form the complex are able to continue to 
differentially repress GDF5 expression.  
The over expression studies suggest that Sp1, Sp3 and DEAF-1 repress the T allele to a 
greater extent than the C allele. Therefore, upon depletion of these factors, a greater 
increase in the expression of the T allele, relative to the C allele, would be expected. 
This would cause the C/T allelic ratio to decrease. Conversely, I observed an increase in 
the C/T allelic ratio upon Sp1, Sp3 and DEAF-1 knockdown. For each factor, the 
expression of both alleles increased, however the C allele increased to a greater extent 
relative to the T allele. This may be a result of the incomplete depletion of the protein of 
each factor. If each factor represses the T allele to a greater extent and there is still 
protein present following siRNA knockdown, then any remaining protein would be 
expected to bind to the T allele more avidly, which could therefore explain the larger 
increase in C allele expression that was observed.  
Overall, I have confirmed the binding of Sp1, Sp3 and P15 in vivo to GDF5. 
Furthermore, Sp1, Sp3, P15 and DEAF-1 have been identified as repressors of GDF5, 
with Sp1, Sp3 and DEAF-1 differentially modulating the expression of the two 
rs143383 GDF5 alleles. The next chapter will investigate further the role of each factor 
using combination over expression and knockdown experiments.  
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Chapter 8: The Interaction of Sp1, Sp3, P15 and DEAF-1 at 
rs143383 
8.1 Introduction 
In Chapter 7, I investigated the effects that the trans-acting factors, Sp1, Sp3, P15 and 
DEAF-1 mediated on the overall and the allelic expression of GDF5. Using siRNA 
depletion and over expression experiments all four factors were shown to repress the 
expression of GDF5. Additionally, each factor was found to repress the T allele to a 
greater extent in comparison with the C allele. The degree to which each factor 
modulated the expression of GDF5 varied, thus I wanted to explore further how these 
four factors may be interacting to mediate their repressive effects. In this chapter I have 
used combination knockdown and combination over expression experiments in order to 
establish how these factors are interacting.  
As described in Chapters 6 and 7, DEAF-1 EGFP can be detected using the DEAF-1 
antibody, however, I have not been able to detect endogenous DEAF-1 protein. 
Therefore the immunoblots for DEAF-1 will be shown following DEAF-1 depletion and 
over expression but depletion of the endogenous protein will not be discussed. 
8.2 Aims 
 To investigate the effect of depleting two factors simultaneously using siRNA 
on the overall and the allelic expression of GDF5. 
 To investigate the effect of over expressing two factors simultaneously on GDF5 
C and T allele promoter activities using a luciferase reporter assay. 
 To deplete each of the four factors, whilst concurrently over expressing each in 
different combinations to compare their individual and combined impacts on 
GDF5 expression.  
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8.3 Results 
8.3.1 Combination Knockdowns 
I first optimised the transfection conditions for the depletion of two factors 
simultaneously; a final siRNA concentration of 100nM and 1x concentration of 
transfection reagent has been used previously for siRNA depletion experiments 
(Chapters 5, 6 and 7). In this chapter I have tested if cells could be transfected using a 
final siRNA concentration of 200nM and 2x concentration of transfection reagent. 
Figure 8.1 shows the protein levels of Sp1, Sp3, P15 and DEAF-1 following treatment 
with 100nM of target siRNA in addition to 100nM NTsiRNA and a concentration of 1x 
or 2x transfection reagent. Sp1, Sp3 and P15 protein levels were depleted following 
treatment with their respective siRNAs in comparison with the NTsiRNA control 
(200nM final concentration) (Figure 8.1 A-C). In each instance the addition of 2x 
concentration of the transfection reagent resulted in a greater depletion of the target 
protein.  
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Figure 8.1  
Optimisation of transfection reagent concentration for siRNA depletion. Immunoblots 
demonstrating Sp1, Sp3, P15 and DEAF-1 protein depletion following siRNA 
treatment. Cells are untreated, NTsiRNA represents treatment with a final concentration 
of 200nM NTsiRNA. Sp1, Sp3, P15 and DEAF-1 siRNA treatments represent cells 
treated with a 200nM final concentration of siRNA; 100nM of the target siRNA and 
100nM NTsiRNA. Protein extracted from cells treated with the NTsiRNA control were 
used for basal protein expression whilst β-Actin was used as a loading control. Two 
different concentrations of transfection reagent were tested (1xTR and 2xTR).  
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I then assessed the effect of transfecting more than one siRNA at the same time and the 
effect of a 2x concentration of transfection reagent on the mRNA expression levels of 
Sp1, Sp3, P15, DEAF-1, GDF5 and GAPDH (Figures 8.2 and 8.3). Sp1 mRNA is 
depleted following treatment with Sp1 siRNA relative to the NTsiRNA control (Sp1 
siRNA and NTsiRNA used at final concentration of 100nM) (Figure 8.2A). 
Additionally, Sp1 mRNA is depleted following treatment with combinations of Sp1 
siRNA with NTsiRNA, with Sp3 siRNA, with P15 siRNA and with DEAF-1 siRNA 
(both siRNA together representing a 200nM final siRNA concentration), relative to the 
100nM NTsiRNA control but not relative to the 200nM NTsiRNA control. This 
reduction in Sp1 gene expression was apparent when transfecting with both 1x and 2x 
transfection reagent concentrations. A reduction in Sp1 gene expression is also apparent 
following transfection with 100nM NTsiRNA treated cells using 2x transfection reagent 
compared with using 1x transfection reagent. 
The expression levels of Sp3, P15 and DEAF-1 follow similar patterns, each time with 
the target siRNA depleting expression of the target gene relative to the 100nM 
NTsiRNA control but not relative to the 200nM NTsiRNA control. Furthermore, 2x 
concentration of transfection reagent appears to deplete gene expression. These results 
suggest that adding a final siRNA concentration of 200nM and adding 2x concentration 
of transfection reagent is affecting gene expression in an inconsistent manner. 
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Figure 8.2 
Expression of Sp1, Sp3, P15 and DEAF-1 following combination depletion. Expression 
levels of Sp1, Sp3, P15 and DEAF-1 mRNA are shown relative to the housekeeping 
gene GAPDH. Cells were treated with different combinations of siRNAs; Sp1 (SP1), 
Sp3 (SP3), P15 or DEAF-1 (D1) alone or in combination with the NTsiRNA control 
(SP1 + NTsiRNA, SP3 + NTsiRNA, P15 + NTsiRNA, D1 + NTsiRNA) or a second 
siRNA (A: SP1 + SP3 siRNA, SP1 + P15 siRNA, SP1 + D1 siRNA. B: SP3 + SP1 
siRNA, SP3 + P15 siRNA, SP3 + D1 siRNA. C: P15 + SP1 siRNA, P15 + SP3 siRNA, 
P15 + D1 siRNA. D: D1 + SP1 siRNA, D1 + SP3 siRNA, D1 + P15 siRNA). Two 
different concentrations of the control NTsiRNA was transfected into cells, 100nM 
(NTsiRNA) and 200nM (NTsiRNA 200). 1x and 2x concentrations of transfection 
reagent were used. Error bars denote the standard error of the mean (SEM), the mean is 
calculated from three replicate experiments.  
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In addition to examining the expression of Sp1, Sp3, P15 and DEAF-1, I also assessed 
the expression levels of GDF5 and GAPDH following these same treatments (Figure 
8.3). I have consistently observed an increase in the expression of GDF5 following Sp1, 
Sp3, P15 and DEAF-1 depletion, shown previously in Chapter 7 (see Figure 7.2). Figure 
8.3A depicts GDF5 expression following different siRNA combinations in addition to 
1x transfection reagent. For each treatment, GDF5 expression is decreased relative to 
the 100nM NTsiRNA control. Following transfection with the NTsiRNA control using 
2x concentration of transfection reagent, the expression of GDF5 is decreased compared 
with using 1x concentration (Figure 8.3B). Sp1, Sp3 and P15 siRNA treatments increase 
the expression of GDF5 relative to the 100nM NTsiRNA control using 2x concentration 
of transfection reagent. Additionally, Sp1 siRNA in combination with DEAF-1 siRNA 
results in a large increase in GDF5 expression relative to the 100nM and 200nM 
NTsiRNA control.  
These treatments are not producing consistent results, with decreases in the expression 
of genes being observed on the addition of a 200nM concentration of siRNA or a 2x 
concentration of transfection reagent. The expression levels of GAPDH were also 
examined and are shown in Figures 8.3C and D. The expression of GAPDH is very low 
in cells treated with 100nM of siRNAs targeting Sp1, Sp3, P15, DEAF-1 and a 
NTsiRNA control using 1x transfection reagent (Figure 8.3C). Cells treated with a 
200nM final concentration of siRNA have increased expression levels of GAPDH but 
the expression levels are inconsistent. A similar pattern of expression is observed in the 
cells transfected using 2x transfection reagent (Figure 8.3D).  
Overall, the results obtained from this optimisation are not reliable and suggest that 
changing the concentration of siRNA or transfection reagent will affect the gene 
expression. The expression levels of Sp1, Sp3, P15 and DEAF-1 were decreased 
following combination siRNA treatments, however the GDF5 and GAPDH expression 
levels were not consistent following these treatments.  
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Figure 8.3 
Expression of GDF5 and GAPDH following combination depletion. Expression levels 
of GDF5 are shown relative to the housekeeping gene GAPDH (Figure 8.3A and B). 
GAPDH expression is shown (Figure 8.3C and D). Cells were treated with different 
combinations of siRNAs; Sp1 (SP1), Sp3 (SP3), P15 or DEAF-1 (D1) alone or in 
combination with the NTsiRNA control (SP1 + NTsiRNA, SP3 + NTsiRNA, P15 + 
NTsiRNA, D1 + NTsiRNA) or a second siRNA (A: SP1 + SP3 siRNA, SP1 + P15 
siRNA, SP1 + D1 siRNA. B: SP3 + SP1 siRNA, SP3 + P15 siRNA, SP3 + D1 siRNA. 
C: P15 + SP1 siRNA, P15 + SP3 siRNA, P15 + D1 siRNA. D: D1 + SP1 siRNA, D1 + 
SP3 siRNA, D1 + P15 siRNA). Two different concentrations of the control NTsiRNA 
was transfected into cells, 100nM (NTsiRNA) and 200nM (NTsiRNA 200). 1x and 2x 
concentrations of transfection reagent were used. Error bars denote the standard error of 
the mean (SEM), the mean is calculated from three replicate experiments.  
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Results from Figure 8.1 suggested that when transfecting 100nM of target siRNA in 
addition to 100nM of NTsiRNA using 1x or 2x concentrations of transfection reagent 
the target protein was successfully depleted. The gene expression analysis however 
seems to suggest that greater concentrations of siRNA and a 2x concentration of 
transfection reagent may be affecting the gene expression. I therefore further assessed 
the protein levels of Sp1, Sp3, P15 and DEAF-1 following treatment with either 200nM 
NTsiRNA or 100nM of each target siRNA (Sp1, Sp3, P15 and DEAF-1) in addition to 
100nM NTsiRNA or combinations of two target siRNAs (Figure 8.4). Sp1 protein is 
decreased following treatment with Sp1 siRNA in addition to NTsiRNA in comparison 
with the NTsiRNA control. There is no protein present in the Sp1 and Sp3 siRNA 
combination treatment, indicating a problem has occurred. Sp1 was decreased to a 
minor extent following Sp1 and P15 siRNA treatment and was not depleted following 
Sp1 and DEAF-1 siRNA combination treatment (Figure 8.4A). 
Sp3 expression is decreased to a minor extent following treatment with Sp3 siRNA, Sp3 
siRNA in addition to P15 siRNA and Sp3 siRNA in addition to DEAF-1 siRNA in 
comparison with the NTsiRNA control. Sp3 + Sp1 siRNA represents the same sample 
as in A (Figure 8.4B). The protein levels of P15 are unaffected following treatment with 
the siRNAs relative to the NTsiRNA control (Figure 8.4C).  
The results from this combination knockdown experiment are inconsistent and further 
optimisations would therefore be needed to progress this experiment. Due to time 
constraints, I was unable to optimise this combination knockdown further.  
150 
 
 
Figure 8.4 
Immunoblots demonstrating Sp1, Sp3, P15 and DEAF-1 protein depletion following 
combination siRNA treatment. Protein extracted from cells treated with the NTsiRNA 
control were used for basal protein expression whilst β-Actin was used as a loading 
control. Cells are untreated (Cells) or transfected with a final concentration of 200nM 
NTsiRNA (NTsiRNA), 100nM of target siRNA plus 100nM of NTsiRNA (Sp1, Sp3, 
P15, DEAF-1 siRNA) or 100nM of target siRNA one and target siRNA two using a 2x 
final concentration of transfection reagent.  
8.3.2 Combination Over expression 
Following the single transfection of the trans-acting factor expression plasmids in 
Chapter 7, I assessed whether the repressive effects observed would be stronger if the 
factors were co-transfected and over expressed together. I first investigated if it was 
possible using the same experimental conditions to over express two of these factors 
simultaneously. The immunoblots following the combination over expressions are 
shown in Figure 8.5. 500ng of each plasmid was transfected into cells as with the single 
transfection experiments, detailed in Materials and Methods section 2.16. Each factor 
has been successfully over expressed alone, and in combination (Figure 8.5 A-D).  
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Figure 8.5 
Combination over expression of the trans-acting factors. Immunoblots demonstrating 
Sp1, Sp3, P15 and DEAF-1 protein levels following over expression compared with the 
empty vector control (Empty). Cells are untreated or transfected with 500μg of empty, 
Sp1, Sp3, P15 or DEAF-1 EGFP vectors, or combinations of each.  β-Actin was used as 
a loading control and the arrows indicate over expressed protein levels.  
 
When Sp1 and Sp3 were jointly over expressed there was a significantly greater 
reduction in expression of both the rs143383 C and the T alleles relative to when they 
were over expressed alone (Figure 8.6A). Furthermore, the C/T allelic ratio significantly 
increased from 1.38 for the Sp1 over expression and 1.48 for the Sp3 over expression to 
1.70 for the joint over expression (p<0.001 for the joint over expression versus Sp1 
alone and p<0.05 for the joint over expression versus Sp3 alone; Table 8.1).  
 
When Sp1 and P15 were jointly over expressed, there was a reduction in the expression 
of both the C and T alleles, relative to when they were over expressed alone, this 
repressive effect was significant for the T allele when compared to P15 over expression 
alone (Figure 8.6B, p<0.001 versus P15 alone). The C/T allelic ratio was not altered 
significantly for joint over expression (p=0.79 versus Sp1 alone and p=0.06 versus P15 
alone; Table 8.1).  
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When Sp1 and DEAF-1 were jointly over expressed there was a reduction in expression 
of both the C and T alleles relative to when they were over expressed alone (Figure 
8.6C). The C/T allelic ratios increased significantly from 1.38 for Sp1 and 1.37 for 
DEAF-1 to 1.55 for the joint over expression (p<0.001 versus the C/T EGFP empty 
vector ratio, Table 8.1). However, these C/T allelic ratio changes were not significant 
when compared with Sp1 or DEAF-1 over expression alone (p = 0.1). 
 
When Sp3 and P15 were jointly over expressed there was an increase in the expression 
of the C allele when compared with Sp3 and P15 over expression alone. Conversely, the 
expression of the T allele was decreased when Sp3 and P15 were jointly over expressed 
when compared with Sp3 and P15 over expression alone (Figure 8.6B). Furthermore, 
the C/T allelic ratio significantly increased from 1.48 for the Sp3 over expression and 
1.24 for P15 over expression to 1.59 for the joint over expression (p=0.22 versus Sp3 
alone, p<0.01 versus P15 alone, Table 8.1).  
 
When Sp3 and DEAF-1 were jointly over expressed, the expression of both C and T 
alleles was reduced relative to Sp3 over expression alone, but increased relative to 
DEAF-1 over expression alone (Figure 8.6C). The C/T allelic ratios also increased from 
1.48 for Sp3 and 1.37 for DEAF-1 to 1.6 for the joint over expression, and this was a 
significant C/T difference compared to DEAF-1 over expression alone (p = 0.01, Table 
8.1).  
 
Finally, when P15 and DEAF-1 were over expressed the expression of both the C and T 
alleles was significantly reduced relative to P15 over expression alone (p<0.001, Figure 
8.6B), but increased relative to DEAF-1 over expression alone. The C/T allelic ratio 
increased to 1.37 for joint over expression from 1.24 for P15 over expression and 
remained unchanged from 1.37 for DEAF-1 over expression alone (p=0.45 versus P15 
alone, p=0.99 versus D1 alone, Table 8.1).    
Overall these results suggest that Sp1 and DEAF-1 together are mediating the largest 
repressive effects on the expression of the C and T alleles. Sp3 appears to be mediating 
the largest differential effect; when over expressed in combination with Sp1, the C/T 
allelic ratio increases significantly to 1.7 due to the T allele being significantly more 
repressed than the C allele. This is also the case when Sp3 is over expressed in 
combination with P15 (increasing the C/T allelic ratio to 1.59) and DEAF-1 (increasing 
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the C/T allelic ratio to 1.6). P15 on the other hand does not appear to mediate any 
additional repressive effects when over expressed in combination with any of the other 
three factors compared to the over expression of each of these factors alone.  
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Figure 8.6 
The effect of trans-acting factor over expression on GDF5 promoter activity. Promoter 
activity of the C and T GDF5 luciferase vectors is shown relative to Renilla. Values are 
normalised to the luciferase levels of the EGFP/pGL3 empty vector (EMPTY). (A) 
Promoter luciferase levels of both C and T allele vectors are shown in addition to the 
empty EGFP vector (C and T) and following over expression of Sp1 alone (C+Sp1 and 
T+Sp1), Sp3 alone (C+Sp3 and T+Sp3) and Sp1 and Sp3 in combination (C+Sp1+Sp3 
and T+Sp1+Sp3). (B) Promoter luciferase levels of both C and T allele vectors are 
shown in addition to the empty EGFP vector (C and T) and following over expression 
of P15 alone (C+P15 and T+P15) and P15 in combination with Sp1 (C+P15+Sp1 and 
T+P15+Sp1), Sp3 (C+P15+Sp3 and T+P15+Sp3) and DEAF-1 (C+P15+DEAF-1 and 
T+P15+DEAF-1). (C) Promoter luciferase levels of both C and T allele vectors are 
shown in addition to the empty EGFP vector (C and T) and following over expression 
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of DEAF-1 alone (C+D1 and T+D1), and DEAF-1 in combination with Sp1 
(C+D1+Sp1 and T+D1+Sp1) and in combination with Sp3 (C+D1+Sp3 and 
T+D1+Sp3). Error bars denote the standard error of the mean (SEM). *p<0.05 
***p<0.001 n/s = not significant, calculated using a Student’s 2 tailed t-test. Three 
replicate experiments were performed, each with an n of 4. 
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Vector  C/T Ratio P Value 
C/T 1.2  
C/T + Sp1 1.38 0.005 
C/T + Sp3 1.48 <0.0001 
C/T + P15 1.24 0.56 
C/T + D1 1.37 0.006 
C/T + Sp1 + Sp3 1.70 <0.0001 (vs. C/T) 
<0.001 (vs. + Sp1) 
0.03 (vs. + Sp3) 
C/T + Sp1 + P15 1.4 0.003 (vs. C/T) 
0.79 (vs. + Sp1) 
0.06 (vs. + P15) 
C/T + Sp1 + D1 1.55 <0.0001 (vs. C/T) 
0.1 (vs. + Sp1) 
0.1 (vs. + D1) 
C/T + Sp3 + P15 1.59 <0.0001 (vs. C/T) 
0.22 (vs. + Sp3) 
0.0002 (vs. + P15) 
C/T + Sp3 + D1 1.6 <0.0001 (vs. C/T) 
0.2 (vs. + Sp3) 
0.01 (vs. + D1) 
C/T + P15 + D1 1.37 
 
 
0.09 (vs. C/T) 
0.45 (vs. + P15) 
0.99 (vs. + D1) 
Table 8.1 
The C/T allelic ratios following over expression of the trans-acting factors. The 
promoter activities of the C and T GDF5 luciferase vectors were compared to derive 
C/T ratios, which are shown for the empty vectors (C/T) and for when these vectors 
were co-transfected in combination with Sp1 (C/T + Sp1), Sp3 (C/T + Sp3), P15 (C/T + 
P15), DEAF-1 (C/T + D1), Sp1 and Sp3 (C/T + Sp1 + Sp3), Sp1 and P15 (C/T + Sp1 + 
P15), Sp1 and DEAF-1 (C/T + Sp1 + DEAF-1), Sp3 and P15 (C/T + Sp3 + P15), Sp3 
and DEAF-1 (C/T + Sp3 + DEAF-1) and P15 and DEAF-1 (C/T + P15 + DEAF-1). P-
values were calculated using a Student’s 2 tailed t-test comparing the allelic ratios of 
each treatment group to either C/T, C/T + Sp1 (+Sp1), C/T + Sp3 (+Sp3), C/T + P15 
(+P15) or C/T + D1 (+D1). Three replicate experiments were performed, each with an n 
of 4.  
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8.3.3 siRNA Knockdown and Over expression 
In addition to depleting two factors in combination and over expressing two factors in 
combination, I wanted to optimise a technique that would enable the depletion of one 
factor and the over expression of another simultaneously. Dhamafect Duo is a 
transfection reagent that enables the transfection of siRNA and plasmid vectors 
concurrently. I first tested if this transfection reagent could be used to deplete protein 
using siRNA or over express protein by transfecting EGFP tagged over expression 
vectors into SW1353 cells. I tested this protocol using Sp3 siRNA and Sp3 EGFP, 
Materials and Methods 2.16. 
The first four lanes of Figure 8.7A show the protein levels of Sp3 following no 
treatment (Cells), treatment with transfection reagent alone (DF Duo), NTsiRNA or Sp3 
siRNA. Sp3 protein levels were depleted following treatment with Sp3 siRNA in 
comparison with the NTsiRNA control. Figure 8.7B depicts the protein levels of Sp3 
following over expression with 1μg of Sp3 EGFP, 2μg of Sp3 EGFP or 1μg of Sp3 
EGFP vector in addition to 1μg of empty EGFP vector. Sp3 protein was over expressed 
in all three treatments in comparison with the empty EGFP vector control. These results 
confirm that I am able to deplete or over express (up to 2μg) Sp3 protein using this 
transfection reagent. Lanes 5-9 of Figure 8.7A show Sp3 protein levels following the 
over expression of either the empty vector or Sp3 EGFP in addition to transfection with 
the NTsiRNA control or Sp3 siRNA. Sp3 protein was depleted following treatment with 
Sp3 siRNA in comparison with NTsiRNA when co transfected with 1μg of empty 
vector. Furthermore, Sp3 was over expressed when transfected into cells with NTsiRNA 
and this over expressed protein was depleted upon co-transfection with Sp3 siRNA. 
These results suggest this transfection reagent can be used to deplete and over express 
proteins concurrently.  
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Figure 8.7 
Immunoblots showing Sp3 protein levels following an optimisation experiment using 
Dharmafect Duo transfection reagent. Cells are untreated protein samples, DF Duo 
represents treatment of cells with transfection reagent alone. (A) Cells were transfected 
with NTsiRNA, Sp3 siRNA, empty vector, empty vector in addition to NTsiRNA 
(Empty + NTsiRNA) or Sp3 siRNA (Empty + Sp3 siRNA) or Sp3 EGFP vector in 
addition to Sp3 siRNA (Sp3 EGFP + Sp3 siRNA) or NTsiRNA (Sp3 EGFP + 
NTsiRNA). (B) Cells were transfected with either 1μg or 2μg of Sp3 EGFP vector (Sp3 
EGFP 1μg or Sp3 EGFP 2μg), 1μg of empty vector (Empty) or 1μg of empty vector in 
addition to 1μg of Sp3 EGFP (Sp3 EGFP + Empty). β-Actin was used as a loading 
control. The arrows indicate endogenous and over expressed protein levels.  
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I then further optimised this experiment by testing different volumes of the Dharmafect 
Duo transfection reagent. Figure 8.8A shows Sp3 protein levels following the over 
expression of the Sp3 EGFP vector using either 4 or 6μl of transfection reagent. The 
expression level of Sp3 EGFP protein was not further increased by adding a greater 
volume of transfection reagent.  
Next, I tested if DEAF-1 protein could be over expressed by transfecting 1µg of DEAF-
1 EGFP vector in addition to 1µg empty vector using the Dharmafect Duo transfection 
reagent. DEAF-1 EGFP was successfully over expressed (Figure 8.8B).  
 
Figure 8.8 
Immunoblots showing further optimisation of Sp3 over expression and the optimisation 
of DEAF-1 over expression using Dharmafect Duo transfection reagent. (A) Cells were 
transfected with 2μg of empty vector using 4μl of transfection reagent or 1μg of Sp3 
EGFP in addition to 1μg of empty vector using two different volumes, 4μl and 6μl of 
transfection reagent. (B) Cells were transfected with either 2μg of empty vector or 1μg 
of DEAF-1 EGFP in addition to 1μg of empty vector. β-Actin was used as a loading 
control. The arrows indicate over expressed protein levels.  
 
Following the successful over expression and concurrent knockdown of Sp3, I then 
assessed if Sp1, Sp3, P15 and DEAF-1 protein expression could be depleted following 
siRNA transfection, whilst concurrently over expressing either empty EGFP vector, Sp3 
EGFP or DEAF-1 EGFP vectors (Figure 8.9A-D). Sp3 was depleted following 
treatment with Sp3 siRNA in comparison with the NTsiRNA control when concurrently 
transfected with the empty EGFP or DEAF-1 EGFP vectors (Figure 8.9A). Sp1 and P15 
protein were depleted following treatment with Sp1 and P15 siRNA respectively when 
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(Figure 8.9C and D). The successful over expression of Sp3 EGFP and DEAF-1 EGFP 
for this experiment is shown in Figures 8.10A and B.  
 
Figure 8.9 
Concurrent over expression and depletion studies: the assessment of depletion. 
Immunoblots showing the depletion of Sp1, Sp3, P15 and DEAF-1 upon transfection 
with siRNA in addition to Sp3 EGFP and DEAF-1 EGFP over expression vectors using 
Dharmafect Duo transfection reagent. Cells are untreated protein samples (A) Sp3 
protein levels following transfection with 1μg of empty vector or 1μg of DEAF-1 EGFP 
in addition to NTsiRNA or Sp3 siRNA. (B) DEAF-1 protein levels following 
transfection with 1μg of empty vector or 1μg of Sp3 EGFP in addition to NTsiRNA or 
DEAF-1 siRNA. (C) Sp1 protein levels following transfection with 1μg of empty 
vector, 1μg of Sp3 EGFP or 1μg DEAF-1 EGFP in addition to NTsiRNA or Sp1 
siRNA. (D) P15 protein levels following transfection with 1μg of empty vector, 1μg of 
Sp3 EGFP or 1μg DEAF-1 EGFP in addition to NTsiRNA or P15 siRNA. β-Actin was 
used as a loading control. The arrows indicate the endogenous protein levels.  
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Figure 8.10 
Concurrent over expression and depletion studies: the assessment of over expression. 
Immunoblots showing the over expression of Sp3 EGFP and DEAF-1 EGFP following 
transfection with siRNA in addition to Sp3 EGFP and DEAF-1 EGFP over expression 
vectors using Dharmafect Duo transfection reagent. (A) Sp3 protein levels following 
transfection with NTsiRNA, Sp1 siRNA, Sp3 siRNA or DEAF-1 siRNA in addition to 
1μg of empty vector or 1μg of Sp3 EGFP. (B) DEAF-1 protein levels following 
transfection with NTsiRNA, Sp1 siRNA, Sp3 siRNA or DEAF-1 siRNA in addition to 
1μg of empty vector or 1μg of Sp3 EGFP. β-Actin was used as a loading control. The 
arrows indicate the over expressed protein levels.  
 
Following the successful concurrent transfection of siRNA and plasmid DNA using this 
transfection reagent, I wanted to assess if I could use this protocol to transfect cells with 
the GDF5 C/T luciferase vectors, in addition to the trans-acting factor over expression 
vectors and siRNAs targeting each factor. This would enable the assessment of the 
effects of each factor on GDF5 promoter activity.  In Chapter 7 I had demonstrated that 
over expression of Sp3 alone consistently decreased the C and T allele promoter activity 
and had a more significant repressive effect on the T allele, decreasing the luciferase 
levels from 6.6 and 5.6 to 5.4 and 3.6 relative luciferase units respectively (Figure 7.4). 
For this new experiment, I observed that whilst over expressing Sp3, regardless of the 
siRNA transfected, the luciferase levels of both the C and T vectors were reduced to 
below 2, with each siRNA appearing to have similar repressive effects. Similarly, over 
expression of DEAF-1 alone (Figure 7.4) consistently decreased the C and T allele 
promoter activity and had a more significant repressive effect on the T allele, decreasing 
the luciferase levels from and 3.7 to 1.5 and 1.13 relative luciferase units  respectively. 
As for Sp3 over expression, upon DEAF-1 over expression, regardless of the siRNA 
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with each siRNA appearing to have similar repressive effects. Although a repressive 
effect was expected, this is greater than the effects seen previously and thus it appears to 
be a result of the co-transfection of the over expression vectors with the siRNA.   
 
 
Figure 8.11 
Over expression and concurrent siRNA knockdown. (A) Promoter activity of the C and 
T GDF5 luciferase vectors is shown. Values are normalised to the luciferase levels of 
the EGFP/pGL3 empty vector (EMPTY). Promoter luciferase levels of both C and T 
allele vectors are shown in addition to the empty EGFP vector (C and T) and following 
over expression of Sp3 EGFP, in addition to a non targeting siRNA (+NTsiRNA), Sp1 
siRNA (+Sp1), P15 siRNA (+P15) and DEAF-1 siRNA (+DEAF-1). (B) Promoter 
activity of the C and T GDF5 luciferase vectors is shown. Values are normalised to the 
luciferase levels of the EGFP/pGL3 empty vector (EMPTY). Promoter luciferase levels 
of both C and T allele vectors are shown in addition to the empty EGFP vector (C and 
T) and following over expression of DEAF-1 EGFP, in addition to a non targeting 
siRNA (+NTsiRNA), Sp1 siRNA (+Sp1), Sp3 siRNA (+Sp3) and P15 siRNA (+P15). 
Error bars denote the standard error of the mean (SEM). This experiment is based on 
one experiment with four technical repeats.  
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Figure 8.12  
Proposed binding model of the four trans-acting factors to rs143383. A region (+9 to 
+301 relative to the transcription start site) of the GDF5 5ʹUTR is depicted, with the 
sequence immediately flanking rs143383 (T allele underlined) shown. We propose that 
DEAF-1 binds directly to rs143383 (at the TTGG site) and that Sp1 and Sp3 bind just 
upstream (to the Sp site GGGCGG), mediating a repressive effect through DEAF-1. 
P15 binds as part of the repressive multi-protein complex and may be serving as a linker 
between Sp1 and the general transcription machinery. ORF is the open reading frame of 
GDF5 whilst ATG is the translation initiation codon. 
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8.4 Discussion 
In Chapter 7 I used siRNA depletion and over expression studies to assess the 
individual effect that the four trans-acting factors Sp1, Sp3, P15 and DEAF-1 had on 
the expression of GDF5. These studies confirmed that all four factors act as repressor 
proteins and that each factor is differentially repressing the expression of the two 
rs143383 alleles. In this chapter I have further investigated the role of each factor using 
combination depletion and combination over expression experiments.  
In the combination knockdown experiments, the protein levels of Sp1, Sp3 and P15 
were all decreased following treatment with 100nM of their respective siRNAs. Using a 
2x concentration of transfection reagent depleted the protein levels to a greater extent in 
comparison to using a 1x concentration. Although the protein levels of Sp1, Sp3 and 
P15 appeared unaffected by the increase in siRNA and transfection reagent, the gene 
expression levels were inconsistent. A concentration of 200nM NTsiRNA reduced the 
expression of Sp1, Sp3, P15, DEAF-1 and GDF5 in comparison with a concentration of 
100nM.  Furthermore the addition of 2x transfection reagent reduced the expression of 
Sp1, Sp3, P15 and DEAF-1.  
The protein levels following the transfection of two siRNAs in combination were 
assessed, none of the factors have been successfully depleted in comparison with the 
NTsiRNA when transfected in combination.  Overall, it is difficult to draw accurate 
conclusions from the data considering the variability in gene expression and the poor 
depletion of protein following the transfection of more than one siRNA. Due to time 
constraints, the optimisation of this experiment could not be continued. Future 
experiments should test lower concentrations of each siRNA, for example 50nM and 
25nM final concentrations to assess if protein levels of each factor could be depleted at 
these concentrations. If successful, this would enable the co-transfection of two or more 
siRNAs concurrently, without an overall increase in siRNA concentration compared 
with previous depletion experiments. The 2x concentration of transfection reagent may 
have been toxic to the cells; future experiments therefore should use a 1x concentration. 
If the protein of the four factors could be depleted using a final siRNA concentration of 
25nM, this would also enable the concurrent transfection of up to four different siRNAs.  
For the combination over expression experiments, I successfully over expressed 
two factors in combination using the same concentrations of each vector as used for the 
single transfection experiments reported on in Chapter 7. The over expression was 
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confirmed at the protein level, and the effect of the over expression upon GDF5 C and T 
allele promoter vectors was assessed. When over expressed together, DEAF-1 and Sp1 
mediated the greatest overall repressive effect whereas over expression of Sp1 and Sp3 
together mediated the greatest differential allelic effect, repressing the T allele to a 
greater extent than the C allele. Over expression of P15 in combination with Sp1, Sp3 or 
DEAF-1 did not contribute any further significant repressive effects compared to over 
expression of the factors alone.  Overall, these combination over expression 
experiments have enabled me to identify which factors appear to be mediating the 
greatest repressive effects, and has identified the combinations of factors that are 
repressing GDF5 to the greatest extent. In order to fully explore the role of each factor, 
further studies could optimise the over expression of three factors in combination and 
assess the repressive effects when all four factors are over expressed concurrently.  
 
Using Dharmafect Duo, I was able to successfully deplete protein following the 
transfection of an siRNA, and over express protein following the transfection of an over 
expression vector. I was also able to deplete the protein levels of Sp1, Sp3 and P15 
whilst concurrently over expressing either the empty EGFP vector, Sp3 EGFP or 
DEAF-1 EGFP vectors. In principal, the over expression of Sp1 and P15 should be 
possible using this same technique, however further work should confirm that they can 
be over expressed when concurrently transfected with siRNAs.  
 
Over expression of Sp3 and DEAF-1 in combination with a NTsiRNA reduced the 
luciferase levels of the GDF5 C and T promoter vectors, beyond that of Sp3 and DEAF-
1 over expression alone (without the siRNA; Chapter 7). There are several potential 
reasons for this and I have listed four of them below: 
1. The transfection reagents used are different and therefore may have differing 
effects. 
2. In the over expression experiments in Chapter 7, the cells were lysed 24 hours 
post transfection, however in the concurrent knockdown and over expression 
experiments reported in this chapter, the cells were lysed at 48 hours. I therefore 
lysed the cells for the luciferase experiment using the same time point (48 hours) 
which could have impacted upon the results.  
3. The values in the previous over expression experiments were normalised to 
renilla; renilla was not used for this experiment because the amount of DNA 
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being transfected was already high and thus the transfection efficiencies have 
not been corrected for. 
4. This effect may be caused by transfection of these vectors with the siRNA. To 
investigate this final reason further, I verified that the siRNAs used for this 
experiment did not target any regions within my GDF5 promoter vector which 
could have resulted in the decrease in luciferase activity observed. The siRNA 
sequences however did not target any regions within this reporter vector.  
 
Further experiments are therefore needed in order to optimise this protocol to enable the 
activity of the GDF5 C and T allele luciferase constructs to be determined following the 
depletion and over expression of the four factors in different combinations. 
Optimisations such as cell number and DNA: transfection reagent ratio could be varied 
in order to first replicate what I have observed previously for the over expression 
experiments, to enable me to then assess the impact of each of the siRNAs. Due to time 
limitations I was unable to perform any further experiments.  
 
Sp1 and Sp3, as previously described in Chapter 4 have been reported to interact with a 
number of proteins, including transcriptional activators and repressors. Sp1 and Sp3 
have also been reported to interact with proteins in the basal transcription machinery; 
promoters that do not contain a TATA box commonly contain an Sp binding site and 
when bound, the Sp proteins have been reported to play a critical role in anchoring the 
basal transcriptional machinery to promote transcriptional initiation [358]. Sp1 
facilitates the binding of TFIID through binding to TBP (TATA binding protein) 
associated factors (TAFs) which then recruit RNA polymerase II [359]. GDF5 does not 
contain a TATA box. It appears likely therefore that in binding to the GDF5 5’UTR Sp1 
and Sp3 may be mediating interactions with the basal transcriptional machinery to 
modulate transcription of the gene.   
Sp1 and Sp3 have been shown in vivo to be associated with the GC boxes of a variety of 
promoters [360]. However, it is not known whether Sp1 and Sp3 bind simultaneously or 
separately to these sites. Some studies have reported that Sp1 and Sp3 do form a multi 
protein complex, however in some cell lines this has not been observed [361, 362]. Sp1 
and Sp3 have been shown to co localise in the nucleus, suggesting interaction between 
these two proteins is possible [361].  
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Both Sp1 and Sp3 have been reported to repress the expression of genes previously, 
however when co expressed, it has been suggested that Sp3 represses gene expression 
by competing with Sp1 for occupancy of the GC binding site, Sp1 usually being 
associated with transcriptional activation [313, 362]. For example, Sp3 has been 
reported to repress Sp1 activation of the COL2A1 gene in primary chondrocytes [363]. 
However, the depletion and over expression studies that I have performed suggest that 
both Sp1 and Sp3 are repressing GDF5 expression.  
As discussed in Chapter 5, P15 can also interact with a number of proteins to activate or 
repress gene expression [326, 329]. In addition, P15 can bind to components of the 
basal transcription machinery and serves as a bridge molecule between upstream 
transcription factors and the PIC [326]. One of the most important functions of P15 is 
considered to be the stabilisation of DNA-protein interactions [364]. Additionally, P15 
directly interacts with the core histones H3 and H2B and induces chromatin 
condensation [329]. Depletion of P15 thus decompacts chromatin, upregulating the 
expression of a number of genes. Furthermore, Sp1 has been reported previously to 
interact with HDAC1 to repress gene expression [365]. Although I did not identify the 
binding of HDAC1 or HDAC2 to the GDF5 probes by EMSA in Chapter 4, it is 
possible that P15 and Sp1 mediate their transcriptional repression by recruiting histone 
modifying proteins such as HDACs which may deacetylate histones and thus repress 
gene expression.  
P15 and Sp1 have previously been reported to interact; P15 directly binds with Sp1 at 
the luteinizing hormone receptor (LHR). P15 is recruited by Sp1 and enhances Sp1 
mediated gene activation, serving as a linker protein with the general transcription 
machinery [366].  Current research by this group is further investigating the linker 
function of P15. 
As I described in Chapter 6, DEAF-1 has been previously reported to form dimers with 
itself and has been suggested to interact with other co repressor proteins through its C 
terminal region [348, 356]. DEAF-1 can also activate gene expression independently of 
promoter binding, perhaps through an interaction with the basal transcription machinery 
[345]. 
In a study examining the binding sequences of DEAF-1, over half of sequences DEAF-
1 was shown to bind to contained two or more copies of the TCGG consensus sequence 
[345]. Within exon one of the GDF5 gene, there are no additional DEAF-1 consensus 
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sequence sites (TCGG), there are however multiple TTGG sites. If DEAF-1 is able to 
bind more avidly to this sequence, it may be that multiple DEAF-1 proteins are able to 
bind to GDF5 and mediate transcriptional activity. Furthermore, previous literature 
suggests that a single base change within the DEAF-1 consensus sequence can alter 
DEAF-1 transcriptional activity [349]. 
DEAF-1 has not been previously reported to interact with Sp1, Sp3 or P15. However, 
each of these proteins can interact with a wide variety of trans-acting factors, therefore 
an interaction is feasible. Both Sp1 and DEAF-1 can form multimers and P15, Sp1 and 
Sp3 have been reported to interact with the basal transcriptional machinery to modulate 
gene expression.  
I have shown within this thesis that all four factors, Sp1, Sp3, P15 and DEAF-1 are 
regulating the expression of GDF5. Using my experimental data, the predicted binding 
regions for each protein and information from previous literature I have prepared a 
model for how I believe Sp1, Sp3, P15 and DEAF-1 are interacting relative to rs143383 
(Figure 8.12). The core consensus site for DEAF-1 (TCGG) resides directly over the 
SNP, whereas the predicted Sp1/Sp3 binding site (underlined) GGGGGCGGTTGG is 
immediately upstream of rs143383 (highlighted bold). The repressive effect that we 
observed for P15 was subtler than that seen for DEAF-1, Sp1 or Sp3. When over 
expressed in combination, Sp1 and Sp3, Sp1 and DEAF-1 and Sp3 and DEAF-1 
mediated additional repressive effects compared to when over expressed alone. I 
propose therefore that DEAF-1, Sp1 and Sp3 are forming a repressive complex that 
forms directly over rs143383 whilst P15 interacts with this complex and serves as a 
linker between Sp1 and the general transcription machinery. As I mentioned previously, 
this role has been proposed for P15 at the LHR promoter [366].  
In our laboratory, we have very recently identified YY1 as a transcriptional activator 
that binds 80bp upstream of rs143383, within the GDF5 promoter [297];YY1 and Sp1 
have previously been shown to interact to modulate gene expression [367]. Therefore, it 
is possible that YY1 may indirectly interact with the complex at rs143383. Future 
experiments could be used to further investigate this possible interaction using co-
immunoprecipitation assays or combined knockdown/over expression studies.  
 
The rs143383 polymorphism is clearly modulating the expression of GDF5, and I 
propose that this effect is being modulated through the binding of the trans-acting 
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factors Sp1, Sp3, P15 and DEAF-1. Other factors have not been identified that may be 
binding within this complex, however it is not possible at this stage to rule out that there 
may be additional trans-acting factors binding within this complex.   
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Chapter 9: The Investigation of Protein Binding to rs143384  
9.1 Introduction 
The functional effects of the rs143383 polymorphism have been previously investigated 
[134, 267, 272].  Egli et. al. observed a reduction in the expression of the T allele 
relative to the C allele in OA patient tissue samples [272]. All of the joint tissues tested 
from nine of the ten heterozygous patients studied showed a reduction in the expression 
of the rs143383 T allele relative to the C allele. In the tenth patient however, there was a 
significantly decreased expression of the C allele relative to the T allele. This was the 
first time that this had been observed and implied the existence of at least one other cis-
acting GDF5 regulatory polymorphism. Egli et. al. sought to identify this polymorphism 
by genotyping a total of 14 polymorphisms from within a 5.5kb region encompassing 
GDF5 in the ten patients. rs143384 was the only SNP for which the tenth patient had a 
unique genotype [272]. 
 rs143384, like rs143383, is located within the 5ʹUTR of GDF5. It is downstream of 
rs143383 and is closer to the translation start codon. As for rs143383, rs143384 is a C/T 
transition SNP.  The patient demonstrating the increased expression at rs143383 was 
CC homozygous at rs143384, whereas the other nine patients were CT heterozygous. 
There is relatively high linkage disequilibrium (LD) between rs143383 and rs143384, 
with a pairwise r
2
 in Europeans of 0.75 (available from HapMAP). The nine patients 
carried CC and TT haplotypes (rs143383 - rs143384), whereas the tenth patient carried 
a TC and CC haplotype [272].   
Further investigations into the role of rs143384, completed by Egli et.al., were carried 
out using luciferase reporter assays to investigate the impact of the rs143384 genotype 
on the allelic expression imbalance of GDF5 [272]. The promoter activity of the four 
possible haplotypes (CC, TT, TC and CT) was investigated in CH8, SW872 and MG63 
cell lines. In all three cell lines, the OA associated T allele at rs143383 was only found 
to mediate decreased expression of GDF5 relative to the C allele when it was on the 
background of a T allele at rs143384 (TT haplotype). When the rs143383 T allele is on 
the background of a C allele at rs143384 (TC haplotype), there was an increase in the 
expression of the rs143383 T allele relative to the C allele. This recapitulated what was 
observed in the tissue samples from the tenth patient [272].  
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Table 9.1 shows the population data available for rs143384. As for rs143383, the T 
allele is the common allele in Europeans and Asians. In West Africans the SNP is not 
polymorphic.  
 
Group Genotype Alleles 
CC CT TT C T 
European 0.124 0.469 0.407 0.358 0.642 
Han Chinese 0.070 0.349 0.581 0.244 0.756 
Japanese  0.093 0.314 0.593 0.250 0.750 
West African 1   1  
 
Table 9.1 
Frequencies of the rs143384 CC, CT and TT genotypes in addition to the C and T allelic 
frequency within different population groups. Population frequency information 
obtained from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/).  
Following my earlier description of the identification of proteins that are binding to and 
modulating GDF5 allelic expression at rs143383, I wanted to investigate further the role 
of rs143384. As noted above, the genotype at rs143384 impacts upon the DAE observed 
at rs143383 and thus there may be an interaction between the proteins binding to 
rs143383 and the proteins binding to rs143384. I therefore sought to characterise protein 
binding to rs143384 using a similar approach to that employed to investigate rs143383, 
using online prediction software tools followed by EMSAs.  Shane Damsell, an 
undergraduate student completed the EMSAs within this chapter as part of a BSc 
project under supervision from Professor John Loughlin and I.  
9.2 Aims 
 To identify protein binding to rs143384.  
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9.3 Results 
9.3.1 Optimisation of EMSA Binding Conditions 
In order to assess if there are any differences in protein binding to the C and T alleles of 
rs143384 I used EMSAs. Nuclear protein was extracted from SW872 cells and the 
EMSA reaction performed as described in Materials and Methods sections 2.4 and 2.6 
respectively. Labelled probes and competitor sequences are shown in Table 1B, 
Appendix.   
 
An optimisation EMSA was performed using 200fmol of rs143384 C or T allele probe 
incubated with SW872 nuclear extract, binding buffer, DTT and Poly (dI:dC) as shown 
in Figure 9.1A (lanes 1, 2 and 15). Different components were also added to assess 
optimal binding conditions, these included salmon sperm (lanes 3 and 4), glycerol 
(lanes 5 and 6), NP40 (lanes 7 and 8), potassium chloride (KCl) (lanes 9 and 10), 
magnesium chloride (MgCl2) (lanes 11and 12) and EDTA (lanes 13 and 14). Four 
protein complexes binding to the two probes are highlighted by arrows. Most of the 
conditions show a similar pattern of binding. However, binding of complex one appears 
to be T allele specific and binding of complex two increases in the presence of EDTA. 
Complex three appears to bind most abundantly in the +Protein sample (lanes 1, 2 and 
15) and complex four appears to only bind in the presence of MgCl2. 
  
Binding to the C and T allele probes was then assessed for a second time using the 
following combinations of the additional components;  MgCl2 and glycerol, MgCl2 and 
NP40, MgCl2 and KCl and MgCl2 and EDTA (Figure 9.1B). MgCl2 was used in all the 
combinations to optimise the conditions for the binding of all four complexes but 
particularly complex four (which was binding in the presence of MgCl2). Binding of 
complexes two and three was strongest in the presence of MgCl2 and EDTA (lanes 13 
and 14), however these conditions prevented the binding of complexes one and four. 
Complexes one, two and three bound in the presence of protein alone (+ Protein, lanes 3 
and 4).  
 
Optimal binding of complexes one, two and three was observed in the presence of 
protein alone and the binding of complexes two and three was enhanced in the presence 
of MgCl2 and EDTA.  Complex four bound only in the presence of MgCl2, and was 
inhibited in the presence of EDTA. The final optimisation therefore assessed the 
specificity of binding to the two probes using these three conditions (protein alone 
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(+Protein), MgCl2, and MgCl2 and EDTA) in addition to increasing amounts of 
unlabelled C and T allele competitors (Figure 9.2 A and B). The complex binding 
specifically to the C allele probe is indicated and is reduced upon addition of increasing 
amounts of the unlabelled C allele competitor (Figure 9.2A). The lower molecular 
weight complex that binds in the presence of MgCl2 is not specific as it is not competed 
by the C allele competitor. Complexes one and two (indicated by arrows) bind 
specifically to the T allele probe (Figure 9.2B) and are reduced on the addition of 
increasing concentrations of unlabelled T allele competitor. Complex one binding is 
inhibited in the presence of MgCl2 and EDTA (lanes 11-15). Of the different conditions 
tested, binding in the presence of protein alone (+ Protein, lanes 1-5) appeared to be 
optimal, thus subsequent EMSAs were performed using nuclear protein extract with no 
added components.   
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Figure 9.1 
Optimisation of the binding conditions of proteins to the C and T allele EMSA probes.              
(A) EMSA Optimisation 1: EMSA analysis optimising the conditions for the binding of 
proteins using C and T allele probes for rs143384 and nuclear extract from SW872. 
Lanes 1, 2 and 15 contain C and T allele probes with no additional components. Lanes 
3-14 contain C and T allele probes in addition to salmon sperm DNA (SSperm), 
glycerol, NP40, potassium chloride (KCl), magnesium chloride (MgCl2) and EDTA. 
The arrows indicate protein complexes binding to the probes. (B) EMSA Optimisation 
2: EMSA analysis using the C and T allele probes and nuclear extract from SW872 
cells. Lanes 1 and 2 do not contain nuclear protein. Lanes 3-15 contain SW872 nuclear 
protein, with no additional components (Lanes 3 and 4), or in addition to MgCl2 (lanes 5 
and 6), MgCl2 and glycerol (MgCl2 and Gly, lanes 7 and 8), MgCl2 and NP40 (MgCl2 
and NP, lanes 9 and 10), MgCl2 and potassium chloride (MgCl2 and KCl, lanes 11 and 
12) and MgCl2 and EDTA (lanes 13 and 14).   
+ Protein     SSperm Glycerol       NP40          KCl MgCl2 EDTA +ProteinCondition
- Protein    + Protein       MgCl2      MgCl2+Gly MgCl2+NP MgCl2+KCl MgCl2+EDTA   
C     T     C       T     C       T       C       T         C        T        C        T        C      T     Allele Probe
1     2      3      4      5        6        7       8          9       10       11       12      13     14  Lane
A: C allele and T allele EMSA Optimisation 1 
B: C and T allele EMSA Optimisation 2
1
2
3
4
5
6
Condition
C      T       C      T       C       T       C       T       C      T        C      T      C      T       C     Allele Probe
1       2        3      4      5         6        7       8        9      10      11     12     13    14     15  Lane
1
2
3
4
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Following optimisation of binding, unlabelled C and T allele competitors were used to 
identify any differences in binding affinity to the two probes (Figure 9.2C).  In 
comparison to the effect of adding increasing amounts of unlabelled C allele competitor 
to compete binding to the C allele probe (Figure 9.2A), complex binding to the C allele 
probe appears to be outcompeted at a lower concentration of unlabelled T allele 
competitor (Figure 9.2C). Furthermore, binding of complex one to the T allele probe 
appears to be competed at a lower concentration of unlabelled T allele competitor 
(Figure 9.2B), in comparison with unlabelled C allele competitor (Figure 9.2C). These 
results suggest that complex two binds more avidly to the T allele compared to the C 
allele, and verifies that complex one appears to be T allele specific.  
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Figure 9.2  
Further optimisation of binding conditions by EMSA analysis and the addition of 
unlabelled competitors. (A) Increasing concentrations of unlabelled C allele competitor 
were added to the EMSA reaction containing the C allele probe and SW872 nuclear 
extract. Three conditions (nuclear extract alone, MgCl2, MgCl2 plus EDTA) were 
assessed, with the arrow indicating the specific complex binding to the probe. (B) 
Increasing concentrations of unlabelled T allele competitor were added to the EMSA 
reaction containing the T allele probe and SW872 nuclear extract. Three conditions 
0  5x    10x    25x    50x       0      5x      10x    25x      50x       0        5x      10x    25x   50x
+ Protein                                       MgCl2                                                MgCl2+EDTA   
A: C allele Competition EMSA
B: T allele Competition EMSA
C Allele Competitor
1       2       3        4        5        6        7         8        9        10        11       12       13      14      15Lane
Condition
+ Protein                                       MgCl2                                                MgCl2+EDTA   Condition
0  5x      10x      25x    50x      0       5x      10x    25x    50x     0       5x      10x    25x    50xT Allele Competitor
1       2        3          4         5        6        7         8        9       10     11      12      13      14       15Lane
1
2
C Probe T Probe
0      5x      25x    50x
T Competitor C Competitor
0      5x      25x     50x
1
2
Allele Competitor
C: Opposite Allele Competition
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(nuclear extract alone, MgCl2, MgCl2 plus EDTA) were assessed, with the arrows 
indicating the specific complexes binding to the probe. (C) Increasing concentrations of 
the C and T allele competitors were added to the EMSA reaction containing the C and T 
allele probes and SW872 nuclear extract. Binding to the C allele probe was competed 
with the T allele competitor and vice versa. The arrows indicate the specific complexes 
binding to the probes.  
9.3.2 Investigation of Binding Region 
The region of binding of the two complexes to GDF5 was then assessed by the addition 
of smaller sized competitor sequences covering different regions of the GDF5 probe to 
the EMSA reaction. Figure 9.3A shows protein binding to the C allele full sized probe 
and the effect of adding increasing concentrations of the full sized competitor and three 
smaller C allele competitors. The competition assay suggests that binding of the protein 
complex can be outcompeted using all four competitors, but competition is strongest 
when competing with the full sized competitor and competitor three (Comp 3). Figure 
9.3B shows protein binding to the T allele full sized probe and the effect of adding 
increasing concentrations of the full sized competitor and three smaller T allele 
competitors. The competition assay suggests that for complex two, binding can be 
competed with all four competitors. Complex one binding however can only be 
competed using either the full sized competitor, or to a lesser extent using competitor 
one (Comp 1).  These results suggest that the binding of complex two to the C and T 
allele probes may require the majority of the probe region, however the binding of the T 
specific complex (complex 1) requires the rs143384 polymorphic region and the region 
upstream. 
 
 
 
   
178 
 
 
Figure 9.3  
EMSA analysis of the binding region. (A) Increasing concentrations (5x, 10x and 50x 
the probe concentration) of the C allele unlabelled competitors of varying sizes (full 
sized competitor, and three smaller competitors covering different regions: Comp 1, 
Comp 2 and Comp 3) were added to the EMSA reaction containing the C allele probe. 
The sequences of each of the competitors are shown below the EMSA, with the 
rs143384 polymorphism highlighted in bold and underlined. (B) Increasing 
concentrations (5x, 10x and 50x the probe concentration) of the T allele unlabelled 
competitors of varying sizes (full sized competitor, and three smaller competitors 
covering different regions: Comp 1, Comp 2 and Comp 3) were added to the EMSA 
reaction containing the T allele probe. The sequences of each of the competitors are 
shown below the EMSA, with the rs143384 polymorphism highlighted in bold and 
underlined.  
 
 
 
T Allele Competitors
0 5x     10x    50x     5x 10x    50x      0 5x     10x    50x    5x 10x   50x     0    
Full Size Comp 1 Comp 2 Comp 3
C Allele Competitors
Full Size -
Comp 1 -
Comp 2 -
Comp 3 -
CAGAGGCACCTTCGCTGCTGCCGCTGTTCTCTT 
CAGAGGCACCTTCGC
CTTCGCTGCTGCCGC
TGCTGCCGCTGTTCTCTT
0 5x     10x    50x    5x 10x    50x      0 5x      10x    50x  5x 10x   50x    0    
Full Size Comp 1 Comp 2 Comp 3
Full Size -
Comp 1 -
Comp 2 -
Comp 3 -
CAGAGGCACCTTTGCTGCTGCCGCTGTTCTCTT 
CAGAGGCACCTTTGC
CTTTGCTGCTGCCGC
TGCTGCCGCTGTTCTCTT
1
2
A: C allele Small Sized Competitors
B: T allele Small Sized Competitors
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9.3.3 Consensus Competition 
Following the discovery that two protein complexes bind to the GDF5 probe and that 
their binding is modulated by the two alleles of rs143384, online databases were used to 
identify proteins predicted to bind at this site, as described in Materials and Methods 
section 2.6. Table 9.2 lists the transcription factors predicted to bind. 
Factor Consensus Sequence (5ʹ-3ʹ) Database  
Pax-5 CGCTTTCG Promo 
HNF3-α TGACCTTTGAC Promo 
LEF-1 CTTTGATC Promo and Tess 
HNF4-α2 TGACCTTTGAC Promo 
ADF-1 GCCGCTGC Promo and Tess 
TCF-4E CTTTGCTC Promo and Tess 
MAC-1 TTTGCTC Promo 
AR 
AR (2) 
TGTTCTGA 
CTGTTCT 
Promo 
GR 
GR (2) 
TGTTCTG 
CATCTGTTCTTG 
Tess 
PR 
PR (2) 
PRβ 
ACTGTTC 
GGATGTTCTG 
TGTTCTC 
Tess 
Pax-9a/b CACCGT Promo 
NF1/L CTGCAGCTGTTGT Promo 
LF-A1 TGCCCTG Promo 
CREM-tau GCTGGTG Promo 
HoxA3 TTGTG Promo 
D.G.S TTCCTTT Promo 
c-Myb CAGTTGAGG Promo 
E2F1 TCCCGCC Promo and Tess 
Table 9.2 
The trans-acting factors predicted to bind to the sequence encompassing rs143384, their 
consensus sequence and the database used for identification.  
Increasing concentrations of consensus sequence competitors for each of these factors 
was added to the EMSA reaction (Figure 9.4A-C). Binding of complex two to the C and 
T allele probes was competed with increasing concentrations of Pax-5, HNF3-α (HNF-
3), LEF-1, HNF4-α2 (HNF-4), ADF-1, TCF-4E and MAC-1 competitors, whilst 
binding of complex one to the T allele probe was competed with LEF-1, HNF4-α2 
(HNF-4), ADF-1, TCF-4E and MAC-1.  
 
AR, GR and PR each have two consensus binding sequences and both of these 
sequences were used for each factor in the competition experiment; however, the effect 
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on complex binding to the T allele for each alternative consensus competitor was not 
consistent (Figure 9.4B).  
 
The random sequence into which the consensus competitor sequence is inserted for 
competition experiments was also examined to ensure that it is not competing for 
complex binding to the probes (Figure 9.4B and 9.5A). There was no competition seen 
on the addition of increasing concentrations of the random competitor, confirming that 
the competition for protein binding observed is specific to the consensus competitor 
sequences.  
 
Binding of complex two to the T allele was also competed with increasing 
concentrations of Pax-9a/b and NF1/L, whilst the binding of complex one was 
competed with increasing concentrations of NF1/L and LF-A1 (Figures 9.4B and C).  
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Figure 9.4 
EMSA competition analysis. (A) The addition of increasing concentrations of 
unlabelled consensus competitors that were predicted to bind to GDF5 to the EMSA 
reaction containing the C and T allele probes; Pax-5, HNF3-α (HNF-3), LEF-1, HNF4-
α2 (HNF-4), ADF-1, TCF-4E, MAC-1. (B) and (C) Binding of the following trans-
acting factors were also assessed for the T allele probe; AR, GR, PR, Pax-9a/b, NF1/L, 
LF-A1, CREM-Tau, HoxA3, DEF/GLO/SQ (D.G.S), c-Myb, PRβ, E2F1. AR, GR and 
PR each have an alternative consensus sequence, which was also assessed; AR(2), 
GR(2) and PR(2). The random sequence into which the consensus sequences of each 
trans-acting factor is inserted was also studied (Random).  
 
C Allele Probe
T Allele Probe
Pax-5       HNF-3          LEF-1          HNF-4                   ADF-1        TCF-4E     MAC-1                             
10x   50x    10x   50x     10x    50x    10x    50x     0       10x    50x    10x   50x    10x   50x
Pax-5       HNF-3          LEF-1          HNF-4                   ADF-1        TCF-4E     MAC-1
10x   50x    10x   50x     10x    50x    10x    50x     0       10x    50x    10x   50x    10x   50x        Competitor
Competitor
A – Consensus Competitor Competition
T Allele Probe
0       10x    50x     10x    50x     10x     50x     10x    50x     10x     50x    10x    50x     10x   50x        0      10 x  50x     10x    50x   Competitor
AR             AR (2)              GR             GR(2)               PR             PR(2)         Random                 Pax-9a/b         NF1/L 
1
2
1
2
B – Consensus Competitor Competition
T Allele Probe
LF-A1      CREM-Tau   HoxA3            D.G.S          c-Myb PRβ E2F1                                         
0     10x    50x     10x    50x     10x    50x     10x     50x     10x     50x     10x    50x     10x   50xCompetitor
1
2
C – Consensus Competitor Competition
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A greater range of concentrations of LEF-1, HNF4-α2 (HNF-4), TCF-4E, MAC-1, 
ADF-1, Pax-5 and HNF3-α (HNF-3) consensus competitors was added to the EMSA 
and the effects are shown in Figure 9.5B and C. Increasing concentrations of LEF-1 and 
HNF4-α2 (HNF-4) competitors consistently affected both complex one and two binding 
to the GDF5 probe, whilst the addition of increasing concentrations of TCF-4E and 
MAC-1 competed complex one binding but did not consistently compete the binding of 
complex two. Increasing concentrations of Pax-5 and HNF3-α (HNF-3) on the other 
hand consistently competed binding of complex two but their effects on the binding of 
complex one were not concentration dependent (Figure 9.5C). 
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Figure 9.5 
EMSA analysis using additional concentrations of competitors. (A) The addition of 
increasing concentrations of the Random unlabelled consensus competitor to the T 
allele probe. (B) The addition of increasing concentrations of LEF-1 and HNF4-α2 
(HNF-4) to the EMSA reaction containing the C and T allele probes, and the addition of 
increasing concentrations of TCF-4E, MAC-1 and ADF-1 to the EMSA reaction 
containing the T allele probe. (C) The addition of increasing concentrations of Pax-5 
and HNF3-α (HNF-3) to the EMSA reaction containing the C and T allele probes.  
 
 
 
5x     10x      50x      0       5x      10x      50x      0
T Allele Probe
Competitor
LEF-1                                 HNF-4
B – C and T Allele Further Consensus Competitor Competition 
TCF-4E                                              MAC-1                                   ADF-1                               
0        5x     10x   25x     50x      0        5x     10x     25x     50x       0      5x      10x     25x     50x    
T Allele Probe
Competitor
1
2
1
2
A– Random Competitor
Random                           
0        5x     10x      25x     50x           
T Allele Probe
Competitor
1
2
C Allele Probe
0        5x      10x      25x     50x         0       5x       10x   50x     
LEF-1                                       HNF-4
T Allele Probe
Pax-5                                           HNF-3                                  
0        5x     10x   25x    50x      0        5x     10x   25x    50x      Competitor
C – C and T Allele Further Consensus Competitor Competition
1
2
Pax-5                        HNF-3                                  
0        5x     10x      50x     5x       10x    50x      0      
C Allele Probe
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9.3.4 Addition of Antibodies  
Based on the results from the competition EMSAs, the binding of LEF-1 and HNF4-α2 
to the GDF5 rs143384 probes was investigated further using antibodies targeting these 
two trans-acting factors. No supershifts were observed however (Figure 9.6).  
 
Figure 9.6 
EMSA antibody analysis. Supershift experiment demonstrating the affect of adding 
antibodies targeting LEF-1 and HNF4-α2 (HNF-4) using the C and T allele probes, 
compared to the IgG rabbit antibody control (Con) and C or T probe alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C     Con  LEF-1 HNF-4   T      Con   LEF-1 HNF-4
Antibody Antibody
C Probe T Probe
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9.4 Discussion 
Protein binding to the rs143384 SNP was investigated by EMSA. One protein complex 
was observed as binding to the C and T alleles, whilst an additional protein complex 
was binding specifically to the T allele. On the addition of increasing amounts of 
unlabelled C and T allele competitor, the binding of the lower molecular weight 
complex was out-competed. Binding of this complex was competed at a lower 
concentration of T allele competitor compared with C allele competitor. The higher 
molecular weight complex binding to the T allele was not outcompeted using increasing 
concentrations of unlabelled C allele competitor. Using smaller sized competitor 
sequences, I refined the region of binding of the T specific complex to the region 
upstream of and encompassing the SNP. The binding of the lower molecular weight 
protein complex was not refined further as each of the smaller sized competitors 
produced a similar degree of competition.   
By competition EMSA, I investigated factors predicted to bind to the probe. Increasing 
concentrations of Pax-5, HNF3-α, LEF-1, HNF4-α2, Pax9a/b and NF1/L competitors 
decreased the binding of complex two to the C and T allele probes. Pax-5, HNF3-α, 
LEF-1 and HNF4-α2 were all investigated at a greater range of competitor 
concentrations. The addition of increasing concentrations of LEF-1 and HNF4-α2 
competitors also competed the binding of complex one. Pax-5, HNF3-α, LEF-1 and 
HNF4-α2 all share four common bases in their consensus sequences, CTTT. This 
sequence is identical to the region encompassing the rs143384 T allele probe, with the C 
allele probe containing the sequence CTTC. This preference for the T allele in the 
consensus sequence for the proteins could therefore explain the more avid binding of 
protein complex two to the T allele. 
The binding of LEF-1 and HNF4-α2 was further investigated by supershift EMSA. 
These proteins did not however appear to be present within the complex binding to the 
GDF5 probe. The antibodies chosen for this analysis were polyclonal, thus it is unlikely 
that the negative result is due to masking of the site of recognition. The negative result 
may be because the antibody is binding to the target protein with low affinity and a 
positive control would be needed in order to investigate this further.  
Due to time constraints we did not investigate the binding of Pax-5 and HNF3-α further 
using antibodies. These two proteins remain valid candidates; paired box protein (Pax-
5) is a member of the paired box (PAX) family of transcription factors and there are 
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examples in the literature of hepatocyte nuclear factor 3 (HNF3) interacting with Sp1 
and Sp3 to regulate gene expression [368, 369].   
The addition of increasing concentrations of TCF-4E and MAC-1, and to a lesser extent, 
ADF-1, consistently decreased the binding of complex one to the T allele. These three 
factors were predicted by the online prediction tool to bind to the T allele only. TCF-4E 
and MAC-1 share seven common bases in their consensus sites, TTTGCTC, and this 
sequence differs by only one base to the T allele rs143384 GDF5 probe (TTTGCTG). 
These two proteins are worthy of further investigation, but as previously mentioned 
time constraints limited the number of antibodies that could be tested. TCF-4E is a 
member of the T cell factor family of DNA binding proteins; TCFs guide β-catenin to 
the promoter regions of specific target genes and are therefore involved in the Wnt 
developmental signalling cascade [370]. Furthermore, an interaction between TCF-4E 
and LEF-1 has been proposed [371]. MAC1 is involved in copper ion homeostasis in 
yeast, its role in humans has not yet been reported [372].  
The identification of the factors binding at rs143384 will enhance our understanding of 
the interaction between this SNP and the OA associated rs143383 SNP. As we have 
already identified protein binding to rs143383, knowledge of the factors binding at 
rs143384 will enable us to identify the mechanism by which rs143383 and rs143384 
interact, and will develop our understanding of the regulation of GDF5 gene expression, 
and of the association of GDF5 with OA. 
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Chapter 10: General Discussion 
Perspective 
The search for loci that are mediating susceptibility to common, complex diseases such 
as OA is ongoing. Through a variety of genetic analyses including candidate gene 
studies and GWAS, many SNPs have been associated with OA. However, the major 
challenge remains to dissect this susceptibility and to understand the molecular 
mechanisms that underlie these associations. To date, rs143383 remains the most robust 
association with OA and was identified following a candidate gene study [134]. 
Luciferase studies confirmed that rs143383 mediates DAE of GDF5, the T allele 
produces less transcript in comparison to the C allele [134]. This DAE was 
hypothesised to be mediated by the differential binding of a trans-acting factor(s) to the 
two alleles [272].   
GDF5 expression is highly regulated, with precise spatial and temporal expression 
required for the normal development of the joint [373]. Thus, the identification of 
factors that are responsible for fine tuning the genes expression within the joint are of 
interest. There have been a small number of studies that have investigated the 
transcriptional regulation of GDF5. The first characterised the promoter region of the 
gene, assessing the regions required for promoter activity using luciferase reporter 
assays. Furthermore, using EMSAs, the investigators also identified the binding of the 
transcription factor YY1 [300]. A second study, performed in our laboratory, identified 
a rare polymorphism within the 5ʹUTR of GDF5 close to the transcription start site 
[374]. Functional studies revealed that the A allele increased GDF5 expression relative 
to the C allele, to such a degree that it was able to compensate for the reduced 
expression mediated by the T allele of rs143383. Interestingly, YY1 was then identified 
using EMSAs and siRNA depletion studies as an activator that is binding more avidly to 
the A allele, thus increasing the expression of GDF5 [297]. Finally, a third group have 
identified the binding of SOX11 to a binding site within the 5ʹUTR of GDF5 [375]. 
This study showed that SOX11 is an activator of GDF5, with SOX11 over expression 
increasing the expression of GDF5. Furthermore, using in-situ hybridisation, they found 
that SOX11 and GDF5 were co-localised in the joint interzone of developing mice 
[375]. 
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Key Results  
The main aim of my thesis was to identify the trans-acting factors that are mediating the 
DAE at rs143383. The key results from the thesis are highlighted below: 
 The SW872 liposarcoma cell line is heterozygous for rs143383 and exhibits 
DAE in the same direction as seen in joint tissues, namely a relative reduction in 
the expression from the T allele.  
 Sp1 and Sp3 were identified using EMSAs as trans-acting factors that are 
binding differentially to the two rs143383 alleles.  
 P15 was identified using an oligonucleotide pull down assay and mass 
spectrometry as binding more avidly to the T allele.  
 Five DEAF-1 antibodies have been investigated, one of which appears to bind 
specifically to the transcription factor. DEAF-1 binding to GDF5 has been 
confirmed in vitro by EMSA.  
 Sp1, Sp3 and P15 bind in vivo to GDF5, assessed by ChIP. 
 Sp1, Sp3, P15 and DEAF-1 repress the expression of GDF5, confirmed by 
siRNA depletion and over expression studies. DEAF-1 represses GDF5 most 
significantly and modulates the DAE.  
 In combination, Sp1 and Sp3, Sp1 and DEAF-1, and Sp3 and DEAF-1 repress 
more avidly the expression of GDF5.  
 Further investigation of a second GDF5 5ʹUTR SNP, rs143384, using EMSAs 
revealed differential protein binding to the C and T alleles of this SNP. 
rs143383 has been reproducibly associated with OA and is the only susceptibility locus 
that has been functionally investigated to this degree. This type of functional work is 
required in order to understand the basis for the disease association and identify the 
factors mediating the functional effect. This will not only provide researchers in the 
field with a more detailed understanding of gene regulation within the OA disease state, 
but could also provide new targets for therapy. The modulation of trans-acting factors 
that are binding differentially to SNPs could represent a means to restore “normal” gene 
expression levels and alter disease progression.  
Role of Sp1, Sp3, P15 and DEAF-1 in Joint Development 
In Chapter 8, I proposed how Sp1, Sp3, P15 and DEAF-1 could be interacting, using 
both information known about each of these factors in addition to the experimental 
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evidence I have generated. All four factors are regulating the expression of GDF5 and 
are therefore likely to be important for the normal formation of the synovial joint.  
Sp1 and Sp3 regulate a large number of genes, some of which are vital for 
musculoskeletal development such as SOX9, COL1A1 and RUNX2. A polymorphic Sp1 
binding site within the COL1A1 gene has been associated with increased incidence of 
osteoporosis in a number of populations [376, 377]. Sp1 was found to have increased 
binding affinity for the associated allele, thus affecting bone mineral density [376, 377]. 
This study also highlights that the activity of Sp1 can be affected by a single base pair 
change in its consensus sequence. Sp1 has also been found to regulate the expression of 
SOX9 in addition to cyclic-AMP response element binding protein (CREB) [378]. 
Furthermore, Sp1 was found to activate RUNX2 expression through an interaction with 
Ets-like factors during osteogenesis [379]. Sp3 has been found to repress the Sp1 
mediated transactivation of the COL2A1 gene in chondrocytes [380]. Sp1 and Sp3 
knockout mice exhibit gross morphological defects, however, there does not appear to 
be any phenotypic overlap between these mice and the GDF5 null brachypodism mouse 
[319, 320]. This is not surprising considering the vast number of genes regulated by the 
Sp proteins.   
P15 also regulates a large number of genes and cooperates with the basal transcriptional 
machinery to modulate gene expression. There have been no studies which have 
investigated the role of P15 in musculoskeletal development and therefore the 
regulation by P15 of joint specific genes is currently unknown. P15 knockout mice are 
lethal, highlighting the important role of this factor during development. However, 
heterozygous knockout mice display no overt phenotype, indicating there may be a 
threshold level of P15 that is required for normal development [330].  
 
There are no reports of DEAF-1 modulating the expression of genes involved in the 
formation of the joint and although DEAF-1 knockout mice display skeletal 
abnormalities such as rib cage defects and abnormalities in their cervical vertebrae, 
there is no obvious overlap between the DEAF-1 knockout mouse and the GDF5 bp 
mouse. However, DEAF-1 is expressed at high levels during development and a large 
proportion of DEAF-1 knockout mice suffer from defective neural tube closure that 
causes death shortly after birth, indicating the importance of this factor for normal 
development [345, 346].  
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Further studies could assess the role of each of these factors further in the development 
of the joint using conditional knockout mice. Homozygous knockout mice for Sp1, Sp3, 
P15 and DEAF-1 are not viable, however, heterozygous knockouts for each of these 
factors are viable (although some DEAF-1 heterozygous mice suffer from excencephaly 
and die) [319, 321, 330, 346]. A conditional deletion of each of these factors in a joint 
tissue specific manner could provide more information as to the importance of each 
factor. Furthermore double, triple or even quadruple conditional knockouts could aid in 
understanding the combined effect of the four factors in the normal development of the 
joint. However, Sp1 and Sp3 compound heterozygous knockout mice are not viable, 
therefore joint depletion of these two factors could not be investigated simultaneously 
[381]. The viable single heterozygous knockout mice for each factor could be 
investigated further in ageing studies or could be challenged to discover if these mice 
are more susceptible to developing joint specific diseases.  
The Impact of rs143383 Beyond OA 
The relevance of the results within this thesis extend beyond OA, since the T allele of 
rs143383 has been associated with a number of other musculoskeletal phenotypes. 
These associations have been previously discussed in my Introduction, section 1.10.1 
and include congenital hip dysplasia, lumbar disc degeneration and Achilles 
tendinopathy [275-277]. Furthermore, this SNP has been associated with variation in 
normal height, hip axis length, and fracture risk in women [273, 274]. Knowledge of the 
factors that are differentially regulating the expression of GDF5 in T allele carriers 
could therefore be applied to these other diseases. As mentioned in the Introduction, 
section 1.9.6, GDF5 treatment has been shown to have therapeutic benefit in tendon and 
ligament injury animal models, in addition to being tested in spinal fusion models and 
for periodontal wound healing [253, 257, 264, 265]. Aside from treatment with 
recombinant GDF5 protein, the factors that have been identified that regulate GDF5 
expression could be targeted to increase GDF5 and could therefore be of use in these 
repair models. The observation that rs143383 is associated with height indicates that the 
effect of the polymorphism is active during skeletal development in addition to in adult 
life. This therefore raises the question of when inhibitors targeting the trans-acting 
factors that regulate GDF5 expression could be of therapeutic benefit; in individuals 
showing signs of OA, increasing GDF5 expression is unlikely to repair tissue damage 
or slow disease progression if the susceptibility to OA is a result of the decreased 
expression of GDF5 during development.  
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Transcription Factor Inhibitors as Therapy 
Numerous studies have shown that variability in the expression of genes underlies the 
pathology of a number of diseases [382]. It is not therefore surprising that targeting 
transcription factors that regulate the expression of genes has been proposed as a 
potential therapeutic strategy. There are a number of examples within the literature of 
trans-acting factors being targeted in order to modulate gene expression [383].  
Strategies that have been employed to inhibit transcription factor activity include: 
- Triple-helix-forming oligonucleotides (TFOs) that bind to the target site of the 
transcription factor and prevent their binding to DNA.  
- Antisense targeting of the transcription factor mRNA to prevent their 
expression. 
- Use of mutant transcription factors which have a dominant negative effect. 
- Targeting of transcription factor metabolism (i.e. inhibiting kinases that activate 
the factor). 
- Preventing the transport of the transcription factor into the nucleus. 
- Targeting transcription factors with aptamers that interfere with transcription 
factor binding. 
- Transcription factor decoy approach, which involves the use of double stranded 
oligonucleotides to interfere with the recruitment of transcription factors to 
DNA.  
All of these approaches have been used to target transcription factors and subsequently 
modulate the expression of genes [383]. One approach which has proven effective in 
vivo and is being considered for clinical application, is the inhibition of transcription 
factors with molecules that mimic the transcription factor binding site. This is known as 
the transcription factor decoy approach [384, 385]. Specifically, these molecules are 
double stranded DNA, designed to mimic the specific cis-element to which the trans-
acting factor binds. On the addition of these molecules, cis-trans interactions are 
attenuated and thus the effect of the trans-acting factor is diminished. This approach has 
been used to target a number of transcription factors, including Sp1, GATA-1, NF- κB, 
AP-1 and E2F [383]. As an example, E2F decoy oligonucleotides have been shown in 
an in vivo model of rat carotid injury to inhibit the expression of a number of target 
genes including c-myc, and as a result inhibited smooth muscle proliferation and 
vascular lesion formation [386]. Furthermore, Sp1 regulates the expression of the 
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urokinase receptor (uPAR), a key molecule in tumour formation. Using transcription 
factor decoy, Sp1 binding to uPAR was inhibited, resulting in decreased uPAR 
expression and reduced breast cancer cell motility, highlighting a potential therapeutic 
benefit for this approach [387].  
Potentially, the inhibition of Sp1, Sp3, P15 and DEAF-1 could be achieved using the 
decoy approach to modulate the expression of GDF5. Since each of these factors has 
been shown in Chapter 7 to repress the expression of GDF5, an increase in the 
transcription of GDF5 would be expected in decoy treated cells. Certain aspects 
however would need to be considered. Firstly, the effect of inhibiting each factor 
independently or in different combinations should be assessed to determine which group 
of factors would need to be inhibited in order to normalise GDF5 expression. Secondly, 
considering the variety of genes targeted by these transcription factors, the inhibitory 
effect should be limited to the joint, thus a targeted delivery approach would be needed. 
Lastly, important safety aspects would need to be considered, such as the stability of the 
decoy molecules in vivo, potential toxicities or effects on the immune response. ChIP 
seq could be utilised in order to identify the other regions of the genome that are 
regulated by each of these factors to predict potential off target effects.  
In the cancer field, oestrogen receptor (ER) antagonists are an example of a therapy 
which has been trialled for the treatment of breast cancers, whose mechanism of action 
is to inhibit the transcriptional effects of the ER [388]. The genes regulated by the ER 
are associated with oncogenesis, regulating cell proliferation, survival, invasion and 
angiogenesis.  Additionally, heat shock factor 1 (HSF1) is a transcription factor that can 
promote oncogenesis, thus a therapeutic role for HSF1 inhibitors is being investigated 
[389]. Aside from cancer, the inhibition of transcription factors has been investigated 
for the treatment of rheumatoid arthritis [390, 391].  Although small molecule inhibitors 
targeted against catabolic factors such as MMPs have been trialled for OA treatment, as 
yet, no inhibitors of transcription factors have been tested [18]. However, transcription 
factors which promote the expression of these catabolic factors are now being 
investigated and could be the targets of future therapeutics, with examples including 
NFAT1 and SAF1 [392, 393].  Additionally a novel DMOAD candidate has recently 
been identified, known as TD-198946, which increases the expression of the 
transcription factor Runx1. Increased expression of Runx1 promotes chondrogenic 
differentiation and suppresses hypertrophy, making this a promising new compound for 
OA therapy [394].  
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The Importance of GDF5 Methylation to rs143383 DAE 
The extent of the rs143383 DAE varies between joint tissues of the same individual and 
also inter-individually, between individuals of the same haplotype, implying that DAE 
may be modulated epigenetically [272]. The epigenetic regulation of GDF5 has been 
investigated within our laboratory [299]. The C alleles of both rs143383 and rs143384 
form CpG dinucleotides that can be methylated. The GDF5 promoter was found to be 
methylated in cell lines (CH8, SW1353, SaOS-2 and COLO205) and in OA patient 
tissues, and treatment with a demethylating agent 5-Aza-2′ deoxycytidine (AZA) 
increased GDF5 expression. Treatment of the heterozygous SW872 cell line with AZA 
significantly increased the DAE between the C and T alleles from a C/T ratio of 1.1 to 
2.24.  There was no difference in the methylation of the C alleles of rs143383 and 
rs143384 following this treatment, however five different CpG sites within the GDF5 
promoter were found to be demethylated. This study suggests that in addition to genetic 
factors, epigenetic factors such as DNA methylation may contribute to the DAE of 
rs143383 [299]. One of the five sites that is demethylated is located 4bp upstream of 
rs143383. Current research in our laboratory is therefore investigating whether the 
binding of the four trans-acting factors that I have identified are affected when this site 
is methylated. If methylation of this site alters the binding of one of these four factors, 
this could account for the change in DAE observed upon demethylation of this site.   
In Chapter 4 I discussed a role for Sp1 in methylation of the promoters of genes, 
whereby Sp1 sites are important for preventing the methylation of CpG islands within 
the APRT gene [316]. Furthermore, the methylation of CpG sites can prevent the 
binding of Sp1 and Sp3 [317, 395]. Methylation of the CpG site 4bp upstream of 
rs143383 could therefore affect Sp1/Sp3 binding, and the binding of these two factors, 
or all four identified factors, could have prevented the demethylation of the rs143383 
CpG site.  
Future Work 
Sp1 and Sp3 were identified following database analysis and EMSAs whilst P15 was 
identified following a pull down experiment followed by mass spectrometry. There is 
no known consensus sequence for the binding of P15 and thus this factor is not present 
on the online prediction databases. P15 could therefore not have been predicted to bind 
using this type of analysis and I was not able to assess by competition EMSA whether 
this factor bound to the rs143383 probes. However, I was able to assess binding to the 
EMSA probes using an antibody targeting P15. 
194 
 
Sp1, Sp3 and DEAF-1 were not detected by the pull down experiment. There are a 
number of possible reasons for this.  
 Firstly, the binding conditions (including the salt concentrations) used in the pull 
down assay were different to those used in the EMSA. As previously observed 
in Chapter 4 (Figure 4.1), altering the EMSA conditions can affect the binding 
of the complexes bound to the rs143383 probes.  
 Secondly, the genomic DNA sequence used in the pull down assay was longer 
(212bp) than that used in the EMSA probes (33bp). I chose to use such a long 
sequence in order not to limit the capture of proteins that may bind over large 
DNA regions. It is possible however that by using such a long sequence, non 
specific proteins were captured that may have disrupted the binding of Sp1, Sp3 
and DEAF-1. 
 Thirdly, a non specific competitor was not used in the pull down assay, thus a 
greater number of proteins may have bound non specifically. In the EMSA 
reaction, the non specific competitor Poly (dI:dC) was used.  
 
Overall, the length of the oligonucleotide probe and the absence of a non specific 
competitor was not considered an issue when designing the pull down experiment, as 
the primary goal was to identify proteins that bound differentially between the C and T 
alleles of rs143383. Therefore, any proteins binding non specifically or at a site distal to 
the polymorphism could be identified and removed from the analysis. However, the 
sensitivity of the pull down could have been attenuated by additional proteins binding. 
Perhaps the use of a shorter DNA sequence, the use of repeat concatamers of rs143383 
and its immediate flanking sequence, or the use of a range of salt concentrations would 
have led to the concurrent identification of Sp1, Sp3 and DEAF-1 by the pull down 
approach. The EMSA and the pull down can therefore be considered complimentary 
approaches, with neither being infallible.   
 
Following on from the identification of the binding of Sp1, Sp3, P15 and DEAF-1 in the 
SW872 liposarcoma cell line, I would extend this analysis by performing this work in a 
chondrogenic cell line, for example SW1353, and in primary human articular 
chondrocytes (HACs). The expression of all four factors in HACs and in tissues 
samples taken from OA and NOF patients could be determined using real time PCR. I 
performed the over expression studies in the chondrogenic cell line SW1353 (Chapter 7 
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and Chapter 8), due to difficulty with transfection efficiency I was unable to replicate 
these experiments in SW872 cells or HACs.   
 
The binding of these four factors was investigated in vivo by ChIP using semi 
quantitative PCR. It would be helpful to optimise an assay for real time PCR to enable 
the quantitative analysis of DNA enrichment following ChIP. Additionally, it would be 
interesting to discover if the four factors were binding more avidly to the T allele, as 
predicted. This could be assessed using the DAE assay for GDF5 to assess if more T 
allele DNA was present in the immunoprecipitated sample.  
 
In Chapter 8, I used combination knockdown and over expression studies to examine 
the role of each of the four factors and to assess if these factors are interacting to 
mediate their repressive effects. I was able to over express two factors concurrently. To 
progress this research, I would look to optimise the over expression of three or four of 
the factors in combination. Additionally, I was unable to optimise the concurrent siRNA 
knockdown of each factor and their over expression in combination with siRNA 
knockdown experiments. These experiments need further optimisations and could then 
be used to assess the contribution of each factor.  
 
Finally, in Chapter 9, I began to investigate protein binding to rs143384. I was not able 
to identify the protein complexes that were binding to the rs143384 EMSA probes 
during my PhD. Further competitors and antibodies could be investigated to try and 
identify these factors. Additionally, an oligonucletide pull down assay could be used, 
similar to that used for rs143383 to identify factors binding at this locus. Once these 
factors have been identified, co-immunoprecipitation experiments or yeast-2-hybrid 
assays could be utilised to assess if there is an interaction between the proteins binding 
at rs143383 and the proteins binding at rs143384. Furthermore, a technique such as 
chromatin conformation capture (3C) could be utilised to determine the spatial 
organisation of the GDF5 genomic region [396]. For example, 3C could be used to 
investigate if the DNA is looping out, bringing rs143383 and rs143384 within close 
proximity, allowing for an interaction to occur between the proteins binding at these 
two loci. Knowledge of all of the factors binding to and regulating GDF5 expression at 
this OA susceptibility locus would provide us with a better understanding of the genetic 
association and could potentially highlight novel targets for therapy.  
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Summary 
Using a variety of techniques I have identified the differential binding to the two alleles 
of rs143383 of four proteins: Sp1, Sp3, P15 and DEAF-1. Depletion of all four factors 
increased the expression of GDF5 whilst DEAF-1 depletion significantly modulated the 
DAE. Conversely, the over expression of all four factors repressed C and T allele 
expression, repressing the T allele more strongly. When over expressed together, 
DEAF-1 and Sp1 mediated the greatest overall repressive effect, whereas over 
expression of Sp1 and Sp3 together mediated the greatest differential allelic effect, 
repressing the T allele to a greater extent compared to the C allele. Overall, I have 
identified trans-acting factors that bind differentially to the alleles of rs143383 and 
which contribute to the DAE that is mediated by this important OA susceptibility locus.  
 
A recently published study has adopted a similar approach to the oligonucleotide pull 
down used in Chapter 4 of this thesis, to investigate differential protein binding to 12 
SNPs associated with type 1 diabetes [397]. The technique used by this group was 
called proteome-wide analysis of SNPs (PWAS) and involves the use of repeat 
concatamers for affinity purification combined with quantitative mass spectrometry to 
screen SNPs for differential protein binding. Several transcription factors were 
identified as binding differentially to four of the associated SNPs, thus this study 
represents an additional example of where the identity of factors binding differentially 
at susceptibility loci can assist in determining the molecular mechanisms responsible for 
the disease association.  
 
GWAS are commonly being used to identify susceptibility loci that are contributing to 
the pathogenesis of complex diseases, thus there is now a need for functional analyses 
to be performed to understand the basis of these associations. Overall, this study offers a 
guide as to how to functionally dissect a common risk allele that mediates its effect by 
modulating the expression of its target gene.  
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Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1A 
The sequences of the rs143383 probes and of the competitor oligonucleotides used in 
the EMSA experiments. The forward primer sequences are shown. The consensus 
binding motif of the competitor proteins was identified using online prediction tools and 
is underlined. The flanking sequences were randomly generated.
Probe/Competitor Sequence (5ʹ-3ʹ) 
 C allele labelled probe GAGAAAGGGGGCGGTCGGCTTTCTCC 
T allele labelled probe 
Small Probe 1 
Small Probe 2 
Small Probe 3 
GAGAAAGGGGGCGGTTGGCTTTCTCC 
GAGAAAGGGGGCGGTCGG 
GGCGGTCGGCTTT 
GGTCGGCTTTCTCC 
Sp1/Sp3/ETF Competitor 
cmyb Competitor 
AATTGGGGGGGCGGGGGTACGTAGCA 
AATTGGACCGGCGGTTGTACGTAGCA 
E2F1 Competitor AATTGGACCAGGGCGGGTACGTAGCA 
EllaEa Competitor        AATTGGGAGGGCGTTAGTACGTAGCA 
EGR1 Competitor AATTGTGTGGGCGGGAGCACGTAGCA 
GCF Competitor AATTGGAAGCGCGGGCCGACGTAGCA 
UHRF1Competitor 
RC2 Competitor 
IA1 Competitor 
P53 Competitor 
NF1 Competitor 
GABP Competitor 
CP2 Competitor 
CTF Competitor 
DRF1.1 Competitor 
KLF16 Competitor 
AATTGGACCTGGCATTGGACGTAGCA 
AATTGGACCTGGGGTTTAACGTAGCA 
ATGTAAGGGGGCGATAGTACGTAGCA 
AATTGGACCTGGGCATGTACGTAGCA 
AATTGGACCTGGCTTTGGCCGTAGCA 
AATTGGACAACCCCCCGTACGTAGCA 
AATTGGACCTGGCCCAATACGTAGCA 
AATTGGACCTGCGTTTGGACGTAGCA 
AATTGGACCGGCGGTGACTCGTAGCA 
AATTGGAGGGGCGGTGGTACGTAGCA 
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Probe/Competitor Sequence (5ʹ-3ʹ) 
 C allele labelled probe CAGAGGCACCTTCGCTGCTGCCGCTGTTCTCTT 
T allele labelled probe 
Small Probe 1 
Small Probe 2 
Small Probe 3 
CAGAGGCACCTTTGCTGCTGCCGCTGTTCTCTT 
CAGAGGCACCTTCGC  
CTTCGCTGCTGCCGC 
TGCTGCCGCTGTTCTCTT 
LEF-1 Competitor 
HNF4-α2 Competitor 
AATTGGACCCTTTGCTCGTCTTAGTACGTAGCA 
AATTGGCACCTTTGCTCGTCTTAGTACGTAGCA 
      HNF3α Competitor AATTGGCACCTTTGCTTACGTCTTAGTACGTAGCA 
Pax-5 Competitor     AATTGGACGCTTTCGACGTCTTAGTACGTAGCA 
TCF-4E Competitor AATTGGACCCTTTGCTCGTCTTAGTACGTAGCA 
MAC-1 Competitor AATTGGACCTTTTGCTCGTCTTAGTACGTAGCA 
       ADF-1Competitor 
AR Competitor 
AR alt. Competitor 
GR Competitor 
GR alt. Competitor 
GRα Competitor 
PR Competitor 
PR alt. Competitor 
PRβ Competitor 
LFA-1 Competitor 
Crem Tau1 Competitor 
HoxA3 Competitor 
Def/Glo/Sq 
Pax-9a/b 
E2F-1 
NF1/L 
c-myb 
AATTGGACCTGCTGCTGCTCTTAGTACGTAGCA 
AATTGGACCTGGCTTACGTCTTAGTGTTCTGAA 
AATTGGACCTGGCTTACGTCTTACTGTTCTGCA 
AATTGGACCTGGCTTACGTCTTAGTGTTCTGCA 
AATTGGACCTGGCTTACGTCCCGCTGTTCTCTA 
AATTGGACCTGGCTTACGTCTTACTGTTCTGCA 
AATTGGACCTGGCTTACGTCTTGCTGTTCAGCA 
AATTGGACCTGGCTTACGTCTCGCTGTTCTGCA 
AATTGGACCTGGCTTACGTCTTAGTGTTCTCCA 
AATTGGACCTGGCTTACGTGCCGCTACGTAGCA 
AATTGGACCTGGCGCTGCTGTTAGTACGTAGCA 
AATTGGACCTGGCTTACGTCTTACTGTTTAGCA 
AATTGGCACCTTTCTTACGTCTTAGTACGTAGCA 
AATTGGCACCTTCTTACGTCTTAGTACGTAGCA 
AATTGGACCTGGCTTACGTGCCGCTACGTAGCA 
AATTGGACCTGGCTTACCTGCCGCTGTTCTGCA 
AATTGGACCTGGCTTACGTCTTACTGTTCTCTA 
 
 
Table 1B 
The sequences of the rs143384 probes and of the competitor oligonucleotides used in 
the EMSA experiments. The forward primer sequences are shown. The consensus 
binding motif of the competitor proteins was identified using online prediction tools and 
is underlined. The flanking sequences were randomly generated.   
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Protein 
 
Company 
 
Catalogue 
No. 
 
Species 
Dilution 
(Immunoblot) 
DEAF-1 (1) Abcam Ab50719 Rabbit 1:2000 
DEAF-1 (2) Abgent AP2711b Rabbit 1:100 
DEAF-1 (3) Abnova H00010522-
D01P 
Rabbit 1:1000 
DEAF-1 (4) Kind donation 
from Paul 
Albert group 
n/a Rabbit 1:1000 
DEAF-1 (5) Kind donation 
from Jane E 
Visvader 
Group. 
n/a Rabbit 1:1000 
β-Actin Sigma A5316 Mouse 1:2000 
EGFP Abcam Ab290 Rabbit 1:2000 
GAPDH Millipore MAB374 Mouse 1:40,000 
Lamin A/C Cell Signalling 2032 Rabbit 1:4000 
Sp1 Santa-Cruz sc-59 (PEP2) Rabbit 1:200 
Sp3 Santa-Cruz Sc-644 (D-
20) 
Rabbit 1:200 
P15 Santa-Cruz Sc-48778 (H-
114) 
Rabbit 1:200 
 
E2F1 Santa-Cruz Sc193 (C-20) Rabbit n/a 
HDAC1 Abcam Ab7028 Rabbit n/a 
HDAC2 Abcam Ab7029 Rabbit n/a 
EGR-1 Santa-Cruz Sc-20689 (H-
250) 
Rabbit n/a 
KLF16 Santa-Cruz Sc-131168 Rabbit n/a 
IgG 
Negative 
Control 
Sigma-Aldrich I5006 Rabbit n/a 
Positive 
ChIP (Anti-
Acetyl 
Histone H3) 
Millipore 06-599B Rabbit n/a 
Negative 
ChIP 
Antibody 
(Rabbit IgG) 
Millipore PP64B Rabbit n/a 
LEF-1 Santa-Cruz Sc-28687 Rabbit n/a 
HNF-4 Santa-Cruz Sc-8987 Rabbit n/a 
 
Table 2 
Details of the antibodies used for the research. 
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Primer Name Primers (5ʹ to 3ʹ) 
Oligonucleotide Pull 
Down GDF5  
F: [biotin]CGTCGAATTCGCATTACGCCATTCTTCCTTC 
R: CGGGTGTGTGTTTGTATCCAG 
ChIP GDF5 (Exon 1) F: CTTCAAGCCCTCAGTCAGTTG 
R: CTGGATACAAACACACACCCG 
ChIP DEAF-1 
Promoter 
F: GACATTCGGCTCGTCTCGG 
R: AGCCGAGACCGAGTCCTGAAC 
HBP1 F: TCGAAGAGTGAACCAGCCTT 
R: GAAGGCCAGGAATTGCACCATCC 
 
Table 3 
Details of the primers used for PCR reactions: Nucleotide sequences of the primers used 
for creating the 212 bp fragment used in the oligonucleotide pull down assay, of the 
primers used for PCR following ChIP, and the primers used for examining the integrity 
of cDNA following synthesis. F, Forward; R, Reverse. 
 
Gene Primers (5ʹ to 3ʹ) Probe (5ʹ to 3ʹ) 
GAPDH F: GGCCATCCACAGTCTTCTG 
R: CAGCCTCAAGATCATCAGCAA 
ATGACCACAGTCCATGCCATCACT 
HPRT1 F: TGCTGAGGATTTGGAAAGGG 
R: ACAGAGGGCTACAATGTGATG 
AGGACTGAACGTCTTGCTCGAGATG 
GDF5 ABi Assay ID: Hs00167060_m1, part number: 4448892 
Sp1 F: TCAACTCTCCTCCATGCCA 
R: CAGGTGATCATGGAGCTCAG 
ACCTGGATTCCTGAAGTACCCAATGC 
Sp3 F: AGTTAGTCTAAGCACTGGTCAG 
R: GAAGAACCTGATCCTGAAGAGTG 
ATCTGCAGGACTGTCAGCATTCTCTC 
P15 F: GAAGCGATGCCTAAATCAAAGG 
R: AGACAGGTGAGACTTCGAGAG 
CAACCTCACTGTCAGAATCACTGCCA 
DEAF-1 F: GTACAGTCCCACCGAGTTTG 
R: GGATCTTAAACCCTCACGCT 
ACCCTTGCAGTGCCTC 
GDF5 
DAE  
F: AGTCAGTTGTGCAGGAGAAAGG 
R: TTCAAGAACGAGTTATTTTCAGCTGC 
GGCGGTTGGCTTTCT (VIC) / 
GGCGGTCGGCTTTCT (FAM) 
 
Table 4 
The primers used for Real Time PCR. Nucleotide sequences of the primers and of the 
probes used for the real time RT-PCR assays measuring gene expression. 
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Primer Name Primers (5ʹ to 3ʹ) 
Sp1 (EcoR1)/(SacII) 
(cloning) 
F: 5ʹ-GGGGGAATTCATGGATGAAATGACAGCTGTG-3ʹ 
R: 5ʹ-GGGGCCGCGGGAAGCCATTGCCACTGATATT-3ʹ 
Sp3 (EcoR1)/(SacII) 
(cloning) 
F: 5ʹ-GGGGGAATTCATGACCGCTCCCGAAAAGCCC-3ʹ 
R: 5ʹ-GGGGCCGCGGCTCCATTGTCTCATTTCCAGA-3ʹ 
 
P15 (EcoR1)/(SacII) 
(cloning) 
F: 5ʹ-GGGGGAATTCATGCCTAAATCAAAGGAACTT-3ʹ 
R: 5ʹ-GGGGCCGCGGTCAGTTTTCTTACTGCATCATC-3ʹ 
EGFP-N1 Reverse 
(sequencing) 
5ʹ-CGTCCAGCTCGACCAGGAT-3ʹ 
Sp1 Internal 
(sequencing) 
F: 5ʹ- CACGATCAGCAGCTCTGGGTC -3ʹ 
R: 5ʹ- AGCTGAGGCAATGGGTGTGAG -3ʹ 
Sp3 Internal 
(sequencing) 
F: 5ʹ-GGTCTGCCAGGAAATATTACG -3ʹ 
R: 5ʹ-GCAAGCTACCCTCCGAAGTCT -3ʹ 
 
Table 5 
The primers used to create the inserts for cloning in the over expression vectors and for 
sequencing of the vectors. Nucleotide sequences of the primers with the restriction 
enzyme sites underlined. F, Forward; R, Reverse. 
 
siRNA Target Gene Catalogue Number (Dharmacon) 
Non-Targeting siRNA 
Control Pool 
D-001810-10 
Sp1 L-026959-00 
Sp3 L-023096-00 
P15 (SUB1) L-009815-00 
DEAF-1 L-020808-01 
 
Table 6  
Details of the siRNAs used for depletion studies.  
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Document 1  
Tiered analysis of the mass spectrometry results. The results have been prioritised based 
on their identification in each repeat experiment and their presence in the background 
control sample. The 1
st
, 2
nd
 and 3
rd
 categories represent proteins identified by all three 
repeat experiments with C/T values that are all either below 1 (binding more to the T 
allele) or above 1 (binding more to the C allele). The categories that follow contain 
proteins identified by all three repeat experiments, with two C/T values that are either 
above or below 1 in each experiment, whilst the third C/T value shows the opposite. In 
the final two categories the protein was only identified in two of the three repeat 
experiments. In each category, the C/T values are given in brackets following the 
protein name, in experimental order. Proteins that were identified in the background 
control sample in addition to the C or T allele samples have the experiment C/T value 
underscored.  
1st – In all 3 experiments, similar C/T ratios observed, not present in background 
 cDNA FLJ57246 – probable Poly(A)-binding protein 1 (1.014, 1.108, 1.331). 
 DNA topoisomerase II (fragment – more likely Beta) (1.019, 1.144, 1.888).   
 DNA dependent protein kinase catalytic subunit (1.108, 1.000, 1.062).  
 Heterogeneous nuclear ribonucleoprotein K (0.514, 0.940, 0.895) 
 Heterogeneous nuclear ribonucleoprotein M (1.137, 1.518, 1.714).  
 Histone H1.5 (1.462, 1.276, 1.235).  
 HSP90 AA1 (fragment) (4.281, 1.660, 1.007).  
 Myosin-9 (1.076, 1.019, 1.044). 
 Poly [ADP-ribose] polymerase 1 (0.875, 0.384, 0.428).  
 POLR2H (RNA poly II) (0.841, 0.870, 0.737).  
 RNA binding motif 14 variant (fragment) (1.007, 1.596, 1.877).  
2
nd
 – In all 3 experiments, similar C/T ratios observed, present in background in 1 
experiment 
 Acidic ribosomal phosphoprotein P1 – binds more to T (0.693, 0.402, 0.743) 
 Activated RNA polymerase II transcriptional coactivator p15 SUB1 (0.955, 0.474, 
0.636) 
 Antigen KI-67 (1.251, 1.175, 1.139) 
 cDNA FLJ57877 – probable cleavage and polyadenylation specificity factor 7 (5.244, 
1.252, 5.170).  
 DNA topoisomerase II alpha (1.135, 1.109, 1.425).  
 H/ACA ribonucleoprotein complex subunit 1 (1.297, 1.023, 1.069). Also subunit 2 
(1.514, n/a, n/a), subunit 4 (0.576, 1.449, 1.162).  
 Polypyrimidine tract-binding protein 1 (2.206, 1.135, 2.752). 
 RPL32 (0.723, 0.568, 0.781).   
 RSL1D1 (fragment) (0.765, 0.370, 0.726).  
 Ribosomal protein L19 (1.682, 1.180, 1.021).  
3
rd
 – In all 3 experiments, similar C/T ratios observed, present in background in 2 
experiments 
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 cDNA FLJ58772 – probable fragile x mental retardation syndrome-related protein 1 
(1.271, 1.744, 1.668).  
 Histone H2A (0.522, 0.966, 0.668).  
 Myosin regulatory light chain 12A (0.966, 0.353, 0.727).  
 Pre-mRNA-processing-splicing factor 8 (1.001, 1.154, 1.207).  
 Protein RRP5 homolog (1.113, 1.034, 3.697).  
 Myosin 10 (1.239, 1.049, 1.542).  
4
th
 – In all 3 experiments, similar C/T ratios observed, present in background in 3 
experiments 
 5
th
 –In 2 experiments a similar C/T ratio is observed, not present in background 
 Plectin-1 (1.043, 1.116, 0.983).  
 Thyroid hormone receptor-associated protein 3  (1.108, 0.988, 0.971).  
 XRCC6 (1.001, 0.764, 0.781).  
 XRCC5 (1.001, 1.086, 0.826).  
 ATP dependent RNA helicase A (0.752, 0.944, 1.120).  
 DNA ligase (0.351, 0.540, 1.163).  
 DNA Topoisomerase 1 (0.648, 1.117, 1.242).  
 Histone H2B type 1B (1.200, 0.644, 0.858).  
 Uncharacterised - DKFZp781L0540 (1.181, 0.868, 0.984).  
 Replication protein A 70kDa DNA binding protein (0.961, 0.986, 1.267).  
 RNA binding motif 14 (0.687, 3.280, 0.978).  
 Splicing factor U2AF (1.462, 0.911, 0.930).  
 SWI/SNF related matrix associated dependent regulator of chromatin (0.833. 2.945, 
0.861).  
6
th
 – In 2 experiments a similar C/T ratio is observed, present in background in 1 
experiment 
 Histone H1x (1.233, 0.923, 1.003). 
 TATA-binding protein-associated factor 2N TAF15 (2.025, 0.261, 0.366). 
 ATP binding cassette sub-family F member 2 (1.233, 0.501, 0.677).   
 cDNA FLJ41699 – cytoskeleton associated protein 4 (0.533, 1.075, 0.978).  
 Small nuclear ribonucleoprotein sm (2.925, 0.689, 0.581). 
 rRNA methytranferase (0.882, 1.080, 1.231). 
 pre-mRNA slicing factor ATP dependent RNA helicase DHX15 (0.472, 0.517, 1.320). 
 DEAD box polypeptide 17 isoform p82 (0.994, 0.416, 1.355).     
 Ewing sarcoma breakpoint region 1 (0.214, 0.290, 1.087).  
 Exosome component 10 (0.573, 0.495, 1.019).  
 Nucleolar and coiled body phosphoprotein 1 (0.831, 0.946, 1.136).  
 Nucleolar transcription factor 1 (1.806, 0.504, 1.216). 
 Periodic tryptophan protein 2 (0.595, 0.514, 1.210).   
 Pre mRNA processing factor 19 (1.121, 1.310, 0.410).  
 Uncharacterised - DKFZp667N107 (1.194, 0.570, 1.189).  
 MSH2 (0.633, 0.299, 1.030).  
 RPL32 (0.723, 0.568, 0.781).  
 Ribosomal protein S8 (1.776, 1.149, 0.964) 
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 RuvB – like 1 (0.889, 1.283, 0.355).  
 Transcription factor HES7 (0.996, 1.631, 0.992).  
 WD repeat containing protein 3 (0.646, 0.281, 1.248).  
7
th
 – In 2 experiments a similar C/T ratio is observed, present in background in 2 
experiments 
 cDNA FLJ92633 – probable CCAAT box binding transcription factor CBF2 (0.994, 
1.090, 1.140). 
 ADP/ATP translocase 2 (1.707, 0.933, 1.053)  
 SNARE protein Ykt6 (1.474, 1.254, 0.383).  
 Ribosomal protein L14 (1.941, 1.310, 0.996).   
 Exosome complex exonuclease MTR3 (1.033, 0.304, 1.039). 
 Fusion isoform a variant (1.652, 0.973, 1.722).  
 Gamma interferon inducible protein 16 – varied results, (n/a, 1.259, 1.141). BUT 
isoform CRA  
 Myb binding domain 1A (1.287, 0.895, 1.248).  
 Neuroblast differentiation associated protein AHNAK (0.887, 1.097, 1.086).  
 Ribosomal protein L18 (1.388, 1.674, 0.467).  
 RPS4X (1.837, 0.867, 1.046).  
 Ribosomal protein L23 (1.382, 0.901, 0.675).  
 THO complex subunit 4 (1.391, 0.992, 0.986) 
 Tropomyosin isoform (0.948, 1.053, 0.619).  
 Vimentin (0.463, 1.234, 1.294) 
8
th
 – In 2 experiments a similar C/T ratio is observed, present in background in 3 
experiments 
 Myosin light polypeptide 6 (2.159, 0.917, 0.557).  
 RPL35A (1.097, 1.286, 0.628).  
9
th– Identified in 2 of the 3 experiments with a similar C/T ratio, not present in the 
background.  
 BEN domain containing protein 3 (n/a, 0.543, 0.961).  
 Poly(A)-binding protein 1 (n/a 1.108, 1.331).  
 Scaffold attachment factor B (n/a, 1.088, 1.297).  
 Zinc finger protein 638 (n/a, 1.012, 1.234).  
 ATP dependent RNA helicase DDX3X (n/a, 6.206, 1.494).  
 Histone H1.2 (n/a, 1.096, 1.298).  
 Histone H2B type 1B C/E/F/G/I (n/a, 0.777, 0.826).  
 Non POU domain containing octamer binding protein (n/a, 1.425, 2.455).  
 PNKP (n/a, 1.382, 1.045).  
 RPL36A (N/A, 0.561, 0.662).  
 UBAP2L (N/A, 1.033, 1.195).  
 RAD23 (N/A, 1.247, 3.001).  
 Small nuclear ribonucleoprotein sm D2 (n/a, 0.630, 0.701).  
 TCOF1 (n/a, 1.179, 1.079). 
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10
th– Identified in 1 or 2 experiments, with a similar C/T ratio, present in the background 
of 1 or more experiments.  
 CAPZB PROTEIN (n/a, 0.642, 0.850).  
 cDNA FLJ27339 – TFIIH basal transcription factor complex helicase subunit (n/a, 
0.758, 0.417). Also subunit xpb identified (n/a, 0.272, 0.814). And subunit p52 (1.026, 
n/a, n/a).  
 cDNA FLJ33908 – DEAD/H box polypeptide 18 (n/a, 2.416, 1.283).  
 cDNA FLJ38853 – lim domain and actin binding protein 1 (n/a, 0.446, 0.975).  
 DNA topoisimerase 3 (n/a, 0.330, 0.882).  
 Dolichyl-diphosphooligosaccharide proteinglycosyltransferase (5.663, 1.209).  
 Heat shock protein beta 1 (1.093, 1.001).  
 HSP 90-BETA (n/a, 0.294, 0.733).  
 N-acetyl transferase 10 (n/a, 2.137, 1.446).  
 Interleukin enhancer-binding factor 3 (n/a, 0.286, 0.733). 
 Eukaryotic translation initiation factor 6 (1.672, 1.157). 
 Heterochromatin protein-1 binding protein 3 (n/a, 0.515, 0.847). 
 Hydroxysteroid (17 beta) dehydrogenase 4 variant (n/a, 0.303, 0.801).  
 LIM domain 7 (n/a, 1.004, 2.121).   
 Niban-like protein 1 (n/a, 1.524, 1.554).  
 NOP2  (n/a, 0.587, 0.821).  
 NOP 56 (n/a, 1.394, 1.665).  
 Peroxiredoxin-1 (1.438, 1.069).  
 PNAS-20 (n/a, 1.182, 1.138).  
 PSIP1 (n/a, 3.600, 8.954).  
 BCAP31 (n/a, 1.194, 1.117).  
 Ribosomal protein L31 (n/a, 0.731, 0.679).  
 Ribosomal Protein L7a (n/a, 0.692, 0.864).  
 U3 small nucleolar RNA interacting protein 2 (n/a, 1.007, 2.812).  
Document 2 
Oligonucleotide pull down mass spectrometry results. Both the unmodified (sheet 1) 
and analysed mass spectrometry data (sheet 2) can be found on the excel file on the 
supplementary disc attached to this thesis.  
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